var title_f33_31_34288="Dapsone: Pediatric drug information";
var content_f33_31_34288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dapsone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/20/39237?source=see_link\">",
"       Dapsone (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10883?source=see_link\">",
"       Dapsone (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13205 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34288=[""].join("\n");
var outline_f33_31_34288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/20/39237?source=related_link\">",
"      Dapsone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10883?source=related_link\">",
"      Dapsone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34289="Aspergillus brain abscesses";
var content_f33_31_34289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Aspergillus brain abscesses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    44-year-old man with hairy-cell leukemia and biopsy-proved cerebral aspergillosis.",
"    <br>",
"     (A) CT scan obtained after injection of contrast material shows multiple ring-enhancing lesions with surrounding edema and mass effect.",
"     <br>",
"      (B) T2-weighted MR image (at slightly lower level than A) shows mutiple hypointense rings (arrows) with surrounding edema in right cerebral hemisphere. Rings are irregular and relatively poorly formed.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       From: Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155. Reprinted with permission from: the American Journal of Roentgenology.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34289=[""].join("\n");
var outline_f33_31_34289=null;
var title_f33_31_34290="Mouth anatomy PI";
var content_f33_31_34290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Inside the mouth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are the different parts of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34290=[""].join("\n");
var outline_f33_31_34290=null;
var title_f33_31_34291="Neomycin, polymyxin B, and dexamethasone: Drug information";
var content_f33_31_34291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and dexamethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/46/21220?source=see_link\">",
"    see \"Neomycin, polymyxin B, and dexamethasone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/0/35842?source=see_link\">",
"    see \"Neomycin, polymyxin B, and dexamethasone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptrol&reg;;",
"     </li>",
"     <li>",
"      Maxitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic/Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ocular inflammation/infection:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Instill 1-2 drops into the conjunctival sac of the affected eye(s) 4-6 times/day; in severe disease, drops may be used hourly and tapered to discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Place ~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; ribbon in the conjunctival sac of the affected eye(s) 3-4 times/day or apply at bedtime as an adjunct with suspension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If signs and symptoms do not improve after 2 days of treatment, the patient should be re-evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/0/35842?source=see_link\">",
"      see \"Neomycin, polymyxin B, and dexamethasone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ocular inflammation/infection:",
"     </b>",
"     Ophthalmic: Suspension: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxitrol&reg;: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per 1 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxitrol&reg;: Neomycin 3.5 mg, polymyxin B sulfate 10,000 units, and dexamethasone 0.1% per 1 mL (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"     <b>",
"      Note:",
"     </b>",
"     Contact lenses should not be worn during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment: Apply into pocket between eyeball and lower lid; patient should look downward before closing eye. Do not touch tip of tube to eye.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Shake well before using. Tilt head back, instill suspension into the conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation. Do not touch dropper to eye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive inflammatory ocular conditions in which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, dexamethasone, or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial or fungal infection of the eye",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Steroids may mask infection or enhance existing ocular infection; prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Prolonged use of corticosteroids may result in glaucoma; damage to the optic nerve, defects in visual acuity and fields of vision, corneal and scleral thinning (leading to perforation), and posterior subcapsular cataract formation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitivity reactions: Sensitivity to neomycin may develop; discontinue if sensitivity reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataract surgery patients: Use following cataract surgery may delay healing or increase the incidence of bleb formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only; not for injection. A maximum of 8 g of ointment or 20 mL of suspension should be prescribed initially; patients should be re-evaluated (eg, intraocular pressure and exams using magnification and fluorescein staining, where appropriate) prior to additional refills. Use &gt;10 days should include routine monitoring of intraocular pressure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F158150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F158148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Maxitrol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10000-0.1 (3.5 g): $122.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maxitrol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-10000-0.1 (5 mL): $102.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor intraocular pressure with use longer than 10 days",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Trol (PE);",
"     </li>",
"     <li>",
"      Biodexan Ofteno (MX);",
"     </li>",
"     <li>",
"      Dexaron Plus (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dexosyn Plus (IN);",
"     </li>",
"     <li>",
"      Dexsul (MX);",
"     </li>",
"     <li>",
"      Inmatrol (ID);",
"     </li>",
"     <li>",
"      Isopto Maxitrol (GR);",
"     </li>",
"     <li>",
"      Isore (PH);",
"     </li>",
"     <li>",
"      Maxitrol (BB, BE, BF, BG, BJ, BM, BS, BZ, CH, CI, CN, CO, CZ, EE, ET, FI, GB, GH, GM, GN, GY, HK, IE, IL, JM, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, SC, SD, SL, SN, SR, TH, TN, TT, TW, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Neobacigrin (MX);",
"     </li>",
"     <li>",
"      Neodex-V (PH);",
"     </li>",
"     <li>",
"      Neodexin (PH);",
"     </li>",
"     <li>",
"      Polydex-N (HK);",
"     </li>",
"     <li>",
"      Soldrin Oft&aacute;lmico (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9688 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34291=[""].join("\n");
var outline_f33_31_34291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158153\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158154\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158166\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158155\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158162\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158156\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158144\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158143\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158164\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158147\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158133\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299753\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158157\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158150\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158148\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158140\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158151\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158146\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/46/21220?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/0/35842?source=related_link\">",
"      Neomycin, polymyxin B, and dexamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34292="Orphenadrine, aspirin, and caffeine: Patient drug information";
var content_f33_31_34292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Orphenadrine, aspirin, and caffeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36422?source=see_link\">",
"     see \"Orphenadrine, aspirin, and caffeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to orphenadrine, aspirin, caffeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Enlarged prostate gland, glaucoma, heart spasms, bowel block, myasthenia gravis, ulcer disease, or trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with rest, PT (physical therapy), pain drugs, and other therapies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10930 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-7A5059B635-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34292=[""].join("\n");
var outline_f33_31_34292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020606\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020608\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020607\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020612\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020613\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020615\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020610\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020611\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020616\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020617\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36422?source=related_link\">",
"      Orphenadrine, aspirin, and caffeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34293="Overview of the treatment of chronic thromboembolic pulmonary hypertension";
var content_f33_31_34293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Peter F Fedullo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34293/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/31/34293/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19764057\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of acute pulmonary embolism is near-total resolution with minimal residual abnormalities; however, a minority of patients will develop chronic thromboembolic pulmonary hypertension (CTEPH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The exact incidence of CTEPH is unknown, but several series suggest that it occurs in 0.57 to 3.8 percent of survivors of acute pulmonary embolism and in over 10 percent of those with recurrent pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Patients with untreated CTEPH are likely to develop progressive disease and have a high risk of dying from right heart failure; therefore virtually all patients should receive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/7\">",
"     7",
"    </a>",
"    ]. In one study, a mean pulmonary artery pressure &gt;30 mmHg (3.99 kPa) appeared to be a threshold value portending a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/8\">",
"     8",
"    </a>",
"    ]. Surgery is the only definitive therapy for CTEPH. Medical therapy is not curative and its effects are relatively modest; therefore, it is indicated in only a few situations.",
"   </p>",
"   <p>",
"    The approach to the treatment of CTEPH is reviewed here. The clinical presentation, diagnostic evaluation, and administration and outcomes of surgical and medical therapy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7320?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Medical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764128\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the management of CTEPH is the initiation of anticoagulant therapy. The purpose of anticoagulant therapy is to prevent both recurrent venous thromboembolism and in situ pulmonary artery thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/2\">",
"     2",
"    </a>",
"    ]. Anticoagulant therapy is initiated using intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous low molecular weight heparin. Once the patient is fully anticoagulated with one of these agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is added and the dose adjusted to achieve an international normalized ratio (INR) of 2.0 to 3.0. The intravenous unfractionated heparin or subcutaneous low molecular weight heparin may be discontinued once the patient is persistently within the target INR range. Warfarin is continued indefinitely (ie, lifelong) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no studies comparing indefinite anticoagulant therapy to either no therapy or a shorter duration of therapy in patients with CTEPH. However, the usual approach to anticoagulant therapy in patients with CTEPH is based upon clinical experience, as well as the extrapolation of data from patients with a single or recurrent acute PE. In such patients, prolonged therapy is associated with fewer recurrent emboli than a shorter duration therapy according to randomized trials, and this effect appears to be larger than the increased risk of bleeding as described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H26#H26\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764309\">",
"    <span class=\"h1\">",
"     EVALUATION FOR PULMONARY THROMBOENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step after the initiation of anticoagulant therapy is the evaluation of all patients with CTEPH for pulmonary thromboendarterectomy. Surgery is the only definitive therapy for CTEPH and pulmonary thromboendarterectomy is the surgical procedure of choice. The evaluation should occur even if the symptoms, hemodynamic abnormalities, or ventilatory impairment seem mild because early surgery may prevent development of an irreversible vasculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ]. The decision to proceed to pulmonary thromboendarterectomy is based upon four criteria: the surgical accessibility of the thrombi; the presence of hemodynamic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventilatory impairment; the impact of the patient&rsquo;s comorbidities on the risks of the surgery; and the willingness and motivation of the patient to undergo surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764466\">",
"    <span class=\"h2\">",
"     Accessibility of the thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary thromboendarterectomy is only able to remove thromboemboli whose proximal location is in the main, lobar, or segmental arteries. Thromboemboli that begin more distally cannot be removed by thromboendarterectomy.",
"   </p>",
"   <p>",
"    Patients who are being considered for pulmonary thromboendarterectomy undergo pulmonary angiography and, in some centers, angioscopy to determine the distribution of the thromboemboli. Once the distribution of the thromboemboli has been determined, the clinician must decide whether proximal (ie, operable) thromboemboli make up a large enough proportion of the total thromboemboli that resection is likely to decrease the pulmonary vascular resistance. If most of the thromboemboli are distal (ie, inoperable) or an irreversible vasculopathy exists, resection of the proximal thromboemboli may not lower pulmonary vascular resistance.",
"   </p>",
"   <p>",
"    This is an important decision because the outcomes are related to decreasing the pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Outcomes are favorable when the pulmonary vascular resistance decreases; in contrast, failure of the pulmonary vascular resistance to decrease following pulmonary thromboendarterectomy is associated with poor outcomes, such as an inability to wean from cardiopulmonary bypass, early postoperative hemodynamic instability, early postoperative death, and poor long-term outcomes, particularly among patients with severe pulmonary hypertension and right ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The judgment about whether there is sufficient proximal disease for thromboendarterectomy to decrease the pulmonary vascular resistance can be made with reasonable accuracy by clinicians with experience in anatomic-hemodynamic correlation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ]. Objective approaches to determining the proportion of proximal and distal disease (ie, pulmonary artery occlusion waveform analysis) have been studied, but are not routinely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764473\">",
"    <span class=\"h2\">",
"     Hemodynamic or ventilatory impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients being considered for pulmonary thromboendarterectomy undergo right heart catheterization. Most have severe hemodynamic abnormalities at rest (eg, pulmonary vascular resistance of 600 to 1200",
"    <span class=\"nowrap\">",
"     dynes-sec/cm5)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ], although less severe abnormalities at rest (ie, pulmonary vascular resistance &gt;300",
"    <span class=\"nowrap\">",
"     dynes-sec/cm5)",
"    </span>",
"    still warrant consideration of surgery given the potential for both progression of the hemodynamic abnormality and development of an irreversible vasculopathy.",
"   </p>",
"   <p>",
"    In the absence of substantial hemodynamic abnormalities at rest, pulmonary thromboendarterectomy should be considered in the following situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pulmonary hypertension markedly worsens with minimal exercise. This suggests that the patient&rsquo;s pulmonary arterial pressure and right ventricular workload will substantially increase during the patient&rsquo;s activities of daily living, which is likely to result in progressive pulmonary hypertension even at rest.",
"     </li>",
"     <li>",
"      The patient has significant exercise impairment. Occasional patients can have significant exercise impairment due to increased dead space and high minute ventilation requirements without substantially altered pulmonary hemodynamics, especially those in which only one main pulmonary artery is involved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764480\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of comorbid conditions is not an absolute contraindication to pulmonary thromboendarterectomy; however, the increased risks imposed by coexisting conditions on both perioperative and long-term outcomes should be carefully reviewed with the patient before the decision is made to proceed to surgery. Age is not a contraindication to surgery; patients up to 80 years of age have successfully undergone a pulmonary thromboendarterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764487\">",
"    <span class=\"h2\">",
"     Patient acceptance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like any other surgical procedure, the patient must accept the balance of potential benefits versus the risks of morbidity and mortality before proceeding to pulmonary thromboendarterectomy. Patient and family cooperation are very important during the postoperative period; thus, it is important that the patient and their family are motivated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764649\">",
"    <span class=\"h2\">",
"     Decision to proceed",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the decision is made to proceed to pulmonary thromboendarterectomy, the patient should be managed as described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\"",
"    </a>",
"    .) Occasionally, surgery will be deferred even if the patient is an operative candidate. Such patients warrant close follow-up so that surgery can be reconsidered if the pulmonary hypertension progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8494452\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS PULMONARY BALLOON ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited observational data suggest a potential role for percutaneous pulmonary balloon angioplasty in selected patients with inoperable CTEPH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balloon pulmonary angioplasty (BPA) was performed in 68 consecutive patients with inoperable CTEPH in a center with special expertise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/14\">",
"       14",
"      </a>",
"      ]. Multiple separate BPA procedures were performed in each patient to reduce the risk of reperfusion injury; the average was four procedures per patient (range two to eight). The World Health Organization functional class improved from 3 to 2 (p&lt;0.01) (",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"       table 1",
"      </a>",
"      ), and mean pulmonary arterial pressure decreased from 45.4 &plusmn; 9.6 to 24 &plusmn; 6.4 mmHg (5.99 to 3.19 kPa). Forty-one patients developed reperfusion pulmonary injury after BPA, and four of these required transient mechanical ventilation. One patient died of right heart failure 28 days after BPA.",
"     </li>",
"     <li>",
"      In a separate series, 29 patients with CTEPH underwent PBA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/15\">",
"       15",
"      </a>",
"      ]. Functional class improved, as did the mean pulmonary artery pressure, 45.3 &plusmn; 9.8 versus 31.8 &plusmn; 10 mmHg (5.99 to 4.26 kPa). Of a total of 51 procedures, 27 (53 percent) resulted in reperfusion pulmonary edema; one patient required intubation and mechanical ventilation, three received noninvasive ventilation, and the others were treated with supplemental oxygen. One patient died of a wiring perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percutaneous BPA carries significant risk of reperfusion injury, cerebral and systemic embolism, and pulmonary artery perforation. Further study is needed before it is used outside of specialized centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6653470\">",
"    <span class=\"h1\">",
"     OTHER SURGICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double-lung transplantation is an alternative surgical option for patients who are not candidates for pulmonary thromboendarterectomy due to the anatomic distribution or extent of their thromboembolic disease, or for patients who have undergone pulmonary thromboendarterectomy with an inadequate hemodynamic outcome and have failed subsequent medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients must meet standard guidelines for selection for transplantation. There are no data on the course of patients with CTEPH following transplantation, compared to patients with other indications for transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764668\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step in the management of patients with CTEPH is the consideration of medical therapy. This applies to those patients in whom surgery is not possible due to a personal choice, the anatomic distribution of their disease, the extent of their disease, or their comorbidities. Medical therapy is not curative and its effects are relatively modest; therefore, it is indicated in only a few special situations. Medical therapy, other than anticoagulation, is not routinely administered prior to pulmonary thromboendarterectomy or lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The only exceptions are that it is occasionally used as a bridge to surgical therapy when profound right ventricular failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe pulmonary hypertension are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"     1",
"    </a>",
"    ]. If the decision is made to proceed with medical therapy, the patient should be managed as described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=see_link\">",
"     \"Chronic thromboembolic pulmonary hypertension: Medical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19764676\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history of acute pulmonary embolism is near-total resolution with minimal residual abnormalities; however, a small minority of patients will develop chronic thromboembolic pulmonary hypertension (CTEPH). (See",
"      <a class=\"local\" href=\"#H19764057\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with CTEPH, we recommend lifelong anticoagulant therapy, rather than a shorter duration of therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Anticoagulant therapy is generally administered using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to a goal international normalized ratio of 2.0 to 3.0. (See",
"      <a class=\"local\" href=\"#H19764128\">",
"       'Anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with CTEPH, we recommend early referral for evaluation for pulmonary thromboendarterectomy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The referral should NOT be delayed even if the symptoms, hemodynamic abnormalities, or ventilatory impairment seem mild. Surgery is the only potentially curative therapy for CTEPH. (See",
"      <a class=\"local\" href=\"#H19764309\">",
"       'Evaluation for pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to proceed to pulmonary thromboendarterectomy is based upon four criteria: the surgical accessibility of the thrombi; the presence of hemodynamic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventilatory impairment; the impact of the patient&rsquo;s comorbidities on the risks of the surgery; and the willingness and motivation of the patient to undergo surgery. (See",
"      <a class=\"local\" href=\"#H19764309\">",
"       'Evaluation for pulmonary thromboendarterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is the only definitive therapy for CTEPH. If the decision is made to proceed to pulmonary thromboendarterectomy, the patient should be managed as described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=see_link\">",
"       \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical therapy is not curative and its effects are relatively modest. If the decision is made to proceed with medical therapy, the patient should be managed as described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=see_link\">",
"       \"Chronic thromboembolic pulmonary hypertension: Medical treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/1\">",
"      Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/2\">",
"      Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/3\">",
"      Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006; 85:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/4\">",
"      Klok FA, van Kralingen KW, van Dijk AP, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010; 95:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/5\">",
"      Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/6\">",
"      Berghaus TM, Barac M, von Scheidt W, Schwaiblmair M. Echocardiographic evaluation for pulmonary hypertension after recurrent pulmonary embolism. Thromb Res 2011; 128:e144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/7\">",
"      Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/8\">",
"      Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001; 119:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/9\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/10\">",
"      Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg 2008; 14:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/11\">",
"      Bergin CJ, Sirlin C, Deutsch R, et al. Predictors of patient response to pulmonary thromboendarterectomy. AJR Am J Roentgenol 2000; 174:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/12\">",
"      Kim NH, Fesler P, Channick RN, et al. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation 2004; 109:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/13\">",
"      Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 2001; 103:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/14\">",
"      Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34293/abstract/15\">",
"      Kataoka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 2012; 5:756.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16637 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-8A62FE5C28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34293=[""].join("\n");
var outline_f33_31_34293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19764676\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19764057\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19764128\">",
"      ANTICOAGULANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19764309\">",
"      EVALUATION FOR PULMONARY THROMBOENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19764466\">",
"      Accessibility of the thrombi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19764473\">",
"      Hemodynamic or ventilatory impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19764480\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19764487\">",
"      Patient acceptance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19764649\">",
"      Decision to proceed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8494452\">",
"      PERCUTANEOUS PULMONARY BALLOON ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6653470\">",
"      OTHER SURGICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19764668\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19764676\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/47/25339\" title=\"table 1\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34294="Scabies skin scraping";
var content_f33_31_34294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies skin scraping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 359px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFnAa4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDx8hE64BPcd6ZboZXLMcKOuKryRJI26QnPsakjfaCiEhBwa8mx+hyTTtayN2zdIYVIPIGevJ+ldFHqTpAi2SZRh8xb5q5rT2QxL5gU54HFdDpbCOIoQCP4UXqfauOobSpKS5pbG7Z3krgNcklQcbl55+grXZVjKvw+/o3ZfrWFpoQRuskYwW6Bh8h9K2bSdIlUxsjc48tj1H0rmlZvQ8+pFxXkb1pqNhFmWVB56qFCEHBYnjivUPDs6zWTHy0hki4/dngg9xXjmnWMDXAulVtoOdoO4IfWvRNA1SKGNtj73RcsO+PStaNXkeh4eNoJ6nS303nRM0Vq8mRjd90GoLLT7d4T5wwT/ADnmk0/VYpLQHgSOm4L0AJHesHxLrQ021V7dkE+MHHPPt+NdLmr8255qi3obP8AZlvA7rMQUY5UHtVO4mS4URQxMwRvuj7pwa5Ww1jVdbuorQbYV6l/4m967Syt5LOxAuyDcZOWA+8O1RJt9LIHHl63ZP58Y2hsgnHbAFUsRwO7K2XYl8AcmrMssbRCQgKB2I5rOutUtzLHHGOQ4L544rGUtSoozktg2qbtgTzMvg9c9CP/AK1bmlW7pCqXCEHnKt29P0pJ/Le5RowD6dOasQyysxJYZ9TQmkxu7JU2FZEWTAHqef8A9VUpQZJivIPD4HTOaSTa19HIz4dTkKDwV78f1pmoI8r+bBKQwIBQL1Geabd0Jbjb6FJhJ90zdMZ6Z61i3Nq1pFm0u2S5DDEbYKk+xPQVuX0klqIzGFkTqXc/c98ViGSOSWaaZwWT7zHgZP8ASs7tblpXM+58TPNCIjEYXDbJwTyrd+fer+j6Ra29w2+4R2lG4ALjIPIUen0rKl0+O9g8wbo7gnO8HIfB6EVoQztLcLBIgJSJQzocEEeho5uxo42VkVNd0uBI5HWIIrdMHp2qolpd2lrCkkaX2njpgfOoxyDjrW/dFpoxBcs8sHY+WAR6Ee9O0u0u4DKIbgGADIVsZJ7CtIysZS21OTsyHv0/s2SWCVuMMOVI/hOa7fTfE95E0lvHOJWhISVbj5ip+o5A+tZupeH5NRK6hAQkmwho8Y3e2RyCD3rK0y9WwJLxYYssLlj8xbsH757ZrZTa1Rm7M9Z0m+nmgdnSBhtBDQvkMamtrw3OTsCFT83BwTWT4XhZXaYBkEq8oT39eOlb7SIlu0jjyz15HIrtpScoWMZKzMu+smeOVnlOeiheAtUbKB1XbK+xSMhByD9a0L4wXMkZucArkrhyOvbjrVCZ1MgDBmdmBOenHQVjOUeZWKWzNmKNNksaEEEEHB6ZpbUx2VoUeUusePnY8mqdtOEvEWRf9b/Ev3fxqxqOxUjBACDgFhxntk1vCXu3RD3IJWWWSW68sCIA8n+I47Uy3ZmhOJGCMuRkdqq3DGTy7VZC/mgkDsoHWhmiSPF1L5Yjxu/2vQVhzXlcu1jSGoQsI40KsenGOKmt4ytxlQQPvNnt6VzFiUh1C5uQWFrGuVUrjcx71sSXN1cKr2owp+ZQw4Y+9VGo3fmFbTQfqdxtchipX0xWJfss8Txthp5AfKXdzxzT9t9JeMZ44kgzgsSMn6VQurh7SV/NhAeMgqcg5GTwPwrKU222NJbFe31E3WqRWrkBNg2kc4ro47eeLBmeAxscBcnOPX0NYFvpksMaTrEu5xnLdVBOTgVPM6XEiyCfYy8Ag8Y9Mdqzi1Hctq+wuqzNLKLZJvLbqSB0X0HvVK4uriztzM1y8cpCgBcHgdufWrstrJNEZFJZwcFsAZPt/jWXqNvHbaexuz5rK2UVzjvSab1CPYuPqP2y2MiRbADuLAk7j1wfr0rGsZFjmkLCaAyneE2ZB9QPf3rQs9PlmSJYZygBDELyQB6H1rC8cXqQS75C0bRMNhUYIUfe/Oly861LUuV2RheIbyTSrW8me5yzPxGy/cXrxXjjatqus38ptXeTb1J5wK7fxdfTaxbER/df5QPXFcZ4euV0u6kPVSpRhjO6uqlZq9tSKkXFqJ1vhC8OkTNcXI8+6ddqblBCH1+ldENY+0pc/Zn2ykFSqHHOOtebWXi4RauJGjURD5SCMgD3rornxTpcEebSWJpyvVV+8aipSne1tzSE4NXuUNV1O5sdBWzdS0jSmSctxu54H5VdbX7zxTocVlb26wxRBec/MSOgX6964/Vrp79w1zNknkgYx9K7r4eWmnx2GZZx55fO5Dyvp+NaTjGnFSa1M4t1JOPQ7nwDrmpeH3htdVVYxMvTOV2jvjseK9GR5NZjWWCfaqDcj4xmvPrGysrt333YEgyzNJ93b3PNZ/g7xSV16XT4b1ntQ5EbpzwPbuK5U3d22RbV0u56LrCm58K3sN4gllSNj937xPavjvxLp5sNUlh2lRnOCK+0bq3knjURtjzOS2MHp6dq+dvjH4dEV9BeWqHy5ycYHJHv+Vd2EqWdmceIhfU4mfRb2KNn8ktjqF5wPWnWVjKy5aLaSOp6GvU1WMXN1aqSiDkB0IBOPXsawLlrZrplAKkfKQABXFKtbRn2mExdSdrRu0cksW25RSRtQ811WmRs6x8FYpMbmHYe1Z1wtlby5YO2DkbeuPepoNWdpPMjbZCOuTyR/Ks2+dXO2rKuk1Y6W/hW3jzI8cLAgeY+ACexNTaXbPqF2lu1uElPBYH9azZdZgvrLbNGsjej4YH0q34R1hLTUjPOFY9CzdvasFHR8xy4mU407x7HpumaKbbTmEqlGX77fwlvb/Gsvc0VywY7JTlFYmtltYFzZ7Y74JEATtjTJOPc1y0sjpOWfeRIflDn9c1E0oaxPKwynWbjUO1jlbymMJ2SMPvYrnbnTlk1DzryVZpVPAA4+tVrfUpgY4hMwC/ewu4tVmznA1WWWRvkCDqu3iqhKxz1qDg2dRp+6FY5IEQgcYIA4+vatG7uLlyGA2qOfw71j6NqkF1KyqCsanOTxWjqV1H95TknoBVSmuXmucipy5uWxBPHdTzYjaIQbT1GST3wKJEigg2PgJj594znHfNJaXDiaMnlGXt2NWbtEnhK7yFAypHb8KiMlLUqUXFlWV4FZTI5DEBtynv2IqCLVPNuDFLgsRlXXo2Pb1rB1CyNkHeGW6fJ5ctnj0HpVjTViVJLhWLHAO0jpz1qW+xqqVlc6GOSKS5RwQs6qVGf15qxOmEWRCQcdelUrqLfATGQCMFCBjB9ap3OqB0ktbtlW4/hw33l9frVxdzFx6E13dNNBIf9jYB6nvmuf0t1e88mYF/LfA39h/Wrs2yVY4kJ3P19sevpUTWqwaoXDAKu1ip5zk+tZ26nRGyVjo9LaJJJQq7ZOoG3nbnrRc2UEzuOFDYG4Dn/AD71BcXRF8jwkFWAIPseOlaRl3kZUEHjpVqXQwcWtTAuJzFMLSRCXVAWdW+Yn/8AVVnSpXUSETiZQSu2Qbdvpk9am1LT3uIriaBtsoxheOtFtaFAquu4Ecl1wfr9T61ptuTdPY2rUvsj8xEQyLl1DblUn39KxfEWgi4kSaMANkFsfKTj7pz3xWlBM9t5aZwijPIz+tWJ7mKQQY+6zBXFaxaZkyLwrqgtLZrTUcwXaHADjl8nG4Hocmtu8ug7GJzknlUBAyf89q5Txm3l26iF8zRfvo2PVQOOvdfate1uY7q0t7mMBlmRXG4ZIOK2dXljYlQuQ3thDcahEXmkSVj8gQ4z6jFWkBt2O7c2OPUk+g/xq3Har5YMgJEZ3jPJHriqurTw3ETfYpYXMX3uclf/AK9TCPu87Kk+hoI8M0DQAYKruVv896bBqAAVS25ETLkjqai0feUVpm5ZQelWL3y4o2KIpkboOgP1rqTbXNexlazMS4lH9qrLFtXzMIB3PfFWbi1ScF/J3TYO0kdDTrGxiV2upwzT4IG7gJ6gD196ksEP2hri8ucjOEhXooB7nuTWcY63fUbfQhv9Nn8hCZD5SkFgOrVp288SxIgO04wB602S+SedlQ5ji4bHAqhqMLpLDqFvIg2A4QjggjB/Grsou8BK/UualbxXVo/lnDlcrng57VzzWDbkku5DIsrDG4/dI6g+g4rTsbxJwvmPucnKnrxXP+OZbidRbW0YzLyAvylSOpJrOTjNcyKStodBOZbqJoo2UMCNrJ9etZN/4ZMO+9tJB9oXLBGPB9awbK7vtGiiKXDSyPkvFL94H2PcY7VujxRYahbfNcImDiRTnr6EVCmmrSK5XvESKW5uY433tEyDDKo4PrisrxG7IigxXExfAQRoSQf9o9qlfxPDHILePdJKclUkG0H0ANZHiC5126tIpoQ8EYYFgCNoH86hWeg4p3ua9pHfPp+y/X7La8AlX2ll/wB7tXnfjnULRrS5ghkcRFiB33dcE5611dzrC/2J9lKyGZ8JuWTcB65rAn09NW3brRUtlBG5B8zY4znvilzcsVI0jG8nc87uNXmGkWwwq+SrIc981g6RtvHeGNN75+9jp712UPhS7Q3UZjWaMnhWOGP0rL1DRZNFCvbY8zoyk4YnrjNdEZx1SIkne8inDoVqtvKbmMiQZzngse2K5ufw7NKZJrQNhf4WGDXoOi363WqwxahZNjAbDZXH1NbOtXNoDcW1gsb3PCttIO31xVRryjdESoxk1Y8mfRpWVBLE0MhXI3f4VTSW4sLyNEmYonzd+a9V1W2+y6YyCIvcsgy33h07HtXFw20EaPLfrtxyoPWtoVnKPvIzlS5Ze6y/4m8U3Fxocdu6JBNIoDMjHLAdBUPgaOfzI7qzJE8XKZPJP/16y/sI1G5G7iMkbTnqM9BXc+FtEhm1G0hst5/eEMEP3qzqOMKfKa01KU+ZnsugeIptbsUjeza3WMBJZs/ez2HcE/pWX8Y9OtJbTTiUIw23Cj0B7V3Wi6PDYaaEliH94joc+tYvi/T31O3hKISFfjI9jWdJSTT7mdezTPJI57ZbSdAzli5VmbO3Pc5rmbyMWrzOqNjsWILVtYkuoXkt47goOFU8LkHkEfSsw214QZ7e2F1anh4kPKnsRn9a5LJs+hwuJ9g/I5u8czybWzk+nekVvIick5XHIA71fvrKWGTzRbtCu77jdfpxUciiVMgAZHIJp81lY+ovGrG8WMhSOa0ypXceRg4NEC3KOHtVYsg+YN396dBZTbSYnxjoAM06aHULZFyN4HcU010Z58qbfuTT0O18Pam93AibxuT/AJZnofbNbN0jwWCszYnkOc5zivOtAvWS4Ec+UL+o4Ptmu2N3mAF1JUDgg9KwqrlVkcXsr1E0y5bsY0Rh82cnd3p9xcyEA7yMjGCOtY1tdtI7lXBA5AzitvT4PtcG4jJAyM1i9NS6i11QadcSQSqXJwDnb2NdskqTxou7BI6f4VwkluzTqWYjbwcV0WnXBiRVHzbOhPcVMpdEcdeinqjpYFCLGrElx8o7ZqjdXDxXBAwVOQMnrVnTr6JpVilkAI5xnpmjVGtpGEEc0Znc5ODnbT5U1dHn35Je8ZIuY3MnnMNmDt2nv9O9aNtpbi2j2IrSeWN6+/pWbLsUbWVRJE25fRh6j3rZ8P33mSCBz8w5jOcgj/GqhZ6MVW8VdGtpln/o4SVTjGMHtWH4g8ORTtvi3h85znP/AOquzARkLBiMjOMVlasRDH5kO6SUc7ema6pQUY2RyKcr3OM0jTru2mYtKJIS/K4HbvW4Y7aS4hIcbs5Yew/+vVqOP7TCd0SYPzfWs66iijZXlAj2HDBeuDXPJ3d0jZNvRkM6MlzHLtO1zsXJ4Fa9sxE6L0UqQCfXrWc0UFzGTAJJPLbtkdv1q/agLYKko3PjkEd6UY2kEpKSLN4/l2QEmAzt261JE4YKZAcAYFZyT754kbJbkgNzxVl9/lSA7Ej7sDnA/Gqk7yIS0JI5CzyZ+7256+9Upplt3VIwsisxL5PIzxmiKdcsYj8pOFbFWUiSNXnePgjGT1NVC4pIx9Rghv8ATgk8jDYXSMkbsqR93HXGa0fBzvHoENvO2J7MmGRVHC4PGD3GO9VrxY9WjkeOPdtHyOeMMPX1rW0+0TT9AE8rlpZ1DyOBjbn09MVrfni7EpWZaXWrKS3dRN5iA4bCnINZum+FEbVX1Qu01192OYsVCoeq7Bwfqear+G4UluLxwzojSgCTHynHQfSu3tY/s7Hsp4GD3rejeb97Yip7uxiXkktqqRpFJIQcfJ2/wq4sjGEvdwmKNBlST1FRaq/lXaj5nD8DHr74q3p9zFqVpJFNGwToeK1SXO4oy1tczU1S1u5/LEiysD16Y/pVTWI7qyuYr2wKXMQQq0ZOMHsaxdZsri1vRBbhJiCSrKcbv94e1W31C80y1Tz7JtrgbSnVvXrWTbbakrmllui/pNw09u4uFNrJtLlT0YdSVPetmO0+16SouMFj82Aeg7Vkmze90u3k2lFDmVRgbuO3HrWxpUkkqo88TpIox6cVpBdH1JaM2DTo4rdmZlCq2ARwAPWqFyVvrqIxsreVlW3cbx7Vt3CRSyXMLMysTn5BgEVmvFBagLHEzopB2g52/T0qJR0t0CLGzCGWJxLbq8rfKBt7+57VzfjDRyy2728qRMSCVWMFuO2fat5NXhkvJINqoy4YEc5/xq1eWdtqbqk7jjGMHFKL6D1R5WunXMmpLNCplQPllc4YH/Gu6jtEmUhp2RjgmE9vpW9pul2enSy/Kw39OOvtnrmkl04SXhKOUkDYKrzkYyR7D3p+zb1Kc7nlXizUUihmisrco3mYVnXpjuaPDM2raTbquplGs5MkTIcnk9D7VrfESyihmcOu3BwzdvYVV0a+jl8MXTKrOsY2FHA/rWdRbRZVPq0R6pnT9SaZZdsbR5HOdzHivPfEN/NFqjz/AGdpzGBtVxkfl9a76ymtruyEOHe5iJCDb90e9UINHubjUftmoRIYQNmwcZHrmoptR1aNZXasclpVlr1/JE2pWi2UbAyKFb966/TsKo634WvPMn8i6CKwMgjkXaxA9COte2ab4fgjt5pyjyrncAWy2B6n+lUdW0yW9jcW5dgFKgAAH1P0rZVbO/RmDi2rX2PJbW7Elh9iaUzTpHt3MxznsD64rlbqyu/tUkN2r5TqSDn8q7PxD4WvtO1P+0LR2UAg5Azn3A+tWdHaW41ZHuChMvG51Pzcetac6prmjqOMPa6M5HT9OksFd55NiMvAavSfgqDJqEjyqIUh+4WPU+3rxT73wTcX1xElxhI5G37QMcCu10XQ7TSLSVvLCug+/nk/SsJ1lPQ0t7NaPQ9PhkS6s1ZzwRgYpsMO6EhxghuAeRisDQ7mO0tY5ZJXG5dirI3APqBWmtzNGzGUnDdMV1Qq2s+qOZrofMGsabq+lSSFZZBbqM/uWzls8ZU1o+G7iWe2meF3ilVcgqoKyA98GsPUfEMtxCXmXbHIvrnimeGNbAvVRSRGufwzjvXGublfMj3JYeS5XF7mtfxk2L3DyCSJhg7hhkPoaxYYEOA3zMOQV6ketd1PbW19F5pACN99T0cevFQPpEFpG0snzD+EKOSB2NYt22O7C42UVaRg2Ci3Ku6JtYgZPX8qXUruK5ZI7cY2n+Ec1XuJR9qkM+9nHKxgcD3qGzSS4n84KRDnG71NDWmp6FOSb9rfUvW6RvIiRxAM3G4jit5bQxxFGPJ4+tZMjGIqShHv/WrDTPOECydehHpUc19DPEUpv309CNYvJnKgc4yc10ujzCG3Vt2BtxVaGyVYieJC5wcfzrWXTY0sFV9yhh2qJnFUrQkkjPS5AuJGJUqx4A5zW3psjXSBkiCxfdB7ms77GlowWbDBhkHFdFo6x3CkKVDqeCKm1zmqVEtRLqy8yKMomJM9e5pLG3ijm3sD5uMZNbYZeVx0+8arSwI7btwK4yQoz+NK7WiZxuUZO8kU3shczFnXHQg1No9kP7R3I3LAgAj7vqRVqIwxxqWkdlOSPkJY/QCrOkPgF5EKNIdyr6D39K0pRaMqtW6sbvmBIwoyNvAPr71Smyzk7wzEY98VZE6OANwyo5GOcetVjbncZGbhjnNbVE76HPFoZEgiSQgknAxz0H9KrtEsRlnJ5cjO4/yrREJ8lhGM7znPTP1qrMnmkpLtKjICgZHH86SjZFN6mZHcXE0ipAhG/rIxx8v07mke7FuGj2Ngt1z+dQztHBOrk4bdtAJPNUb+aWG4OzaVdumP73bmovqXFJouQXiDURhlwEyQO/FO1TUIo4iImYs3Rcdc1QstLMk0xk3IoYDitCW0hhRp5kYpGNwPov8AjT5W9ROUUP061Y2bOxZAoz8vOPWr1pbmYLFIpZXGcOeB/wDr7VNaxm8tUaImOJcEEDl/Yf41uafapPiV1IkjIGD2I6fWuhUua1jHn7mQtvHBE0aL88mEPHqa2NWt7afQmt1by4QoHHoKdqVqhAbCsFH3fWqq+RPYtG6Mdq5KgkVpH923Bi+JKRVt7aBwto7tEPvjyzjdW3PP5aBI8FgPu9TXGX9xJHdtcWUmyaJgrpjgpjnA7n3rX0PU3m1MozCeBot3mhcFTn7rClSbiuVaXHKz1Zc1mJ7iGMyQt5fVWjPzVDZxeWzyW0jFmG1ULnGffPStLUJBJbAR5ADDBHQ+1c3eXT3TLPbSFJEOyWMAtkfUd8dK3nZPQy3L15pYmDF8rOyYBXqfYGoLnS59WsvskzvCYSCrnnHHPWtnQ7xbq2wDgp0DDawx6iotTu7rZm2hDjOCMgfqaOWFrg20N01ZbSEWhzJHgKHHX6mtGSWKJ+G68Kncn1xWW0832eUyIqXMqYVEbOfcn29adpUjXcUsb/u5UwMjp9QaqLS90XmyrqfmWl3DKWd4Xfnjoai1V4raJu5k5jT1qbUkWFY4UdpX3Zy3GKhacCN45SrSBcrjg1nJ2dirX3KWk2sF04kwEGGKsOCGHUVrGFdsTTBVf7o29ceprA8OTvHFM8wVpY32sRk5BOT+PQD6VpXd0zRLFb7gZGw0nHyjvj3qINJajeptvHFMQYmk3j7pzgD3FXITEq4jC5H3mHf1ye9ctbXE0c7JJITGykLjna2etEdrJBOVDE7/ALzBiefT2rSNbrYTj0Od8dXgkvlkFus9shwE/vN715qlrdwa2HacQWsuHKLkgHuPb8a9b8S6cY4ZmEeWkU49M/0ryzUWvIr3NwAsTrtbzAcBex4rCSlJtW0Z1UnGNpXtY6v/AEex0SRljSO6d9yMvJYep/lVzTZHE9vDOI5EdRhepDe9cTbSXl3dLActEoGxl43AV02jJdy34gSUIyZRHjG3jtj/ABrDVKz6FyikrrqdjcXA062MQZQoAHI7mkS6jn0SIwxky3LMu5RwB/ezXnPjjXJY9SjsyxaTbiUk4zgc4x3rWt757fSLMW9xIGJDRwlfun0z3FUrx1MuQ6PUrd5YQrLG+DhVYcYrlzoL2BKC1KSTPne/QDqcf0rrIbyK+t4miUm4DhXj/wBr/CoPFN3ZWdzDc39zJ5ydOTt/IdKafu3uSk07WKl6bi5VIoJ1t0IGJZDgsR2/GrGmadd3l4sM96xiVQHC9MnpTZLq0vIRchS0aJuB28Ejoa6XwZp0Pki5fLyN+8ALHH1I9aKcbySQSbV7nQ2ujwRvC7qshiGEOOB71ZuFhmbbwSvXbyasodwPGPY1QvZoI5NiyQLKOWUsAceteryqEfdObdnxxNo7Q/bLMSgywH92MfeQ9Kl8CacJpR5yY8w8MDkgg+lW/EcM9vf2tyCTK6lGOeo9RWLZ6i9g6fZ2K3EbcH+7ntivOjLnhbufUzpVIyS5tY6I9oMMVrbgoke9+COwHrWPq145xHj92ybuOgPtXI/8Jk96PJBweOGPQ1I93cOknBAYck88e1c0otOzRWFwN/fuSX/lyKHCgSIMZBwT75qS2uo4bURhTuXOCeayrfzWvQrqzE/dOOBXQ6dpqrKPMzgdC3Rj6j1pNWR38tOzvuhLORry3K7MYbaS3cVXnEMd0IoXwwGcDuK6e3tYIFdiMoFBwfUjmuPmdTq7SKnfaAo596UWm2jHmlujqIfMa0je3fEoIAA71uQu8zBWcuRgEDBAP1rz4a5La36wW0RZnGck8fSrEGt6hpdw1xctaICcBASxJ7cd6l0pHLUja7PS76wuHtl27cKp3hsk4x296wdNW5td0aSFx1DAc/hVa38V3U9zAJAGAAJiAwVPf9K1mvYb61+1W8Do2clRwCPUCrs1oeW007S1Ohgkje03rISwGMkYP41WtLzbIUJ+frtzjHNLZXaFc4UK2DxxketVNUkhi1FGjXOBhsHHH+e1QlrcyvvFnW6fapDKsiru3E7s9v8ACnXNmzSYixHGOoHUelGnyiSHYGGQNyMPQ96vbWmQY4J44711Rj0Ryt9WUU8uPa9x+6IyRLjge/HatOPO0DarALksDkexFOaxR2CZIjIOV9fesbzG0e5lh+eaFwXRN2Cp9B7e1OceUUXqXbiWVSQgwDwCBTWhZ1LuVZfT1qeNvPhDorKXAba64Iz/AFqjLcvYWoEqGQ7yCOp+n1rO3VloztUt5LiJorZImlJAL9cexPaudmjvFeH7dBLIq5DNCQR7e9d7YywmBXjQJG3zKB7jmq9wqBpN4AXGQp7+tUoKwc7Whz2nNeQ/OxRYfmZUdd2Oep9/pmr80g1C0AhlBxyCvrWzbWiT2G+4AKY5GOOaZJYRxSho49qD76rwT/jTmnC1iYWbLukJ9itgHBLOMse+Sf8APFaU7SGIPDlFTkgjG6sMMZWHzMm35gCSNx96bbX80gZiPlQFcFuvPXHpWka1lZoXJrdFqF5Zptk0wkRX+cFcbe4571JqJMUZlhB28AgDIxn2qveQiezj8yMOCd7hSV+b2x/KpbZ5sMkrCOEqNu4YKH0Y96Ss9wZh39nbTXUU8kklsJA67g+3noM/hmtvw7F9kt3ZkSOMk7GAwzrngkVUu7JGlUJMmeoU/dBHcVZ0yR4nP2iDzGY53FunGMCtItRerJepaulkuReQFt0ckY27fl2ccYP1rMtYzA8Y8oxLn7u/0+nWtrztsDlwqRrz8qkkfhWHFaXMuqLcyt+7KERhs8Z5PFaTei7kpal7VtMWWJZI5JYnYcSROUIz396ntLdorVvt9ybiRAP3p+Un0zT2jlkgAJOD1GePrVNobsGRVeJkB5WRSPxyOtPmv0Bo0VWOSBuQ0bjuKpC1liR2tZcsDgDqR/jVRb2UkRSxlG6HaeM1a0+ZVRiWJIOCfrUOal7o7MjvYmltgGbZIOSaxIbiKG5QyHe8mU245PPX6Vqaq4mkjW1ZXlL4dAecDqfaqCWLDUDgoZ2XMbMP8/8A16yqLXQqNraheTNAA0Ue3zDknscdOaxbnTry7uYtQglKqpwi/dVDnH3RxXSiN7hpLW9UKAoYbRxx/Sm3sRltVt41ZIVO5huwT9Pahq61CLa1INzIRPAsZB++cng9Mmrum3EiygydsMB1/GqNjsWLyXdJCyYkIIGTjpn16VZja20628yacfOvl7yeg/ClDuDItU1RL1xbCIyuGyFHbHr/ADrlNVEOrQzW6Qo0i5QcY/WtfS44JbzEe1YUbapC4z6/U1o6jpEM1xst3EM7LtDKPmUHrmj3p63KTUGrnmljNb2DiC5MbBeAQcbR3HvSt4lhg8QxR6eP3IBYsRnBI4/yK7s+BdPuraR5pfNJU8jufU15HqVpHol9JHECpjJ29S2D71nKi0uZ9Tqp1ITly9jA8SauNS8XhLqF1s42zI33Sw79elegQ/8AE4to5dLUxWcB2xsDnBA6+31rhri1stVsZ5iDBL0IGST/APrrc8J3l94es5LOSzl+zXChhvGCM8fl0NXOzjeOjQKHK7M3dL1K50y/ZWUyR5yXTBzzyPWt291ey1VXSW23xsMBiPumsOxvlSe1EFsI7ndkGQ8Y+nc12v8AZtxsWa1s4reTBJkdsL19vWsVG68x1JpSV0V/DMcEZ8q9CtavkRKeQnvXoumWUcR3QsAmMKMdBXD6Fp0Wob7nUAke19qLGSASOw9a9Ct1/dIEKkDjiuvCxl12OStKLem4wCdpmMQHlZwc9fwrj/GXg0a1dC6hupYZ2wH3KHBAHHHau6SSMllQglDhsdjTMB+3Tiu/lOdOzPmfXLIy6WJGUMyYZG9D/wDqrh9YsftMTXO0LInBYcH8a9R8R+XDA8BcbSNowc89uK4ySxNy5jcf6O/yuM45PevEpNx1Z9RGpGdr9Tzm1IW8VroMC5wrZ/X6V3wumFjDDbxGd2649MUyfw3aRGM3I3lWwrKcHHuO1aNq1rpTLbbtrSLtBc8fhWtStGptqa0qdSkuW9kaei2QijEkwHmdCSf0rWtLT7SNzrlc4XbWSymaNo0ZsP8AdYdF9q0dDstUsJC8bpJBx16/lXJbnle9jWvUdCD0uNucQv5cvRkGcD61zlxaxos8ynaSuFY9voa2fFmpSpc2qPZN80BBK8jbvPNYl9PHdwxxqQqMecnFU4ODsjPD4hVYczXyMQW7PeRGKUOqZG0Hk1bezbUbiCRLR90EgY7uMqD29K0Z4DZ2ccmnpEZNwy6/XmrJ3C8Ro9zmYbSjHaM+ufStee2qIqKUk13KWqaXLLrEl5PevbWkibwFbAB6Eew/nXR6fPInhgX8Es0i+cFUZwAnAwc9QP61n6xo0mqWKqbwBoW3mPbuGB2GeoqyPEd7bWaaeLGL7Tcv5UUfTae5x6Y5p8zmlY86UbHe6MqyKBMFjc5YAj2/lVbXbfZHlV+ZTww64qDwvFLDffvrlrp413KT0J74Hb6Vsazb+dPHI/EYx8g9fWpclE5bNyKel6gy2SxRFjKDtUOcEnsc+ldLo99cXdrH+7KSfxcfnWPYaaWK3AVWkRsZJxkf5xW1ZxzQSKbZAyscNnjA9D+Jqovm2M6iSOmtv9SN2AyjoP6VWnmiaXLIpZRjOOarPb3oRmaSL1UBjj8aigUtbeavzGTnnjB7101JSslYxVtyX7Q0SP5C7hnIOemfeqFxH58zoXyFIJGM5J6VfmdDbsM4+lJDbCMGST+LqzDJB7AVHI5bjukJHGpX58KqjjHb/Cq9zbfaL+F2yIypAPrWnbWb5O9xg5JUjGfep57ZIGEwbaAv3SflHuBW/stNTNy1I9OXfbSWxxgZAPcelV9RuEs8NO+1f7zHFT6dLufzPlIcdV6UXdpbX75lVHKnI3dPbipqR5oruVBmL/aFu+55C4t1GWKjlv6mpLeUXnzWSw20OPuy8uR24q5c2tsqKwjjV1OAOlQRxpLMxBO0DkDgj/Cudpr3WXfqiaDzjc5mnjMIGRx3+lT+ZDOHiY7kfg9vpXPXl/dWqyspjlhidS0h4YDuD61qWssN4q3FrJExJyRuB/yafN2Abpy7TJDMd7gk9c8eorYhiV4x5q4Yf5yKqwpuxObcRyRZUZPTPUirVjMWBEmATkgY7e1a0421ZLZdiWMt8khyOoznFV3KG62cccZJpt3cvFbTCzij+0D7hbgE+/tWe0sxRZX2vKPvBeB+HpXVKaWiM7dzXgwRj+7xx0NZuozMWHlkLt+8R6VnQ6oyal5MuCXG5FUYA9f/ANdT6nHNcQbrHauPmJYk5JIzx9M8Vm6ikrILEKOtxOu0gKxOfWqM9tLbXl5c2zNvUAFD/Hx1xV+0nhtUO8dM53Hoe+aj1fbN5cts3zjGGU9q5akko83U2pxu7GXp2rwSki3icEKSSwz846rnt61Zvb6NpLZIn/fuQ3yc9sEe1Z720SW099Z48915iYY3e2B396fp+oSXN0oEMKxP0lQnJPp+fWo52o3L5LvRG+JI1eMZzIDtzjJ6Umo26S2rrFKu/vhsd+mazNSure0likuLjZKQQoRMgZ+lTQ28z2UiwgSBkO0qdvUdADWyl0MmjnpdMurC+Seyk2KWVZI/vAjv+OOa2ZNNS71BhLK0RRNvBxnnqo/SqtvayfYJViLR3OVByT83rjNWLcCTWXmZjiJugbPy46fSpWg3qa9raW1tGsMaDaqbQW6tjsTVQ3kJt5t7MrH5UPfIOME9/wDCrepWd1Nbr9mZC8jBSG42D+8aYbVXyJ44wxwA45yemce/NXZrYnTqPhkjstKknBjVnXIEfArgtV0f+2LRr14lVW+6euecV2WpxyvYm1idAzfLlsYAHp7VXktxdR/Y5f8Aj3lCbWUbQSvJqW+a0S4vl1OP8LeB0F15jIpiznG70rutcsrSO0cm3XeFwdoGMdAa0bKBUZtqpGq/KBG39aj1NoZoXtFlEPGWcnJINXCnyxbl1FUqObT7HAWnh7ytSSd5m2kht685OeBntXewKlzayW5G1mBUq/Qe9UoNOWK3RLOXNuAdynkn05pyxz3FqwgkPnR9OffpntXOtJXsW5OSs3sTHSI7XS/KSZnkjU7XX7wOO3vV7wrqf2mJbe4UrdKgZgBgc+3Y1S0g2kdxLbIJFkUgyFz1z0I9uop09qtvqfnQqqO4w0g/u5yBiuinJxszKXY3reRftU0fJJyd2OPzq6oVTgfWqMMYVImUjnt1zVgTJE20ADiuyErJ3M2jxe3s4rpJppIt5ZsgtVC/0+O2icQAKqdWbrXb6fZyLpKwzoiRiPls5IbsarNZKkLy3NxFcgjBwPlA9hXjVYS3Wx6mGxCjqzym0iaS9eR2yjdFPQe9RaraRuxEsRfyzg4H616PNpEP2KWaBkUE5CbdxKjnNczdRq16pcq4kAHlt2OOtPka1OynjlKVjD0aX7O6KkUgQHa6k5ByeDXVwXkMu2OR2jzlSMEAkds1y19LcwuC7RpsPyso6j3rR0G4F40cNzISEVmXIxgn37ms5LmV7HVLvczNcvIjqUEcUkki+Tk4HUbjx9K5C2uJJ7yQuQkcbH5R2roZ4wdSk8hmkOzoecck4rI02zTFzdPlxvwT/drZWtdhH3Voy9JcMbRYrUnKLnMi8fWpBq8C2ryttyAUiIbIdvQfjVa4h3W3loXJ6l0fkj09qks7SKS0x5QeF+HV+hz0I9CKLRtqS5yT0EguruxZHkaNlKgMdxJ6evQZrcttZjubm2llsw07EAxbDubggFW/LNcybZws1lK4iZfmhcnhx3BHetPRJJ47UxtG4CHCvy3ltx19j2NXKKlqcMm0ej+E2a1Drc5LnLyEnJJJ7H2/pXSPNFdRDCnKdc/zrzxbmVLMzujSdFckkFOepx1rtNFmiWCIziRTICokH3enH0/GsJq6OdpXuiSOeJYhsbM277qk5Ga2LCQrJkSs0qgnA5yPf2rhb65NjqsVxIW3YIwe+O6+1dTo9+qwxO6sTMS29BncuKEuV6EzV0b5uJZI2USuNp52rnI9KglvltnSFI2AYEqSMhfrVO3mkIkjj+QE8lqIlzdgyMSCcbDyGParcpNmPKkjRtrdIogzyb26nnk1p24aSMNJMqgn5c8fzqta2Jlnd5GYRkYXB6VBNsheW2jkZ1YHarnODW8G4asydnodD0C7uvr71n6rKscTKjLvYYXeeAe2aoIXaBJ/OcBRyu44HtVbUBcSqIxGwWU4LcfL6H3q5VnJWSBQFtrmaPTxIE3SRHBUdz6Vd0hZrayjExZ5sZY5z15xUWnRZSVZBtY8sCOjd6njvFitWlm+SKMYOfWs4ruVoPmhMt0txGNrhdrof4h/iKp6lCLdBME8xSDvCHDKcdR/UVds9Qtyx3yx8jKgsM7fWqmuzAWdyIF8xnjJUr347e9ae7bmJ62OI8Nf2bPLOuoO3nyk4aTI3LnoKvTeH3inM2kytak8h4m4I9weKyTKILe1nli/dAnJbB+f19qm1LUriTRDe6VcR/aEO1lQ5wPXb61zptaI1ki3Hr+qaXMsd9MLuF3OWTj6AnsfSu0trlL+yWSFgX7N02E9setcD4f1KAxrJfCFLluqHpIvqR2NX9I1WLQL1lu43XSboh45Qd3kt6H1X+Vbxk3o2ZtaXR38Nt/oZjllznqay9RZbR4nJUxyPtwp6mn3V3bS2m+1mjdGOQ0b5B96jNvHNYslwXII3L2xitXZ6GfmQ6vaeYUlhkaKb+B0x+R9qjS6YIG3q0+3kL8oJHXip9PgM6urP+7OCBnnpyPan32iRGDe8rxANkupHTpkj09qjllLWw72G38kMmyNkCBgCdwww9qypb0WkjLHGrRopAA6j2rRubaO/gJQyAp8qupypI71jLbS+bslO4EcSEDBNctdyWp00VF7kEFzZ3DO5DKSfu7cEZ5rPWRLTUGU/JZXDDDEkBXPb8euavXLQ2e8zIWVu64JH1FZ8EtvqkbWzENbMCGHcVyN/wAx2xgrXijSklW1mknB37EAUMc7vWtuyvS1oJJIHSSThQf/AK1cdZpcQ3j216cxwjFvL1yvofeuoleeKFAjknAIyP8APFdNKVpaHJXirIpXs81pG8m1t0rfKG4IPbH1p+j2lw0MvmpIkrNuLAkEjrite3lintvtNyis8PzAleBT7bUIJJoHiRHV8jcp6f5xXTZNKRzczWhI06x2zBGk84ZDcE81TguLi6VI2UELktgZwe1a8p847Vb5QOw6E+vrWO5ktbs2lltAzuYk5Jz6VU1YSfRiaizQWbM8ZaYKQhHHFR6EftVnJcyT75FGxNv8PbGPWtC6ngYxq8il26kgsf06VDbRR2fnPHsjE5BcrxuI9qXKk0NO6sVtM1V11ZbOfYNwIDeuP5Zqv4l8y2un1GyKtGP3csZXJ56H2qfU7GP+0YpbMkB13Ssx6kDjHvXP65d3cUFxHNkxR4Jxzkev505OycXsEddVuXdO1mdzFBLCYEYEo27IJ9/Stq0nWa3FrGrBxw4P1rhdCvbZZ5LSZ3M2P3L5GcHt6da6bT757O9t4rrYkjZzIBnIHr6Vzax0ZvJLodLFZrBJkIq5GGXqPwqjrAZIsxMzTTNsigJ6t2P09fap7u/CSB1ZGi2/6zd0qMTW86W97IVRmOFkOQQTwPzrXmivdRmovdklpfXVvpaf2gggdTtyPm59R7e1XLSWa6TzJSChHyuvG78O1Vr20neSLcwZAQSB6iqV+JLWXe119nR+nO4MfXHY1qpNNQeyItuSWunWktsrIZJQe24qBWNqmjokTyK0ttIhyP3hKkfyq5putxi2eBWGUXC4jKqR7/41Q1XWkYxxXLLH5gxuznB96mok1oODdzjb03VtdoWnaFRlP97P9KzbixuJbWKeGRyh+XcG4UqeTirurrPdXqwQqGCfO7Y5GOlWPDqkRXVrcOPO3mURkjAz/D9e9Zv4ToT966Kp09GxJI6smPmVuC57das2ukQo4uJgzqCf3akgGtg6WphmdsYY/KAMke4qeCykt2G4kqeASTkH/Cua9lc7HVvoctq2hJDDJdWjszbioG3BIAxyK4i8IsLSWOFGbecmJhg5r2C/hvW+zwwQE7nPmMO3JNY93Y28nmwXdosj5xlhn8R6VrGSvexipzSSueHRagYL9pZSVDEhuowD6Ct7S76IyoI5yschIOVwTjocVS8c6BLp9+JHRmgYEq3bPvUGlxT3OlrcRRnzY8lcenua6XGE4KSKhUmpOL16nSNcWz62tvIGccjcwyC1WHzaagLq2mf7I3yMucY9TWHLM9zBAkxEDox3MOpBHQH1rU0qVIpGimDorqNjuOp6dPSsmrJJGqkpts3YNVltZVhvVR4LlfLaTJAb+m4evcVt2bTQR2slsJZbZn2SKFyYwD0X0yO5rl7drX+zp7a5jPlRS5ZN+4keqnscdDWxoOpRrdzWMVwfMRRLFKW5dCMf4U0tLnFU3Os1qKzW/hkt7eeONUUsGGRt45PcVp6c06WyCJC0YOQ6gcA8kcdqyJ9QFxazedcqjpt2qzAFlxjoetdD4duIIdOMEXyuTufBycn/AOtWUlqS27WLJklMe62hyHHz7h6dxTLGNfJLPnz4iQrdsdvypkKQrOU3SROxJDLJ3+lTpb3CkhG3HdkbuN2KbabRmlZamn9plhKT8MpXbjHUfSqmqXttaAXV4ywrjIyeSfYVWv8AV545fKhjV7pk3ZYHy4V/vN/Qd64DW5o5zJdajeNcyp8qBB8pI52j2qpPzCKuddJ4yw4S1sT5D5D+YQG/Af41s/2jbyQWksU+VlbBR+Oa+db3xRcfaQZAVhB3ZVSMjGMfhXReAtVSNmvNaVnjIxbgtjAz3HpzWiptK7CTV7HuV5KReBl5BINZ3iKZYNNvY9y/aCoZEY9d3G6orjWrNXjkQq6iEMwHb0GO9ecaxql5LLdW1yPPlMgPmZIbbngY7AA4qLa3CKudfd3UFm8OXAEKLGpA4xjnPvzWhpF2JgRjLKT1OVII715++pHZAbvc6k7Rx1IGMYqxDqbW2owugkijLYIJzkH+lRGN3c0nHoQ3V8sMVzbKjMEcjafm2kE5IXrW5b6baXFjYvEgVrjkbDk4xknI/rXM6zGLZ7m9VT5xA+YDH3jwD611PgiN4rLcyb4VAfI6qT1x6CqkuqFeyQ3V9Nhiu4ZkjLkfKQBy3oc/zqxFb3fmGCCSJ4vLZ1DvnjuCOwrW8STm3FsLONZ5ZXyqEZK/4iqEejTQySy3DRLPOM/KOAO4FTqtRXuZOnzGzluJ7BZoDk5ROQMdQB0I/Kup03xHDdRZvJIwFUZblT/3yayJrI+bOfONvC3yBEAzIe2M1j65pMdukZnu2ZGYF3m6lepAI71anFkuB1Ooa/JaXUKaWIpmkXcTn7q+/vXRW0V1Nax3F3cRyqcOqqpVOa860s2MkaW0W2J3B2fNxIPY9a7TTxqFjZQxlRcW0XJZflIAx27j6VaeuorWR0E8Bl09WhIK+x4x6Vg3txDFJ5D7sNgYXotdAb6GO3ea2dZLVgSVA5X19/wrn7t0nkDQxDZtyGx1/wAKyxdrJrc1wyu7MxNQh+3naGJOcKx6/Ss63iaxlJ8tEbBXJHU+vFWzNOly7FgoBwMjPFQXc3muHk+bac/LXBzWV2erCDb5VsRtFdXLFg2FByCTx+P1rdtdXt1QJJgNnac+p9PrWTDfCABvKBibAJJ4rStdPtmvBOxBOc4z0OOKcZtamVeC2Z0Vs0ZgEEAiy65bJ4x/Sq9vADb+aWZWjIjB6HbnqKqTtBb2YEL8sTjB5amwXLnMbsEUsgPfdgZ4xXZTq3jZnmzp2d0aWq3CJaslvIyOGxnH61DawGzsWu7mbzGdeMDLH6CpdXsorq3jt0iKICHEjN1P+fWorTThp8G4QSPGRgiNify963trcyb0K93bXSxwPEqxQOfnC53KD/F+HpWfYzy24Y6nG82w7EJ+bJB6nHT1rbmV5mEMsLmBB8is2WII7+o/rVOG3RUFtIWgjmXGzvwe3uRwaJK4LQo3d79r8TWiwXO14cnyH4G0r970P/1qguXt5/OjuPMcshSMt3+v1NGvWNvJdwNHDJEUO0SRuQw9sd/xomBS3WARh5Yx8pcck+uB0qXJ9Ckrg2kacbJXmVPtG0BXGAdwHauX8RXssECWMlo1tIGC+audrA1rLZ3C3sa34Hl8lV28HPqexp3ivSJrm0i8lXd1IdGOcH/Z+tVFczQX5RNHtprOJVuGaa2Ch9xBJA7kDv8ASu3s0tnhSdZVlRvmTacqfeuO0S4vbq3hFxKY54/3ZjRMDp71v2bPEm+4gFtk4wnRsdziueLSfmazVzWvdXj7vs2jgZxmuN1bUp7+62RoQEGSAAwOeh5qLXbtZJpBEpwnVSMZFYd/rJthCIQWcLtPrj3oc3UlY1VL2cebqzodDvdMjjy8gMjEuWPzYGeBVTxDdW9+xSziaaUnCLjA+tdMtjaW9m0NpaRGdsgJGPmdj2z2qzp+kQW67LVIxK4w5xkA91HtXXy9jiUtTnDp01tpsxuJIZb1+dyYGRxxUPhbTrW/uLhJwPMibO08Hd169xW03hWcTKs04de21snmukh0SKK5zGMIEA6ck9OtCpyluhufKrJla002MzM0gAVANmB0qtfRhmKRANsI3Htit35YR5UeTxWbNGqs0kodkYdulTUpxUbIIzd7spB5oJ0eCPzYWGGUnBHuK5vxPDPDP9ot13R/xj1Heul+2xSXAtwu1icAVsSaZDNbbTjn6VzRpSm7Qd7HR7RR1kjx7xZpkGqaW6ptGcOqkjg/jXCaLFAY/s00jxTo2Ni/Lge9ereLtEaywJ/lUn5ZP4fofavNdUt/Lv42kdrS7l+5wNjL7UU01eEjo542UomVrVhcaZcRrdJ59nIdxdhwv0NWrC3too4WE8o2fMEzkn2zV64tNREU6Txi7tkjY7A+1xnuoPUe2a5ddYSztmTgl8KA6coB61slKSsCnGMrvY2dY1CFFVI7cKjgY3d/XFcvpguBfG5tn8sw/cPOCB/OtbV40/siA/aPNVm3BSRg57D05pth/omnzsVVJMqV3Ag59v0opy5E7eh31acJxV15m7DruoTwx293FCgkPyswBYgdceg7V6ToFjf/ANiRXEReOKYBVAG9yR0PPQV5na2yi2juLtowgHmPkdfY59xmtCLxzeae+nJHcvc2Epw0kZ/1PP3cegzVytNWSPIlRlTl5HqWnQ31urR+UFeP7plK/N9cZ/OuigkbPmyQlWQZC5yOnOPUVytrrn2i0BeaDzduR2JwOoqpc+JriG1ZoN0znKrkfL7n3x7VzRqdUipUJPQdrGoY8O38kInFw7o8pJx1bv8AQY49K565nt5dLeRlRrmdcRtDygPOB7fjSXmtw3TSPJJJNbeaDtaQICcY6f0qnrXiOy0q2S0mjRLe4bZgcYPUYqkm3bdhyuK12IhbW0lgjzmIsSYzhfl9u1Sw28LaJcTum61VfLBCAAMD29qyTrujwWUVtLOsdzM5BY8lR7+x9a3ba+afw9PbCMLboPKBbHzqpzjHv61q00rsi7bstRul6mYra2eNQ7REEOuMOPSnC+vmN/CfKX7SfPRwgLA/3c1m6ZateAx28BWNHLiRzyM9gPStF7eCF0kiVnYtsY56cdfapdrsrlSWpm63tTTomJPnY3M2c7mJ6e2KY2oQ6jpojO6O4iHPYtj/AOvUPiOG8tiFyDGWxgENk/hWA63EUzMAd2c5x830rSMUxNs6Tw5ftehxfoxI4WPPUg8bs/ga9a0yaCPTpEVAZlBjYAYwPf2FeIPOghjN0rhp2BkdAclfQemK9R8PahaX9hF5E0b7YMls7SccAH0PrU1E736Gej6nWaNYbds95lrnylQAD7oHXFN8Qyh7c20aiSRl/dKMZDevsKo6e96dGht7qdlZedxbDMnbn6cZquGOk6skkjSyO0YO9sErz6eg6VOmzIaJI/DdxJa/bJtUVpZEUgNCD5f0zVW08Ox3dwZ7+U3jKpCsxKg+uQOMV0qXayI6S4TB3lSOAT/k09YY5Iv9FQx8Z3g4GKrToGpgx2GmhQGsUjZDjcAOB25/pVq1mu7B9iq09spDBidzIP8ACrCGG0idHcGMHLF+uatmbbHFJFhmZRgA5Bojcl6C3UMEsHn2REcrjdlOh+v+NZc108dsm63KSH7wJGKtNI9tcM9vEWXG6WFhg890P9KbqFzb3cirC4aNl3BgO1Z1bNXZtS+JaHIapeqh+XaAT971pbj53hkEjeWkeGUDjJ/i/Cs/xCIrdmiUhXc/ec8ms+612Oz09YEZQwG1sjOfb2rigtGz31ByUFT3NdbsIPk2PGDtxjcAfU+1XItRkZTFhXu1faHU4VY+vA9a5ex1qCWB1WQ7+hjcZCn8Oo96vWcqJA0tqm2UkbwT+OM00uXRE1qM27zR195dieylXBTau33/AApNH+0Wk0kckRuE+8Co5zjp9D/Osa4vLUA+Yu1gAcg9Sema39Iv/K3BYJpGABYqOAT29acVZ2PPrQtG51ctwot7dzE6gja6ntnoT9KmknMMWIdr7hnBP3eOtVYbpQHtLsiM7QyknhgfeqF5drbxsIkDT52sTzgdjivTTtqeZvoRfb5pm8kbxKSW2t/EP72frVK8l1CW0ZVihnVTuT5uB759RVmWVrq4gFkrRpJjLgYLgDk8dBQfntCl3cPJbwkDKAA8djjtWb06lWsZ8CXMd0JLkGXcRjaRhQOxPrmoNdsL15/tMU0MaqQwkBwfxqxfvezsgjRIkyFVCvGO2TVGWSaO7Ml7PGSCQbcLtwAPT+velfcrVleCS/e4SK5ZnhY481uv1rpEvBY6ZJatcxg8hXk5wTXH6xMkeoW0SnZIB5gLtjYp52tn9KlvmuLqOMGCfJYENAdyt9c80RTTuJ6qw+O4LRyXcSMfmO9N3K4/iU9CKujxLaR6S811Lh4Y9xJHC+n1JqHRbETrNExnQLyyyHjH09aZq2gWtnpN280x+yOhD84ytDipOwOVlZnLatr91c2ckktl5y7D5yK3KR9yR347Vt6Z4ciutMguXnYpIAUATI244+nFcNosi3Jlt73VT/Z7kB1S3IkdPdsdO1eqWWvQwafEIjGsAwihx2A4wB2xU1FytI1jJ8vu7m5psM2nXf2hlPlSD5M9QD1J+tb9nF5jieMYG7oO49frTrxVmBJ+7602wuIYt8cJ3AHJz0FehC0ZJdDjauXEt1jkaXl5WOcnHA9BQVYsQWO0+wpY5lddwByemO9VriZ9yoDye1OTSVw3FaN1JaEqW6HccCqV9NLFCxeJMegOa0Ujbys5O4/pUDw+ZHtkGe2axqJ7IqJzdvbmWXz/AJCQe1dNazAgEnt371mXMMdopYkha5TU/FkVm2y2HmEHnOQo/HvXFGXsJanVGEq2kVc7LxHYR6tYS2ciBkccn0ryTUfD91pO611WM3OnKCUm27miHYGvSdP1c3FpHMgUiRQfl+YZ9Khub83LPDdxD7ORhi3I+hrao4VNb6mUJSpuyPF7tHtJIrcnz7A/dmwWCD+7mqOtadaWNk321BcW1yC20YwpHQg9ea7PUo9N0eeRdJYtDI3MDPkA/wB5Qf5Vi3nhzek11ZNHOp+9b7T8hJHGDyM/lUR016HRzqbszgNEjiubWSOMg26yKyrIcHrxz3FdFqtuJbYpFE7WoPIB4T/61X9N8NyQebbKqxlmyQpxtBPPFd14d8Holvc/2ldCWKcjcY+MKBjBqJ1bzTR20pexpe8eL+Pb64tdNNlJIGlkCNuUchMdK5rwVqNxBrEVgkKSC7kRGV2xkZzwa6b4v6dJb+JLa1sba5+zEfKxUszc8e/SsfUPDNzHqk1xZ2lythAElaSZThRx1I988CvRockaXK+p5WInKpO66Hsl1bSPcxC4QKgAf7PFyQc/xN6D2qLWwkGnSPFcPEhyqAc59l9K5zQPHk1xHfaXEkaHaDHJISSwHDL9fSsq/wDG+n6aEtZo2M0c25o9v7sZHX2PIrkVD3rWN3Xly8xU1jU7mw0p5GVRFCRhABuJJ+99a4PX/EFxrlxEZlCJEMKq/Mfcn1Nen+NbjT5vC8t9bNDMxChivIkXH+ea8b08hr4EqTg5wDzjNd+DgnFya1RyYuck+VPRnRNBbhrCEzIZnCpJubgLnj9M17LDbwM2RcMIhH5YRBwcDv68V5TF4XkvNTa4adPLLKRjrnj8ute1aYFeCKWCRd8Y8vkdCO//AOuufFtO3Ky8Onq2jS0fSXitjtkVRtBXjplfu/lTrvSWltjEf3TooYoeOPX3ot5Zo7UKs0jfMCN/8ZPbFdJZWylyb1m3oAgUj5R7D1rkUTSUmjzrXYJGMCwRxxyRnEmBjI9R69jWNfabfeesjQjyycbk7+mPb2r0jVtOtmnvIxmQMo8rB27Cev0rMjaW20qS0vIXZlJQH+H2Oe2BzVKVgUupw0Rl1CdbHT1HmIcEEAE++7t9a73wfpml3Gm+Wlw8F7uxIp4YODz7EelciLNbW9EMLBmwHlKt83TIJPuOa0bHUJdK1BZYpDPHK3zI65yKUp68q2NvY3jzPc9Y1Pw/Jd+RPbSqtzCuCRwJh/dPp061fsore/RVmiCzR9VkAyD3xXBa3rE9rZp/ZdyVW4OfLY/L64IPT8Ko6d4z1F5VE1skUwlBWRAWHoVJ7A1XNB21OdUqjV0tD0qSwiBnkV9wb5WA6+wrOmutgZCfs+0BYwvC1Zl1aK4jjmtGDI3Em0Z2sOo/Cs3V2M8aszDyywyh6tSlJLYlK5BNE8doyqfO3tneTnGeo9xXC+LvHk2hajBF5vl2+4RZ2btxHqOuK3lupw/lRhSxO1Y1OM84z9K808U+B9W12/uLlyYorcMZSTkKfb24q6PK9ZCnzJaHpOpazLd2ENzp12JmUZdUYHYfSkW+k063TUFSWW3uMefEeqMf41P8xXAfCdxcQXtj9oZpbdf30jDAQZ4wO/1NekaRdLLYyaeY45ZQdoBOdynvx1rGvSakdFGoklcyvEl/by2IkeBDv/hYAkH0rx7xLfyQXLIHbC/wngV6b4k8PNaLI9kZAuS3kN93J7c814t4smmOpMpVFA+UjOeanDU05cp9Ng6kKdL2nV6F2w1KXKlAyueMr3ruNE8QyqmJT5m3odvp6HvXk1nO8bbcjd1JPpXR6LfkkJK2FT7qjpitq1FWuegnGvFJnrFjrfnO6SorGQllQ84xjnNdLoGpXaGWRpgEQ5EYwB+PqRXjsV+EurORZmDMSDGOSFrd0fUPs11JcCYAMcbc5wc9/U1ySg0tDyauDi+ZI90Wxj1TzW1VXaOIgoFfGR1zx1qG4G62cTCO1jDeWuOSy9j+Vc7Z+IrldPKwKZJDgtnGMHoT/hV9r27k8n7TGFdGCnH8R7GupO8Fc+anBxk0X4pUtrgQQbisagMO34/4VTk067YvHb3TLDIcspxyPY9qmXyoZ4oopv8ASppPMO58kKOvFWJo4GkilSdfOBzsQ5Q/X1pJEt2M0aa19qyAXTwFCuJAOcAccd/Sr7+F47a++0TTm7jdeWb7wPqPSh5iLr98cbFzlRnB96kuLp5LWHG0xkF92MckY/yKcXumF+xT+yWCLOrQIwLFiH5Lkj1PasyKMeZD56eR5bKoKqR16BR9O9aNldmS3iW4Rcy5Uyr2IpzxiSWE24LlW4Y8nA65pase25YuprKVS/lAbmx5u/bkD1FcB49vYrx7jT7R2lBiw0avwcdAD0Fd9qskSaXIBaiQiLczjG047YNeZaXY6br+tvJqSzxOQWjUvt3IOp4xmtJS5YczCnHmlY1fB0uqJZyRzaMHDqEykyjoOgz2roL7w5O7L9maMAgExgj5PUGsj+zNHt7qSEpMLUt8pEzDB+ma6OxvUC7YtsaY4VgDnHGRzXLKcdb/ANfidHJO947HbXTBQTxg8cGsuFY2vCZV2nrgEjNN1bVII7Rp2kRYU+9n+VcJN4mS7vG8q68nbwARgk+2a7JzUXqctOnKfwnq5dcAKeR70iKpfc4B2jqa8XuPGV7YiVlvomC/wyDp+FcDrfjvxLqyvFFqEkVuWIxENuf61Srxlsjphl1ad9j3XxH8QbOxuXtdPeOeZOHwcgH0zWBL8RL6FP3yQliOAF/pXgCi/GWidw6n5mBwa6PTgGQPHcl5OAwPJVvqa56s6l+bmPboZXh1G1RXO6u/GGtarexfI3k7sbNmM/SpvE+oj7CY4lgWY8HAwVP0qnBeqltGSmWU7Wk7q3r+dPGky315HI/Eec8jg/U5rjcnJ6g4UoSuo8qj+IeGkngTz5jOq9GjRzg/gK27K9mu714I/tEViFyzv82T3APvS3NtPb2Y+zEKZDt+VsMSeMD/ABqW9nl061+yxqS7DLHjAbvVQbWpw4icKknZbmpdRWs0CBlTYOhb+nvWXe6aItslo8mSMfu/vL7n1FRaZM0lsAQFzztPer7SD7M7IAz9OM9P8apSadjkatqc/dXFzZqJXjLENydoBz61teGPEtm0hWQSIyAsVI+XPc1QlimnkH2hEcdOevtVs+HmuZI0ICQgZIAwTSj7r2NpyjOCUjYigttT1A3mnuscMZLvhQZZnPTk9FrNufDVwljLbygypcFvPgQ5Doeq88ZH602w0690e4aaHbMjYCpnBwO1akWp3BjMrRv5YPOf4eetaKaWiOaUHunoeReO/Do0nQLpvDFrsmjYeZtjJlCr1ZT2GOteQ6fH/a7y/a45pZVAIlBOcehr7C1GW3FmZSgy44OBzntXl+s+Briygn1BIVKMAAsY5ILZ3H6dK66OIcU4ta9xKEZu7enbuec21nf3vh46DpPkjnPztjIJyQD9a0PCfw8Sxi+0a+oEwYqY1fhVI4JI6816D4b8LxK8httkbbd5IIwc9h6GniA2hEEkf2mTzCqkk7lH+FOVeSXLDS5DhGUuaXQwbG1WziliuSiQwtsTaQTjA2g+49a19ORb22SEl4vMfczA4D/3Wz3FSX2nCz1Q/aiu25gVtxHyhxwcfpUumBGlkOzyxGNsOOAp9fxrCTV7mqfu2AXFzZ3MC3YAXzVHmIwYn3A9K7uzu5J1K3cqF+pyOVHauIuGS61K0iAZ1R9xcL1x/wDXrpLaE2skixok5ce5bJ6ADtin0M5q5varLYp5PnGF7odMjke59q5TxgqXV0YIELxGPeXBwFz1H6c+1ZWsSXDX2JthudpgSJgQy55Lf/WqXTipsRbTb2VFwxPy7hyWoempEY66nD6xdX1vq9tEpKR3SYdgB/DwPwxXe6VbW0sUCxrkuoDsw5U++a5fU989/prSFAE+UEjlhngt+ldGt1Z6SJGlV/tDKAEHUN61zVJ3Z7MqNqUe7K3jJJLERtFC0sRcKWTPy+5FYUBu1uxDIrKl2QDj7uPU+nNdfaXt/qLMlxp/7ub7xkbaCPX1rQFqklvPHZ26ySwkefIo+WMAg7c/xNjsKcXzOxg6ssPFwfUk8NC6s9KgRrZyvljzuctkk/Nn9a6WLTprm1SWaRI41QhWXkn/AA9at2oSLU7hWXC+UHCgYO3OOBVfVrl0kWK2yIHJ3ZUnB7CulJWuzzZNt3MmCxhgmii8zZK33VJ5b3HpWbqultNbakEvJU3HlTkDH09BWvJNYzakvm7FvU2oAW+6e1RazeOrPBb27SsT+8JUqAPr0rFycXoXGLloeeeC9LtPDt3fEMj+Z+9lLkgEdOcfyrX0vXrL7dctCy7yA0WI9mSOoX2Fc5qlzdW+oy3NzawvYRMvnQZyW+bg5qzIiNcEqNsDESoQpBHPINE53+Z00qC69DT8aXrXVx+7uGAADEpxj39hXh3jKNUv0dHDnoeeSK+hRNBcQbUt287plxgY749a818ZaZDcGYgDONwDDmihNwmrnrYdRqU3BOx5A0+4ZzyMYAHWrMNy8O0oSM+tQTRD7WY1XgE7vb2pXYK+B06YNeo9dC6bmm5N7OxuWOopcyxCUAFWG7PGQO9Xn1jaMR/KV+UY6Y9veubEbJKuFITGc5rpfDehyareopU+QfvEdTWFWMIq72Oygprmcnqej/DC5n1VGtxE3zHAY5yzex7YHWvQWuhpt1KpA8qAY3v8xDHk1q+AdFTw5oySGOJSGywAzx/+qqd3Hbajqk03lwvHA23aRzuJ6E1yRacec+ZxU1Ks1HYy3aG3AvbiYOZYw0vU5zyAPTjtXL+IviALe5RtMi3A/wB4YwMdhXUeK447M3CvErYhGyJRjPPLEe1ecp4ca6jeUsxQgtGi9SM9a0bUVqPB0oVp++7I73wB4ufWZnhkhdXlxukLbgfb2rorjWQt6lpBbtNEp2nYM8/7IH9a8d8O2WoWGpTSaesrFUJZIwSVXufrXqHh6SSPQTPaRAy24ZndjjJP8T/4VMbSuTi6cKU3y7Drjzp0c/YFllil/dyRyeWRg9CKsW+pG8dYLfzLaYFS4YbQMdPrTIDJZ6YhLRvezfvXBQlT/wDrqBo765hjklVFiT5g4Xt3Ge1V10Oa2gzVZru+06SOaTy7l8xqkYx0PDH2q9PpMg0qweWHzp4HEm4INyDHzDjtUdjfae9zc6jINibfIhRRkEdzjpz/AEqTV7+8l8N3ENsACY2WN4j7cZz61lOXvWNIU5NaGbrrJLJEsMsAuJAVDyY25/r+FQW7y2srfaGj8xVCDanb6HOKw9OtG1G2nu5dNuPJWAW9pAwxtbu/0B710txbSCONp/LLlF5B4HGPz4rGpBJaHdh6rUuSQ+eJZElhv8hguQpzgt61w8oMF3JvVJN5OGk5P09q9A1fULqRFBRUjB+9ySR71mX1hYXEaFY43mcfMqn9R6Vre9zmpNU3c5PUtIe6t90ULZYYLbuhrBs9A1CPUFRG2jOGJGSF7/SuykshCZTDLKnkc7WbIaqd2dREcaoMTk7gT79efSldpWZ30sRK9o9TnvElokVxCiPwPvIo/wAKpSGK0s1aGUKznpjBz61a/tu6tXYXaxzSqxyF+UVct3s9VWO6lmgiEbYMTrw3t9KSTS1PQ9pOHKprT5mTp+t3LSeUhVlJ5JbjPrivS/D18ILNpbuKR1Py9QcD2rgpbXyL8G3+xFWOWQDgiuy0K5toYGS8tYAFAJbzT+lDs1ZHNjbSUZKJrK8kri6giZ4k5KscYGfvYqxqIt7yESMxWVuNv949hXI33iCzvdTKWrsilcFTu6emO9bdxpz3mk7/ADWQKMpsURsDWfK1ZM4qsOW0rWbLnleTaqiSKJMfN7fTNVxNPFayFZC2OQMd6wV1PyvLjaQySr6jBrW3tGVKSxdt3PY+3aq6mLTLWlTSXxjlnQxgHBYdQa6ZCYZFbduXqDuzXG3E7WJKxyGSOZsgdh+NWALZ4G827ITG0jzMAemD61VlYxaOrub+CPcDiRhggDnntz61Wl3NbuZH3g/eB4/SsqJSCEj3RZHytn9c1YmPlpumJYMPmIb88VL0GlZWKXnTNDc2tq/7uMqrr/vn5fpW/Y3jxwHT5yn2iOIb2ySMZ9ffFcvolxHcXs8QWaDZ877hwx7HPTgVstJHIrMrFUJHmTsMZHp9PetHK2hLhcm1GKK4ZbhYvspHIZB88v4dMVWvFt5lgutrRzKR1+8MdQR3+tXbW6VInaPcMgurt8wPoB7VVgiTWNTAJc28BLLcKer9Cg9QKSd9hWtuFyDNp7O0MQ2Kec5BH+NVGtLaK0jubYbkAV2Vud3HcfWtC8ezjtVgjuEaTbhowM7ifYdKw3ubh0nsgAFjbcCM8rj7oP1p2BPqUraG7mvorqyCSIpZHjzg4PXHfPeulsdXt7Z8vIVXIXeR83HABI6+9YKYZbK5053VyQsi4xjb1P8AQ1Pp2lprt3ci1zFbRN8yA7t59c9vpWiSZLL3iRrSTU1uIowLvy9gZ+Vb6e+KwdPuJYJUFyUZz94MDgg+59KuahBd2csUEs6kxngSLn5c889hVWNFS9JRGniXhoyehP8AFz0x2p2BO2hFqOlXEXiAWl8QkNwubdjyM98H1x2q3JdWGm/aLzVpEE8eId3Vmbsqr61r6vfWGq6P9jmE9xewEMsUH+sXjhi38OKwrPS9FNgsqafImorJvV5rjznjP94Me9ZSoJu7OuGNagoPoaekxa5qsPntZtptrMSEMzDzWXGNxXsMdq7TT9LMVk0NjIqIIzuAGecdc+prz/XfGNnZ6DdMLq5jMAG+6Ee5XPTbx1yewqv4T+JV3d2IvrW2tri1LFZYdhhcMPfJBGOa2p0be9bQ4qlVzPRL3U4reWxunby1a3O5vvYOB0/WsvxH4gCaI0MWVv5wSiKpzj1/Gse68TWYi0VfJVbxn2fZ7rIAByC3HUDiodf06OG7hvZTJLK5AmlIILEdNo7YGMChyUbORMINlWzj1a+229/BBOq/dl3MrxMOwIHP1NXJbHWZYT5+s8R5+Rk3oB9TzUWr+I5NG0q5nijWW4RMKGYAnP8AFj3rnvC3imPxLbS3NtI0FxBhZUdshse3vWMlNrmSsjqjyuXL1HXLzIl9GZHuIXaJzmNVeP5uQuOowOM1t30tpHGXK7vl+bBwRx1P4Vk61LaG8hS4hfz5VGETjGMEkEHg45pJ9MuoY5YvtgX5gEBXcDnpn3xWUtbPY66S0dyf7XDHYW9taXsjzTDciE7insDj9KzrjRXmdftNyUAB3grk1o2lrDbp5SweXeKSX53fk3v6Vu2cS3sEiALK6YXfnOe/JrKUnF+6d9OrCMbNHgnjLRYdNuma1XbH1yGzuz3Nc1DBHLIS+frXrHjvQJrtZFjjJni+8vPP09a43S/DNyxRrxDbxFj80nygAdTXpUa65Lvc7KMacd2mjNs7R7hk4JGQAD3r3X4daTHY2iT3sTCAEEsvOfbjpXmFrZ28d9EsVyjFSCHB+U+2a9S0fUBp9hDbkRMpbcHc52r/AF+lc9efO0mhY+pejy0nueh/b5XlBQP5DDCAphQPUk1SuNLe6U/ZljhjaQyyoq5Ehx1yelU/EOtOIbee0iBGA7sBksvfjpiqg8Ts6pOfKS4KExwA5CjPBI9frQned7ny7py5L2K13omoQzuhjMzM2YpWbkKOgOPY1oW+lrJBDFepBFIvCMMhmUcHnv8AhVJdZmjtLiS5uTGpO4yS8ls9h61DqHi3S9Umgtlmh/djZhJT5iHHUDvWr96/YzSktOp3XhnTbfSjM6xKpnXcuDklh1/MVmazp1jawyyxyTRM7FtsZ4z1yc9cVJo9vfR26N5izx8ESbgNw7bh61a+a5kngntN0MAChiwGQauNlGyRnJNyuzmLHz1u5L65lW5ikXarBMFvem6tNjR5beyZIZZyV4k3FAPUep6Voi1hsbhyJnjEp4TIwnpgf0Fcj4snE9432JlMa/fuCOWOOn0rFycXzM6qFJ15KESrYShdLillykdod0ceNwb1B/Gln1W4/su4fT4pNwQugIyFP9awL0TrBvhVQFPzNn16Vag1V7XSpSMFogxLngZHauac3Kzse9DBKlFyvcg+1COzvjFeSbTFFKrmYktJycAfXtXoGiXd7caZCrxLI+0Mx28Zx0rg72W7t9ON6dK07ds3u4J8wD19M12ng/Wd1sba9VY2jjRl2dGVhwR37U5uyucdWm+WyjqyawcG18mWWSUjsBwPx9KzLuOA3BS2dTITnoQBT9PSSa0lt2LIpdijg9OwLf8A16vS2lvZ20IuJJDIBtJAABrovZnkp30MZNNuHnxsDtnsTkVQ1dL1bp/OkVFCcMT/AC711kElsymWS5IZV4TdyRXOeI7qTU1KWyP5o43DkAVE02rnVhaiU0nojhNaBt3MvkeYW5JBHP1rmjeMk29EKLklgR0+ldXNZTxS4mnLy8AjaBge1Fx4LlntTNHLE0j/AMPmA5qqbjFan0ixENnI56Gaa9MjQBRsHzMTjitSXxFJdW0cEEcUZiA5xhmNS6f4Zv7KNkCQSuxyy5+WtbTtPjsXiWS0jmuJXyRC5IX6UOUX8OplVxMLfvFZrYpeF4Jby+8+6Z85wCFxXpdr5D3y28ivOdmQN2dn+0fQVxHijWtO0q1Mgu/KmPSBFO846gntWfonxE0+O32RQNaRsvzgMCzN6gmnToTqJyseLmGNhUkrHQa/e6JpetFL+WGJiCE3A5IHViB/WrPg7xDomsRXUWgRKHt8F3mjILg8AivKPizNDP8A2VdWzPNDLAVDvycg5Ofc16j8P9NXR/DdtbWNmLa41CISyvKd5XjlyfYdBWsqUYUVLqzg9pKVS3Q1L2BZPN8x1mliO7gfIn1OcCpNBvtNvIJooruAvgKGIBB9ePWuP8YvrLA6L4fVf7OcESXBJJY99zf4Vxl34Z1Xw5aW92skik/NI0MnQUqdKM425tWKcpp7HtP9u6JFdT6a90kN1CoaZBnCDtj+uK0oVhv9PSKCdHTKnep6815l4A8MtqmrReKtRvzHDsLSK68ygAg7j0AwOfWul0DVIrjUbuy8I6kv2VculrcxblA/i2HrjNRUpR2T1QKbav0Ozs7eGBpknUIiD5cN2PtUggto5W8x1w3zKp5+tYaReIdkh3WjMQMeWoyPQHdyPWtKCweG2eXVZM3SDhw5w5Pcf4VjKHmUpkGrs00XlWqCBGIVQflyPw6c9qmWGWyRYprl1sYkP+jxDbuPTr1yTWFe3c+q65awaYs0cUOW2lchnx3PpW5Y6LcadGZdRu2uBKQEcDKjPZh6D2rXk5URz3ZB/Zpt4GkXfJcnkkD5U9QD7DiuXvfFSwmXy7MeWo2Ij8YAyAR6/jXcTlntBFcsq4wAgOAecAnHavKfFnie3068jhvrP7Tcy/OGjONiZxwO7YzVU/edkhvuyqnjCXzvLWaDyZjlYx95WxyoH06itXSddvtHvsW+10l2ls/x59T2FcL4p8L31x4ihvdF3LDMqSxyN8pix0J9DV24n1HS7WaTy3mnAMZdkyUY8/jXXywaXKY8zV1JHrV3cDUN13OGWT/VsC20HPQe4qbRLe3mRbGICK8lkK5bH3QM9a8v8MeKr28DWllDMboR8seR/ve3NZGiXXirSvFatqM08UKzBrjzmwJFH93PqOmKj2N27spz0Vj3CO5stGvpk1EWayQoPOlDgKueAW780zUdQ03SoZL+5u4V0h1EhcDCOPQY5P0r528T6/c3/i3UYjJM8V7dDcWX52TPyDHQ7e1esXdlpV9oEHhtjOkNuoEUkf3yRznkYz1zROjyWu99yYvnvY37LWvCfxAtdR0lFEFhDF5zrJGI12jq4x0xWb/wi+kRaHHF4avrdbWF2cTxvuDHuWJ61hS+HLLRvh9r8WkXsgnnQPLdTqAwVD/q+Pug9/Wub+DFouow6rYyX7fvYHP2UZHP98npwcUci5XKLdkwTakkzq9RE/iO0gsY5bdr7Ty5ikVuHXqAG7+uK2vD2oT30FoutxhEjbYbokyAOOBke/HPSvJvDt1/Ymp3WlT3gjlW5xE2MqWH+12B4re8ReMtY0KZm060gcTMfO3Rl8HjgY6Z/nVVKPM1FaroOFSyueo3dtEsiyPZwvExKGV+X44ByPXNc9pegwaTfSy6VYttuW2OpQYbJ/MAHuKi07xDaRLZSy3H2a71ECR7dnGQDxjYe+etdvpGoHykYxopcbUQnJ+ua46qnDQ6ISTVzjdQIs/Eyw3ayCBFIIjXdsZh1/Hpn0q7HetDYmCaG8nZww/d4LKueAc9O1XvEEL/AG8PbTRxTSDqy7sH/D2rkr+5uUI8stJdSEq0WcrDzzjFZONzrpO6JIL42WrI1zA4llJjijR8k+59x6V3+kyDRtL8hYgspJkZuoJPWvO7GxMl5DeSBBLb/O/O49ePx612U96s8aq0gZAOqnPFZ132OvD0U9JGLqusyrflvIhdQR8rA8+vOeK8r+J+rtqWokxTlLYLt8pWJWvRtauLOO2mieYtJICAwXHHevD/ABjKj63LFER5aELgV24KLk/eLxCpQj7SC029SudSuo4wq3DeWP0H9K9M8B+NJYLb7PqjwXMMQzGWHzj1Ga8jU/Lhl4x1FSwSsJB82C3BOOtd9WgpxszGnW5pcs1dP10Pddb+IWmsxjSHZCTuUGTkH6elZml+I59VtX2yxSSiQRxp0xnn8v515gsabBtAx79/Y1a0yNmvoliOxpHA6457GuN4aCiz1Pqkl8KR61L4ZSeB7nX9SnlugjeVAspVUH+z9P1rmoDY6ZeKl1H50ZUgSMeTxwfY0mpzXMps11ASNFD8rMpOSD1JP9Kdqui20Ni0kDvdKxBQqfujPaudS2U3v0N44SNGN+r8j1b4X+K7d9OME12hkPzeU+M+ldtrmu2un2zPLGWkZRgEDk44ORXyYZRDMGg81HHQk4NdXoes6neW4gErzFcFBJ8xAq3B0lo9Dz6+UKrP2nTqeiHxZJc3nnXVvIluG+dNucEen41narcNfahJeTBoSy/KgHAXsMetakFpp0iwzXcrmd14VAFTI7ZqbVAjW3msI1QdSBnB9hXHOT69Qw/sI1Eqcdjk7G5TH+lTIvGMHnd+HersSRfYrgT4e2YNvDcDZ6/Wm6db20tzF9phdkJBG0YNO1oRXUc1paOApBQsegHany31R2Snep7NLoZuoXemyWqW327VHt2RVeNosAjoAW616d4S0COziee+kZ5ZlXaWHCoBwo+leY3FzPK4tkS0JnthBJumXG4H7wNej2eqXdnawwM5KxoqZyDuOOtFV7I8+rSnKPLHc5yK11BVdhdNsJ3De20Ef1q9awX15C5lYOi/KUTqR9a5aLXPEWuXSQ3dkI44xhSqbScHqaztTvfHUeuCbSgEt9oiQZGG7biD1NdihzOzkjxXeKvynXyz29nDM91HItumQ5AGD+IrBPjC7v7e8t/DFgrSRJu8wLjju2T0x6VU0+HWby48jXp8xNJsK5AUE9Sa9NltbTQ/Dl1baXbIsixHb5aj5sjrmk2l8WoW67Hytq2v6rc3eLu4YENlgMjn1Nbumz65cabJLa3k2zAVW3cj0GKuWOgTXWrSG5tWMr53B+59qo6bPqlprvlxWTQKGK+QI8fL7568d67XOMlywtdFUqcoP2k3dGrD4d8VCxi33dwFlUybfMOUHvV7Tr/UvBUUsV+okjuU+Zt/zE+x9c16T4ZLT+H5TKTI0TH92xG7HavO/iLpztqsVxI5kbH3WPCn1rnpVHOfJJfgPE6QujivEKXV9MHBkknYZ8ojhAfSuaW2mhuJEYElDg45ArsLwyQ/uWYYGWkI68VzohQvbKS8azNliP7ua9OlJqNuh5U/eZ6P8K5Tf6fdWklpDdRxMHKSLkr7qTxmvXfDs8K6agnKrM4wVkPO3/P8q81+FkSWbat9i3CBogvznP4jH1r0mTSVMECONzxDntnNeVi2udrod1BPkWpct4rS7uTaWsceSMOccCuD8UaBd3GqSae80j2+4JFBCCS7N03Hso9a9J8PaWmmtLIcFnPQk/LVfUoo4bp7oFUfj5icYx71yp8jUka3buiCTSobPw1b6WIvLMyGEgYBORyR2rD8K+EbXwtLJLZM01zJ8v2mcDMeeuxR/M10ms3qXHhqW8KMtxGQVUc4K8nH1HeuA1Lx3DrumX1loVxcW+piMsk8iYQgckA9j7mtYqcrqO3Ui6S1O6Ovx6Xdx2MFtNdTSMQZNu0Djkn1ofTpb95ftZnWyUhhb7+OTnvXiPhL4i6zZ2D2snkyXMUhIuZ+WPsD3rUsPjnqUOoGHVrCCWEsFbYcMpz1FdP1WpF2Rg60ep7ejR2sqGy04iJV2odwUH2qLVdbs9OjB1ab7HBIrKQ5Bw2ccY/pUmhXcWraZDdW08csD/Oqk42+2Oo5ri/ij4OvPFeo2OL2G2tIoy0pycAk84rnirytIvTdGtNfJMhlsnScsvyFTkYzzn26GsvxLeaZpwQX8lnFcrEZIkcqCcDg49zRFb6DYWVrpdprUaziMRSHfnzCccE98V514j8Aa5qfj68bU5Aumqv2h7jdndGo5RO5bjgds1pGlGU/edkhqo+X3dWJ4K8T3fjHWLm11KGJB5fmGWFWzGAemM4rudJtJ7iza7u0jkMUpVjnaR6E545H868x8FeM4/8AhYU0ttDa2OmXqmDZgJtQcoWI6tn+dXPiJ4ydYbrw9aRrG6OBPNFLw56nZjoPxroqUJOajFWT/AiFZKN27s9S0SPT3nM0MMUXmE5YAAuR9KuWHhu2lvbvULi4a8nlXaVmHyKOwAPXHSvP/AkAsfDdvAr/AGy6mb7QrBtyqCMYz68dK7Gy1G4jRIZ49oXk7XziuCqnCTUWdkE5Rux39g2lneLqNtawLcRkh2aMNsPoO4qybv7Xe+aT5YXAV44ycnvUUyyquyVlJkOBGW2k/wCNQ20F4k8htJPM2vyxwAg7g49+OKSbau2JxS0Zl+OvCTXQZ/tLzWrqN8Kgx/MemfWsPwp4QGjyXUum3ssc5wry43KOM7ePeu2tbk6leCw1ZN0UUgkKoxw5x8q4/U/hWndXFtZaXKirEgAZRsHCerEVrCtJR5L7mcqTbvbU8o8TWeiXE9rrOoWc0bklLkxghSQOGUD+LjpXUMLTUdATXPDtwpsjiC7i6PuXgPz0OK4vxD4fv9TiFlFeyLZSyqbUSngu3t1Hr+Fdh4U8Nv4N0j7Hf4uIZWwxXPzSdMKPSujmhKCd9SKtKdKfK1oeffETwlqV3rMN3YiO4jniURoZQrrj6/zzXqHgYaxZ+H9OGvxAXIJV2Zw24fwscd8cVBr+mSxzR3i/JBGAoifrFnrXQ2n7nRhtIDIMjaeCTycZrCtXlOmoFUqcYty7kGswWMhVZP3cr53bs8elcVqzxaVFKtsBHKxBLKSQ3+euK69pre7likiLNjdujJx39K5HxUsZkliVwhXJGeoJ7fj61zUvisz0UrLQu+Fna6LxwyBmPzOoO48H9OOa7CGx/su7E7QQqpU529G9OKwPBWhLpFrbzT3QDf692QdDj7uO9dJq+qxzJ5zJtdRypXAxjrn6UpKLbd9CnKpKSgl6nknxh8Qx/aoILYKLllzI68BE/hA+tePt80ruW+Y8k1veOdSXUvE97PFzHuwPoOMCudOC/Q+vBr3MPTcaavuc9esm4xey2JQxGd46+lSeZkYU8/TpUDbiVycAdacqsMkH2rVrqxwqSvZamraTeZEAp+YcMGqypIO5Tgg5HqKyrWQRSEsCFYenetRXYhRjbkZJrnlGzPpMFW9pTXNuj0Hw/qtnc6SILpnec8uXXOB7GpNNv30jWFJRWspDzGuOfwPeuN0gR72zN5b/AMIPT8K3dOm8xyk4V2AwoIOT9K86pSUW7bHpezUldnVeJ/C9nqVpJqVrBJaDGScjbu9MiuHSeTT3CBtnHrya76x1C+t7OHCJKIlKujpnePXB9Kwta0v+17tfsgXzpDgBfl/DFZ052XLPY5qalC6lY2/AHm3slxPcM8vy7EB+baTXSajqNppmnSrOm6b7qqD1Pr9K5Xw3Z3/hRZBco53DDYPC/jWZ4t1gXpVlLxuQd4Pp9e9ZygpzdtjjnR56qktvISTWLuWd5POYGUYbHHHoPSrNm6TW14s8wiQw5MhHQevFZ939ji0+GO2XzLnG9m/z0pYLcsVTcqNKmxg54wfWtHFbo7FyypuSVjcsbmzgt1zoUknA4MAbHvXXSyXF0sPlHYoTkEdOnFY9ppeoQNAovrGSRkxvdQcADjvXonh7S3somaZYpGcD2x/+uuectf8Ahzx5V40/etr8v0MWHXbewtna+AV/uAYwcGsXU9ShjuoZLXdtHIVhkMfX2rnvE9vc2V9vuLgOCpxkZ3N9K1tNvbZ9CC7CLn7p83g8+ldsoxS5keDB62ZDd3K3GsRI5SGLcHd1+bZjuRXrxhs47GMbQyMoZmPVjjqTXiWk28txqzRvalotzKHz9/I6fSujl8SS6RbrbK+TGCrLK3ysB/Dj1pyilGy3IlFuWmxV8Ta/ZaLrpkZUCltwC8k+orkfFui6h41kj1XQ4mAtxsaNm2s3fI9/atuayi14/a3B5yQSOmOwrS8P38+nxzIqbIR8pyO1Zw/d+8t0dV3KPLumcNpw1CymksA9wTblTOc9ePm57Ct/VNRtJEha9bCx8AD77fX0pUliubnVZCyxsyDao6tg8cVxmohob0Sak52jnZ/Cv1NdVP33c5K3uaD9Qs47/TdVvrSLaoJ25JJx/nvWL4ZskutTvUvGVo7eERLt7E9h+tWJ9beLTri1hjDrPIHBzgADoPfmn+DrR4rG4uZ9wS5k2hsHnHX+tdcbxg76HK7Skkj0Tw/FbaT4SkmgvALmRwPLwDuXdyMdfevUoryO6sYJrdxtUDnHIPcYrz6WGCw8KvbWsiPIg83zCudjZzgGr1lr0cWmy3odZkljU7I+u7GCceleVVvNX8zujHVHeS3MUGnyTSyBVxk7uMfjXH3kqahIjyCUxlwVx3z04rk7/VNW12SK1kla3gJyoVccfj1NdFpOmSaVpcrrdSXN8wzhzlYwOgGe/v0FZqF9mW06a1Wps+JTZDSYrRn8tpG2uu4DJ6Yz61494ybS9OlbS/DirGijF1KGLNI3dM+grPl8U6/dzT3EtmLiG3LeWSuCnOP+BGsXRo57t5JpRs53Hdwcmu+lR9n70mYpOt7sf68ypc6fdyzExxE7eRg9QR+lRi3u3iDsqFUPIJGVxXR6RfXTancwBS8flkHC5z/n1qg15BZtIlxACxyNo/i/Gu6FSTVjiq0o05WuemfDHVUttVtrFboGa8g8wwB0BLegJ6ZANQfG3xJ5VzFp6M1sgwHcuGAHXAx1x71D8JvCllZQ/wDCQSxSXF7CfNj3H7i8jgd2PvXBfEuc6r4mkj83f5ZLfMcYJ7fyrCnGNStoVPSnqaS3Gm2lil8+pxtbyZEYWL52YdcAdMetdZp3xV08xaba3UMjSlTHNctzs4IDn3Ixke1eLnTWULGZHLH5hGW+7n+vSr1zbQwWVrJ5OyRAwcg5Mhz/ABZ/nXRKhTmrS1Mo1GttDQ1i4Gtajbadb2VhZ+bNhDDGIgzNxubPbvVDxVotz4X19tMvJ4Jpo1VzLA25Ru9+5rV8W6rD4ps7G4siYpLC2W3kgkjxz03Bh978eaxLKSG0tlaaFJb0DKtOCy47DFVSUkl3WlvMc2m2e5eEvDc3hrSlT7U1xC+ZA3l7cK4HbtjrWtNsgBeWVUgKAs+3nnocDv7CvFfCOt+JLrW9PL3t09ukmHWd8xlP4l9+K9+gt5LjV9LsLJYUgmSS4ErfM64HGAe/PFeXXoOE7yd2zuhiFKNloQXVtNfWyiJHgtY2/wCWw2u+Pbqo+tczc/FTT7DxD/Zi2b3UCuLd543CgHodo9B/Sup8QaVc+RqEFvO++aBo96DBRiOpHbPrXhGmfD3X9U+1xtbC0ltyATOdquM4OD3x1pUKVJqTqPQKsqmnKrn0ONMguPttzGp3i4JboCcAd6o6xZPM9rLKrNAqszqq5yRjAP8Anmud+GEOtaRpV3pt8I7lYpA/mtKd2GHQZ6jjPNdiuoLCj28m6UN9xkAJX8O+K46tO02ovQ6KdW0dTnS1l+8vdQWNLu3mPlITgQDt9SepNJo3juzvtUEblWihJzLt+Xd0Bx1+pqK+8LwXGrtLdXNwAo+fcu7ep789xUdh4DgN7JLJMptzj5UHzSLjjJ7e9a80Iq3UcVGo71Wzsp9T0nVdOmSCUSSKNsiMCGGfr1Hoa5Tbc2sEiRMTC7MwU8bc9K2LfTbawad7WJVubgrGrschQByPyyag1uP7PbMsQHlHplsEH0rNyWyFCKjLTY4oTM17L9nZz8hB5xz14p2pWqxWlvFNE0s8zqzFOc+h/Wp9EtBc6vcLOCJI0CHbj5MHP8jW3qViZHjkj3b3zFFgc4HfNOclFnoUFzSL4/eWKJDIUlReWI4IHtXBfEfxJNpmjGOIAXVxmJWA4VO5FdPa2t9GFQzkjn73J49a4X4xaRJFb2N2X3xsM7SeQD1NGGUZTinqrm1eXs4zs9XojyuQKFXGS3U1TKNgsgPB5q8wzGdmBg1BztJPfivdhI8/E0lNr9CGKQkkbev5VYUZcbOnrTUwGA69jipFUHhGwevI4pzYsNB2SbuPaT5cAk46fWtCGTzB2zx9KzIwyvtcDapyfSr9sWjY5+ZCODjp7fSsprQ9fCVJc2vU0raTawBGVzziu38OxLG3nsCyMuBt5b8+xxXD2ykMiLwH6Fh/Wu48K2kk13JFaTpHbr+8ZzkgEdOnftXBifhPcUvcdzfljgcqqSygBeAxxtx2qp4avpH15XjVJFRPmLDnaD1FdAlxZ3F5D9qUuY8K7cDjGN4HpzVLTtMjXUm/suKaSHPzSSjaW57ewrz4ysnc4aleEoypzWrR6RFBDrdrM7IFXghWGc+/tXh/jnSLiy1aYCIpCT8pHpXtOlxwaQ+EY4272Ocsea5X4ivHOJHdAckEYHOcU6M+SWh5eArShWUN0efaFAkkLts4UZ2noa2rOyW+vrd5bVJVHyqCvX2rE0PzrmWSCJBtb72AcLXoGiachd5DPcQwW0OHZJNvA5JA7mtKsrStc9jE1eSLukdn4d8N2M2meXJa2wxnD+WCee1dFa28UMX2eBGATGWbnNcBa3dhB5q/8VBCAFPDkZDdCfTNehwwu8SZJX5RgP16d/esWmkrnykpqUm1oeceLrMw6tAsxWeIMWy3GCe2fpWLfwLHJFIEG+E/LxgY9RXS+Jra5u9PiSOD/TSnzxnGMDvntWJIxa3R3KHAAILdOOhrrl7uqMqUlJWZWttUMt+J2k38YAAxg1U8VLbag9rM6Fg8mJecAn0+lYWoJJCTbLwqktHKD94dfzp0azzJG7q7hedgYBc/40ctmrHVGi3Hmt5HVQ6hb2lv5ayxAKuwIo6CsbUtZs7OdLeW9SGef5fLc5wvr7VylxbXNnqBurqCeWMnMce47m/D0rDhsYLbWH1bxNcjc7kxQI29mOOASOgHArWnRjJ80mZzc6S5Uuu52+gW97qdzqdxbAuYkKxPjIZR39q5HWb9dQtZXuIj56fKR0wR6j1r0zwTqDWToY1BDJ0AxtB7Gn658MRq+pJfWlybZpHEh+TcuacasYySZz1aTs3Jnjos576W2tLWJjM+FRVB79ea9it/DLW+nWsTkJDY4Zgv8bY4/Wtnw/4En0e8+36nfG+nC4jVYQoT3rpUZo72GC8jWWKTO1sdG6gHHanWxPMrRMYUlF3PIfiVoWu6rcacmmCZ9PYZnZG24fPVvoKs2vhq8gAS3u4pWRsbJAARx19CK9V1G2+2WpliRoOw5649K808b6yfC32a7kspLqQsyDb0UY6k+ntWKqzfLTX9ep1U6cJJ1Huip4013WvD3h22uLTTrW1kL+TNKreYyHHbPQH1qTwd4jttR0U33iDVEF2flntyCgCDoQO49xzXBeK/Gl7rzRadHF9ns8YfLffJ9QelafgHwvYeJLOaC/u5TdJjY0bAbMfwjPXiup01TpfvFb0OfSc7xf3nW+KL+xufDf2nSZ0e3edURY1IHHqO2c1i3vh83Gm2t60q2qOhkYAdAKf8QNOttA0KPTrKJktnYPuBz86jGHPqeuabpmqpe+F2srhGmmmXywAOApHb0HeojHmipQ7j9pKnLlfY6n4b2+iS2V2LSaC7uflWQkghR2/qaxfF2iaPaSzSwkCRlJwOST9O1cJ4Sstb8Pao91Zui2nlkSyocqfRSPWtD7ZJd6siajc7768ZcBBlVGeOK6PZcs24yujndRyVpLU9Ftb9PD/gmZ7hzEPLCwL0ZjzyfxNeDTXEst7LLKxcu3JI65r1T4pziwt7aw8xZHEYaRlGM+gxXn99p0keg2lw0DAzNnPdq0wyUY8z6mVbV2XQ6Hwl4bj8RGRrcqojHzs3B47LV+KztdS1aK2RB5EKEMBwTjtz196t6Brdto/hGC2t7ZvtbZ/eJkEseN35HpXUaJoQsLFbjUADc3gOMDjBGc+3pWNSbUnd6dDSnFNJHmXiq0tdKX7Np8SRpIBuWMHr7+prm7m5+02hRNvnqMNkdQOMCuu1/S5dV8QXFpppYmKMzyyHp9Pb2rlJfDF/IFMLoLVjje7jAOeQxGcH2rtpuKiuZ6nPNNy0M+x1C70+R2j3I2Pu8gD8K94+B+rz6tpv2q4jUyWc/liTcSQ23I464614pqU0mmolhL9nuJIshpgCd4PYH0x3r03TraPwt4Os7bR7yeDU9ejWeSOU4+ygjBYY9e3tWeJtKFu/9MqkuWVzufEPxK0XSbie3jEtzqcsmXCRbi68cH0rmm+Iccl6YV025tFJwMOGdVI5471w2l6pYWU7R29n9okLYmvZHLO3PUegrT1PRYpV+2WheSIfNye9croU6btJfM3jKcvgZ6V4S1m2EohtiLlJ49gwPl+Unr74POa330+3e7SZD86LkjOPoQP0ryXwHey2viWFdwit5sM+Rnbk7SfbtXs0kJukLRCUSL8gYLkP65HYe9claHJOy6m8J8yuyrDdyzQXNwshyrbNrfNkH0qKHyp41Eu1MDDOrYwakubOO3so2nP2VQxacO/C4/iB7isey17R724aK3uYvJJ2lzhc89cdh9ay9m7XaNPaLZF2/uIrfyYzOXY5cMvPTHPFc5quozXEotrCMzgtuMsnRf8A69dncWWnNIstmY0jiJwFbI55/H6VzXiC9itrJns3hlS3YM7jhSOpGfbnIpQaTszRRcldDPCFtHHpbXssUzPMzBpn7DPcDv2rqJp4ZDbRRBWdiNuBwB3NY3kzQeH7JYXISRA+V5zu+Y5HbrUnhefbfyXMjrJDENka4wPzrGrfmbZ3U4p03KPQzfidq0Hh6SzQnyZpVLyCNeXA6ZNeI+L/ABNd+I5gr7kt4+UQncT/APWrsfiubi88SXElxvldypGOmG6KB7VwFxAI327cMfbFelh4QhrHc76GA56UZyld7mKGkYcqVUjp/WkkiI3ZXjqMDir8kIeYEsCQMYBqzBYXE4yIiVx+Q9a63US2IWCck4t3ZiJFJvBRAR03Z4p4RvMO5Sp9Qc1t3Ol3FjCJJFLxdGOMgVWCARkqvyEn5yMKPxqva82qIjgVStzO3kVCBtKn9etTxRO5VowNg98c1Ach41++xOQF9K0bd2jVkYDB524xz2qZaI3oJSm1JEseVKgk5Heuk8Oa7e+H4LkWsUbfal+ZpFzgetc+6MEDEEFuhI60hkdYggb5QeB2z3rCUVPRnsNK1nsdJpeoy3WoxTzRiQREYHI3e3FeyafbPKsT2xSGZY93kgcD6mvF/BlwbbUlI24J6NjGR9a9s8OSjUpVVAPIAyJQoyPXj0NebilaVkeVjk9Jpepr2jrcLJPtcyRqFclcYPt61wviG7k1G6uYGiCCAn7v0616dP5dlbSiTLIUzjPT6D1rxrXtQhaW6itHbzS+SWGMcYxWNJNnLl656raGeEZIIb+RUwHfCqTx9RXo9/axfZ109ZtjSQlXdQOM+teZ+EdElmu43cncrc7jXp0mivcafcwqg80xlFbPft/hTqNKe51Zjbm36bFqRZ7ewjuRc2NxNf232OQmX5MjOGU9+/FdRZyuLeGNQD5aBM4IJwAM81yVx5NzoaabFod1BfGPylBixEjdN2/px1zW7FbppccaM++TYA0m7O4gDJ596ubskj56MbtvqW7vSonLvnKjjDE4NcJ4l8P2s0G+yDW8vmAb/wCE49B3r1yYRGIeYvDHAArm/EGnSXGI7WMtjnA4r0KkeVXSucEJXdrniV3o98+uoz+VdtKPLRVBARR3Pv71sJYKsG3y8MvBz0H0r1HRNAh02Np7wq97Jznso9BXIeLL6JmnhgG0ISpwMEmuWumkr7nqYKtOc/Zw2PNNRt7i51Gby3Cqg5duTt9APSki0C0miWe6iM3lYddwx83sPSrLTxo7dVY/xe9VptWlUBVG7txWanK3u6H0kcE2nzBoUrzaoXZ2XDevBr3Tw9O0uniIja47eteD6K0o1uJkRMO3KnuK930OVmgi82IjtuHFXrzHjZrHktFo2oIEfI3cgcg1h+JLFo7TzoUJaFhJgHqAef0rUu2MEfnKd23rjtz1qR72KaBSGBUjk5rRxR4SlYx1kIjjkQl4JF3DHbP8uK5PXLmzHMiCWLOHVl3Y962b+9j022vMM32YsNg7Jkc49s1xM98WvR9nABJ3MQv8q56y949TL6cpXscZ4k8NaNqmoyXdtqCWdwxzIZslSOhIHritfwbp32KeXTdFmguC+JJLg8liOAR6fSrvjDWI9L0M3wgEt1kKFK8Z9T7Vx+gasmtTQSTW8cEiv96MYBPpx0rppynKnzS2Q6tKLnyx39DuPF9smr+FLq2mLC/tDxuzlj7Dv3rxvTL6aGzmgSEiROMnqBnv6V7zaraRaxGYlKSum0MWJ469D2rhtZ0zTNS1HzXk2MZTu8ocqM/zrShXUFytXTOSphJVW3HdHDw6sdOdZJYS7r0QsdpPbgV1Xw6sjq+pi9ljWO5di3zfLtz6egrV0fwLbvqtptumkjP7wK6DJ98njNd9faDYWkLpb3SxspHLAE9B1rWtioONobswp4eUJ++eN+N7n7f41lhmjdNpVHQHO0AdvrXS6rcaNPowgkfyY40G1UGWGOgxWBr9teaPrF7f3FgJ4HwouYxlR6/nUv8AaGh39iXs4zHfNhQhQ4JNa/FGLXTsZfDJmj4IsYtc1xpIHeC0sxu2Y6n+pNd54iv1nsZZIsxragEsRt2/5Gaq+HvCl34e0U3Zk2PMglfb05HSuc8b60j6P9jtjtmuH2lO+M//AK+fSsr+0noV8Mbvc5XULO+vdBuLiyjuGS9nAlaIEnC84OOoJ/lVnTtJn0DwjdQ3cfkXl9KHjt5RyU24yR271tSeIIPDWiQWdoiTMIzGG5GGJySPxpfAVrf6hqR8Q6qrXdpbSD5mPVv4V+nc44Fbc0uVt7GVlolub3gPwhZ6FZRazqoE0Mke5llXKxuOVUZ7Gue8X3b3V2bwozzT7mYA48sEYX8hxjpW/wCPvFk0M8VjNDjT5H8xdh+4Oy5HbOcGuUU3U1peyxLIYLgk7z2C8YHr15qI788h2v7kTk4LZ7e2kARWC8FiuAo7YPfNbXhrWZYoZoLh2IkPlxHjaGPTJPSsbzxDBJBcP5nzYVO455xVq3kuI547BbRfMuSBHGBlyPUjtW7fMtSFeLQQ3V1beIGPlMiqhjkIBOzPVhj3Ga7mx8eatNb2mneHIUudR4WW7dvkZuuQp9B1qnrVpLpWnLZD9zqN5/x8KQGKxkcD255q14aso/D9sb+CBzEg+Rhg5OMsM9vfFZSkpRu16GkYu9r6dSbxNpM6wwX/AIp1K41TUZZNq2obZFyOTtH8K8Vf8GyaHpuh3T6jbJbqF82aVAG+Ud27/SuC1rWbrxNqbOpAjSQhGA4A9qq/8JQ2h6jNpms2Md7YOoWRgMl1PVhntz09qn2TmuVu/wAy+fl95aGpqnjDTodUhvPD80qWQOJbcghyueVJJ4yOeK6/xNdWraPs05MWk6KYE453dvrzXnd94U8OadoC6gddma8unP2SEIoBTp83fjpmunt0jkPhzTRLmbcrSL1wBzz7VhiYwVpQPRy9c3MpPU9CklkttMhtlXLpCEJ+gqjY6ddFEeCYyKwzt3Y2/Sr97dxo8QkiGwDk5yc/SrNtdRo26I/KOcBdua8ttvVnpv8AdpqCOa1m1gleWSKIQ3sa7DLJnp6Y9a4a58LT6hefKync3zsDkCvSdbu01Cfy4E8xm+U5xj86yb9l0q0AyuQMcnFawqSg/d3OrCSnblXU41vBIs3ijEsEsrnOzd83ToKfCHsmaAQA7ThskVT1LXD9s+0q5Ur8q4P59O9RaVdw3WoBzG85HJXJrp5Ztc0tTqi50nZNE91cko2VCKD8w6H6Yrc01Gv4YYvs0UthbFfkeMEkE854qnd2qX2ox+Ykdopwi71ypPpXW6A66dZ3FvG0TlOA8igbfp6/jWcpWVkZ4iu5R91Xexha9omh2iNcCBNv3mKjBIPp9K8+uI4ZJs2wVVYnZ/sivQNXhm1cuGkg8wqSqBtufQ4PSuJ1XSLvTFAkj2MTkjO78sVtQenvPUdCyvda9TNk3oNrk7l7dR/9aoIyHkIdvcDpira2rTzBXO1hzxz+lTDT5UCylJGib7jspwfXBrq5ktzabblZ7It6PalpRLt3xKOQMg57V7d8P4lg0xz8wcS7F81cEH0rzbw5oF2J7G7kVJInBcoCW2gf3vT1r1eO7jQJtcEFgwHfp0rzMVPmdjjx1aMo+zga3iNxBpTs5ywz7BTjrXhcTCfV/Nf5kLZO3/69ekeObie4skSEk7hyN3X2rmvD+hRsFa8GA5yzKeUA681NOXLHUWBSoUXJ7s0vDySahOq2ilHDbc9CfavXYdKSz0+Sa8e5+WAo/lPjI6kgf3veuPs1gi1O2sorEESrmLAGTt9zxux+dd1bRjV9PuNPjiuYmljKbpFIEZ6ZGev0qqUOad2eNmOKdSytY5LWrmyi0+Ka3HiPySQVLMeQe/Wr+nRf2xvAM0DwgK8U/wAsinHBP19a1JRd36nSprnRhPInkSzrc7mIxg4j7HHbtW1p+gTRand3MpiIKJBCoJJ8tAcMx/vHNdlfCSnqkebRxLp7GjO5CHaAzDnpWVFbXckjTO4Qg8D2+tazyoACQTzjjpSnaqkHoa65xvrc5kUpLVSpL/Mcda4PxTpELXCyLCqgdXB6f413l7OFiKqfq3YVweu3r3c7RRqptwPmlYY56cCuDFKLsluduElOEuaOhxup+Flnh84EDPPSudvdKhtLUuclgODXfapLLb2pEZDADAArhtdkuLiNj5WBXBHe1z6jC4itLR63OesJ3XUvPVR8pG0V7NpF9JPpSFF57jNfPxuJVuyB8qhsZ969d8Da3CIBE7gswxXTOD6E5tS5o+0tsd3p17IqOlxG2OegzSXUCtue3AVH5KHgGrttNDNhsjAHPrWL4i1fyMGzKEg/P9KLuOkj5nk9rJuCMfU1UJ5VxtRWJBU8g1zkeli3ld5cRR5+TnqPQVJ4h8Qpduse3aOy9fyrNne5i015G3SyM4Koewz1rPl5m9T2KUauHppyVrmZ4lghmAgx50T/AHw3OB6fWqGnR21pJFBCixRKSSxHQ9gPetiWZ55RbCLbPkkr6c1UsbCVdXZ7uVXRQFChauPw2bOpz5EnAq6hNMJSPOcsPlBB5ptra3kFu8ro3lsCDg8gn1rr4NLtTO9yTGyKAAe+R3xUMl0wuYIIpElDOSJQuBt75H0qoSb0OSvi4r4FZkEA1FjBb2m0z4Xy8c7fXPtVmPQdWuGuGubiXamPkY4A9Pwrr/C8KWlt5tqUadiSzkAAD0z6VdmMrymedXd1Q58s/wCRV8/JoeTKTk7s4iHRtQt0lit5ILuAYLxEZwPbNTnRYyrDT9Kt1UrjzHYbs/THXit23u/NnkhsZoxOw2MoIyrDuPpXE+IPHA8M6nLp9+kkkyL5jpEFAGemSfWqUpuXLFXYKnBxcpPYvy6vf2BEMInE0w2NaSr+7kwOoPb8K8w1q8Zdclury1khHREZT8p+te82OjDxF4T068MLRzXMYl+ck7VxkN7H6Vwur6TewTvazGa6tyMbZIsOR3x61rTrqPxbmXslPSLOT8J+HNR8f6ylrawvHZRnM9wOVjX0+pr3hotNsNCXS9NWKKC2UjYMZz0J/H1rlfAni2Hw/bjT4bZGUMNwjGCM9D71f8fx2t1p761p0ZhZziXaTlfceme4q5vn3Mo6Ox5J43uZ4/FksErkxmNAhPIKc8V0mmXFslrb7NkEaQqctzjPBz65rC1OD/hI7a1MWEv4QQS3G72J7ZrGuNP163bZ/Z925HyggfKfx9KuSU4qLdmiqfNTbaV7mv4wv9OtL+C5sbayeRU2Kdp+91zj+tbvw80U6Nb3Pi7W4y7qC8ZbrIx7D+lc34d8G6pqGox3mp2wEUTACLqT9a9J+LUc48KaVGItlpDMpmCtx0449KynON1Sg/V/oXyyS55o5mzgOqS3V9fnzLy6PmkkDCIeirVj4pzJpXhTT7WzYiBsF+fbpmovD7QXELy+WRDjYGd+SB1H0qDxNjWIBYRGFlXDHccqp7ZNF17RNvRFKLlH3epyXha8jCBUCrHwWYqBtJ6ZPpWxc6TpupXUDX5ScA4iA4OQeQcfw1k3Ol2Flama7uVthtxIEyd30H1rmdOW8uHaOBjFav1kkHJGeorWyl+8TsbU4SuqbV/Q17jRj4n1xraOeKztLUsDMwyijP3QK6zwpDA+sz3aT+bBEgs4pWHIC9TQ2jR2tvZ6Fa7jc3ih8A5ZE7s34frW5JpCaRHHaWVvmGPqGO0kd+eufeuWpiOePLf0/wAzupYWNGd1q1q/U0rSS3uWCO25kP3j0PPpRrs0ljPgyFRIAqluAc+hrJtryJL392rQZPzRn5vxzXU2YguIVk1aUOVBMEbY+b04rikrPU7JScLNGIEa0gDybkQ/db++RXK+Jrya5USBZFTJA3DrXZ+I59OgtoYJNjMWwEXnA/rXO61NIbNWESeUNoKqPug8VVOyd2jelWlZM8zvEeWYZQ7M8bRnNdb4WsZYUe5W3LIv33Q8r7471f0/S4LqVV3gbP8AWZ7D0zXYXGm29tZwx2uUhOGYEHG71FdFTEXXKaVa/LJ23Zh6f9m1DUIooLqNnLfN5oww98HpThbypezwSbVijbDZODj+tLq1ruulkHMoPyMowR9TVaHTb+6l8x0dZE2iTeMK4zwc/SsG4s0TcFeckkyLVYUkmkjt9xMh+UDqD25pLHw7qWqsLW8liiJO1Wde3v6V01vod0Jj5UfAwXk2/d9xXaWXh9PttvcJeFZdhBOM7hR7S2xx4jGqmmqe/c830/wbFYTmG+3SNnI4xn1PFdNc+HLa/sUtbdiZVwVzlU98fStzULVrXVZVjk4dcFieR/8Ar9ahDvLaqqMkLjPDv831xUzk27nIsTUnFNs5qW2WydbSOKWFYxsMavkuep5/nVuNkbYbdl4yCBzlq1ns4vmkjkMjjndL196yWtvI8xoOeCwPvWTl3NqT5tepDcKbrUGEjhIUXJ9MiqTXxi1iPbNHFB93PXAH88+lZGqa61vbG0VWM0nHy/ePvivSPhB4N8iwXWtZVJp50BjiK7vL9/rW8aXVlVq0cNBue/Q2/D/huTV1ju7uCaGyYDZG77Wcjo+McD2rub6C9/si+t4miDPEwg2ZU5x09qEvlXdgfd9O9QnVoWHlX80MG4blVpQrAevJr0KHs6VtdT5utKdR3exjX99pUnh5rGz0qc3hi2RWwtirxyYwCWxxg85zXWWJuVtoRdIpmEah2U5yccmqGt6tZnQ7/wAnUIPN8h9mydd27BxjB61p2BLWFqWyWMSEknknaK9FptXucq0KMKSFAXbI9hROCVx096nHKfLUEroJPLyNxHTNc8l7ti07GHfMwVg+CM9a8/8AEETmYiMsNzDOP516NqIULk43dq4/UImnkO7A57CvFrpxmetg3FfEc7IgliAmfMoxls8Ej+VZGsahFEgQr94Y45rodZto4LfI4ODuzXnGqvtuTgk88Uua795Hr4LD+2blGTSRBc2FpOm+Nlyx9MYNR2YuLCZTCC6jn5RmtmxkgnAVowz9Dn1rqtP0azljEaSbJnGABxirTetjoxGLlQXs62tyLRfEzhY0IIZhjmjVpg0mWwu9vlJPH0qnd6JLp8pVH8zacnA6fU1ds9LN2FmupSEj5AB71nKSluckYU6T9pTa1LFt4Ztp4BNKAHPzDNMu9HkW0cDbs3Bif7wByBW5ZFpISuflX19KtRxl7UxucAHI9KmLd9Dir1pS0mzz62kik1aaacFZpxgq42lcHoKmaIWt+HwfJwfmI4/OtfWLR3kVoFE88JBA6gj0qtfQNqdv9pZXhhJ2+WfvLjqDW8u5lTm5PluVLq3m1R44rEgEkEuvTA7kimAJpt+LiSMPEwCbEXCgg8lvRfpWxosHCxxrs2jCLjGT3zitl9MuI2LT2sZXAB2/eAHrVQqLZGVeDi9dxh1bTbZFify44WXcvmcKT6+/0FXrTUYJYIJG3R26lm/efL5hHQL/ADrJmjt49NdnVVhQkRljlye233qJItTvI445YsRt94NjOO2ferkkc8FfqcDong6W38YXGqzahIlpBN50KNnfN3wfQAmvSdK0XRtd1BtT1fTIZ7y2KpCZEzjIJJP94fWtAafdkCGS3Z1HAlI+YqO+ajhFzaXRt7C2lliKfMzgptJ9+5p+0k1eWgSS+wb8V9GH8pcxonygL90flWVq32W8uvJa4UMpyDjgj/ePBqKOW7t5W86LChcgkFlI9DR5nlO8yLGhI5Rhx+FZXT0HFNbHG+MdG07S4zqOnyxyMnDxx8nr97j0qhJe3c3h1kMhMEuSEODzxz7V1euG31PRrmBhJFI0ZH7vgH6+orzmxZLR7X7Q0kaR4RgRncM8c+v17V0Qd1oJxZb8M2llmG4v5PKljkLbRnLsD+v0r0K5judTlilvHVbTjag+UH04qtYeHit7FfmFQwYEJ0Xb6/Wui1CBTEzL5jluFjx09yK5qs+d3Oim1F2RReC5iKrbtFsUcqvyn6e9X2+w61o01nfQgmUGJlKEAn057io47iKOLy71AXIIyBwR6Yq3p8Qktt0Z2RIMgS9TSp6PUzqu6PItX+F2s6bG6aHqaG3b5ngnzwPQMOtcz/wivifT4ZrfNr+95MjE/wAq+hLu7HkrC5XzGXc3OeO1cp4iXFpJMkuwLxgDmtZYipF23Lw1GFSSU1b5nicvhq0sbg3Gu3r30oAyCcIvoMelO0ZJNR1FpYIQLdWHBGPlHQCork/2lrLLv3qXPIORnPY11Fg40a3aQqptQhOTjI/xq51JNa6tntujDDaUtEHhSzu9U8X6hrEd41rBaOtvtBycEZwuenIrrJG8/UmAdHDEjzD2J9fSvPNF1Vp7ueIkwG6k81dvRVxxz+HWu30q3lNm7s2+ONgGds7tp5Bz3NZVYvmPOTkoKfcydbsJ11oWygiRmBjkC4bPsaj1sXlqkcjyB1IKHaOvrWrrV/bxXSXK3weOFBvZlxjHXBrn9RvbvxDcQw6ar29mDl5XA3Pn17AfrU8rTTeyOyniXKytdk2gaZLdTC/uJVC4Mccbcn24/LmtbX4AtmXkjO4gqAvXJ6/hVdofsM8YhMkxiAyOgI9PrVnVXOqJElnDIMsFZnyCB3yP0rOTvLmKeIlzalDwnpL/AGVBJ5jQu+XGOGPbNdfeTFUSGZED5wgAPTFR6Jb+QkFpEZkZOWLIOfWruqW8yrJcySNv+6oEf8j61MneRhUq3ldorpAsasJPLYsu5S4wQP8A9ddH4dKXVpClwy+ZGuXAACgk/rXIXbvY6XJPeTPGxISCNWVyR1JbHeu78JwyHRYjJAfN5yD1q/ZpanJXrymg17baQQrF5RWU/dUYJPcn2rn/ALZFpxZ5ZTMwGfkk+77dKkvbS/W/ZQqyM7FT83b0Fc/qKx2V0rXCzxKjYKhMpIR2z1qlGOyMoX2ZpPrI1aDNnbljkBpZD932Y+h9qdPaskyyXO0MSN5B4Pt749quabEt1YsFhWybZuKFcs4/2R/jXNagLk6pMsEhNuV43jKKfTjoay6WZ10lzTtE2baaNrqYrumiHAGMYH0PUVleKbuaOBIdPtzLcZ3fLwEHq1WPCchhvJIrvkFPkOep/wAK6O70dbkwGPCxnmTA5as+b3rtHW4rDz5WzjND8Kxx+Zd6kyyXsifNJngE9lH6V7R4TsVsvDdrAxYmJfXmuR+y21s0MZYkoQwUc5PvXoWnNHLbpKp+UgAjNduEi5PmkeVjsR7R8q2RWaNy5IJ3PgsPaq50a1u7hZbq1hmI+UNKgPHpWwNrOFbG5fut04NZOvzytq1ppv2trGCWFpC8ZCtKwONoY8DA5rs+rKbu3sef7SyskaMeg6SEUtpln+MQFTpcqzFIHTanHyngY7VyupWK6Zps93Hq15HLEu5UmuRKkjdl2989OK0pYFMccmzyJXVWdUOMEjJH4V1OpyxujG12Rahrf2S1VpAgB43E9/T3NUbW5llu/tJUpERk57j3p1y0MOyGaMSSL3b1qaaxZ7WMSJuUjdtBxXJKUnv0NUlsZ+qatC5dVPI67jgH8axJp4RHlTJ8x+QntVy60uGMsTuXnJC9RWNrF3CIuAFVeAa8+pJSd2elhqTk7RMDxVcyyukRZipGeDXOnQXuMNJMVjz07k1U1yd7u73QXbkr23VfszcNYeXJcIkrcKM4x7mp5Ha6Z9BGpKhBQSsjPeaOzuljibLBgvIxmutsWkuA08LtuHykg8j6GuOm09jOolk+djjPeu10gmxi2Rruj7lh1q1ZpHNmLUUne5cN4IZmiSF3MqhUjZu/rWrpcazweVLGIkHUjuaigs0uXa5eHE5XKsDyoPpS2f7mPymdsoeAevNKfY8iD7F64hgt42SLIUDJPXNSWNjc3cJ8wlYuoI64qXRNJl1C/M9wzC2Q52seM+ldlHboi4jI2+1bUqGlzlq1buxztrpEVq2EThjznv71zGuWskWpvY23y28h3/d798V6PsOV3DPNR3+lQXIDNgPnIJ9a3qUuaPu7mVKpyzuzhdJ0sWt15hyW4289+4rau2YRoGA2SnDL13j0+lMv9L1Mr5EFysSFsmYr8+OwH+NR2+kalcBoby9R4nQqxRNrkHrz2Ncag07S3OqpNVLSRh3lode1yK00/YrQ4lmkzlEXPGPVjXeWcUEKojrtYY5POfqao2ek2ukweVYRrCO5ByTj1NPhnTcyTMD+NdSeqVrnLLa5vSzAhNmPbmntB5sYYgZIwKz124AglVv9kmpo7twxQ9R2PeumyfxGV+w2eFLeHY6Flc8cdD71i32nRzFWuAx3fKAvAOfWunVvNBJBDDt61R1qELZG4XrF8xArCrR622NITtscle6fGFZY7dEZThR2NYtr4UguUklvY0Cs5YAnBH4f1r0CCFZmDkAtj5W7EUzVII5bKVOC20jPocdaxjTum0aOq1oc6kcsO3zHRrcfLwT19vWpZ7+OGRFMilsYwDipNJhiGmos8wd4+inkZHasLVtL83UFuHkSIkZCdqyqU3a5pSlFyszYjjt78Cb7ojODu6/5NVPFV1fWukXU1qRAF2Kjlc7ATgnH40yyuFiuEYR5iBCseoPp+NdHM9td2UsLYaGRfLKHn9PU1dJcquTU+LU8ufUtS0k7p9tyhIOQcOxPrVDxC2oarZK9+otLaTkJE+T+LetdL/YE1vdeVeTAW0f3Jv4So/hJ/vYqO9V76K8t7aGBrOCPGASzfj2rKPNtbU7lVhFqR5NYacPthMZ8qBercdR2FO8T373cMGnRYKcO+O6f3c+/NaOo6fcWmjbgBG0koRFJyAG6N9TXJXYnspm+0AvLv28jO9h0H4V0QXNK7PSjONaPLbQ6DybVo/tIlWKNkEe5fvRqO2PUikn8RPNEunadfM1mjDbHEuWz2yxrP0XTkuZVk1NjJHuy0A4Uf416Zbw2kdkp062tkhK4+RAADUSqRp6bsWIw0nJOexxmj+H4HhnbWJHEQfetsXJBPZj6n9KuQMGEkdmyJFAd4jxtUg+/rS6qTJKyyktjnIfBU9iD2NY1/ZXU8cdz9ne3BbLymTO856Ad6lS59ZMVSi4NJI7HSbdLmAMtwGvHO0iQYAA9PWte3niRcGQPNEcsQpIB7imWEJubKK3iiMbNnYSMFemfzrX02zJvYYgIlhOcHuD6H8e9c7avdmFVWfKUbSC684XIlMeQQuVznPetSHT7u4SEDzZJT93zCCAAev0/WtCW0kFwI4wwB5dR3qYRFQFtJXjdMdT1H90+9CkckpX1Rl6XoPmaozXy7hHnczjv6L7V1F1dLC6FDtLHaATgVli9jtbgO6zSSIMeYX3BjTbrUBcCIGDeWJx+VXzLcycZSNMtHaiOS4H7yQnDL6/3c1HNyzhlRy2HQ4zn2x6+9NWSO6/dspbywoOelRXQnxmKL/Vn5c+lQ5WHCDel9SKGERXDz3W8SMMqMdB71Hf23n2koSMKcZPFW5NYitbVTcAeZjGMdR71xus+LxC0scRWKIEhccnFSoJ6o6qVKtVl7qHWulwperLcOqLH02t1FTz+L7aynFsJ95XG3jp7CvMNZ8VSS+YIyQSSQw61kaTeeZJNLOSJP4WzW8MO/iZ6tTD8y/fO77Htug6xFLd3V9O4ZmXagzjFei+H74XVqNpDIfwxXzPZXF152FDbH7ivaPBWpx2elxyTB3C8OV5CA9zVwlKE0kefmOBjSp863O/aOMCF5A5MZ6r2B9R6VS8T6lpcMFrb6hG8yTP8iNAZAfpx19qXTr2WdSUnS4jPRkxkfUVW8RTWZggh1cuvz+ZCsOTJvXuoHORXpwmvvPnpJopRan4YtJ18nT3jnA3bhZSEqfbIrWnYRsrI6yFgCfMU9DyPxrJl8U2Dz7JvtVueMSTwMgz7t2q1p93aXJkBYtKDknPBFTOd3ZiSKjsql7u6yZHOI4wOg/xNapvlaAZUqcYANZN+qtZMysWkUbhgVkT6uskG0yeS2MZauSdXlTt1OinSu0HiTWYLdHjDgE/eOa8p1vWo5nlRlkKnvyAa3jKv9ovcuGlgGQruMge4rkfFGo+ZcgQuu0ZyuK5FG89T6jLqKiYs9yRkxjYB19TXR+DLJtWuBvbbsIGe35Vxj5aY7m+cncw9Pau38Co8LNI0wjjYd+5/wrqslZHfmN1h5SW56Bp/h2K45k2+emQxx196jvbaS0gMZRpFHQjr+XpWho94I2kl8xRC3CnHX3qlqOsRNMQq7/Qd81zS+K8T5dOcvi1GTXIht43hd1lZMMDkfhii1S4uZAY8OW9eorPuGUqkjrk9OP54rofCcUjSq/AjHqMZpxV52LnBQpOZ1GnPLBaiF42XHcd61YLmPbuYgKBg+qmgL8o44A6VVkjE5y4KKOmBjNd+sWeR0L1teQyyFo3B5I9askb+dwxXMm0t7QSNE7IxbtT0u542H70FfepeIjHSRapN6o1JgPNA5NRyMI24I+lUH1OUniMMSeqmkileWYNPG4/CueU02+V6mig18RHqV1cRlRCvzH27Vi3VtPJOrSynJHQd66maOJ2XdkfhSQQWxn37wSvTNHsqkpKz0BVYxjaxhWFtLC/zC5Ho3atNtWS1UJdspJ6Gul822ZApKY6VkavY2E3zuqnHoM11SpygrxlcwUk3qNtL6RcPbnzUYfczzV1ZvtlvJE48supBBFYtnHHGxMCOMHitQyTT4WWJUOOHU81FOcpxs2OSUXsVbVk02FxK2BEdmO59BisSTWHl17MMLCNwI2Vz8re4H+c1ev4BZ6itzK/mxS4Vix+4w6VJc20F1DIUJSVsADGDx6VaTirL8Sbp6szNWvEsvNSFVdiM5UcA+1U5St0qvcOgbbwrDG445z6Cr19ppdEFw5GRygHGBWTbQRyfaHbKBDjBPHtWMpX0NYpWuJZywRM8H3TIpyzZ/wAgVfaRtPZc7ZGbGSOfxqulvDOp+0yRxwjhSjYb6g+lUru2QQr9mvkfYeI3I5x0/CsuRt8yN3NPRkuqxPNG9zHMnloC2xxkE9afp1oWhRlmQRzMrKwH/jp/lSWU6BViuGi+0yNk7kyoHsakntdrERyxxktvLbvuDsR6mqsyG0tDlZtOZNbvluQr2tmfOMZJKtK3CAHvgZJFcnrGjLLdW1zCpEce6OTPVmI4wO5HNes6lYW8Ph5msjF5nmb2djlnbPJJ9TXBa3qdqYvIht7iWaP52DL0Yd93Q/hQ4yTTR2YWvZ2v1OLl/dzyRomNoGRjpUqa1NY2TiMqHbhR7+tVtSNwszTw200wZcuRgkD8KxdPe5klluGKeUuV2yDP0A9Kapprm6HvKr7SKprV/kbmg6bfeJLubHmCPO52jOeg9jXolro2mfZY4JZGWeBFwZ2+6O454P1rgPC2tfYYXhiWJAzHLleRn3HNdRaavKt0qNM8ynAweQPzrOu9fI55YWvPWWx0QvbdAlu08ZaMjAzmrq3gHyKVbjPCYDfnXF6qY4rvdMsZ3Y2koM5+oqbTYtQuGZIpnMPPyg5/Q1hypETwz5OeR3sGos0q73Vdo43n+vetJ7dpdstu+3zOGBOfoa85uLu/sYwJl8wZwpcdfwpYNZkVcO0kaH7216XL3Zh9TnPWCPRBFEkuy4k83IwKs6fBEWBGVK9FPQ1yY1m2gt423kkjJJ7n61Zl1+0EsEsSqN0ZGc7iDxRZHO8PUbsddMYLVDtjADHPy+tY+p6/JGwijiRRnGSpJI9qyrLxEJ5gJTknpmt+CG3unjcDkdjzzSU3cU8O6T99HD65Dd3EZaQPGM5HHOK848TafdQ5lJbYfc19KvpcMkRjlRGxlsZ6e1c94u8O2j6W+5FXA6VcHOLvY9LC5lTilCSPmZLWRnG8HB6CvQPCfheK7iikkKmLOSp71m6jprRzbIwCFP0/Wu18M6Tdw2QfyhKSvG04H5+tdFSpzWTeh3YysoUm4PU0YNAt451jjTMQ69+K2bXw3ZpcC382Rd+QQjkZHuKXSg8aKZJHin7Z/lXQ2Fm0Epke4JGcnIAZj71jCMnO54OKxTas2aOnWEWlWY+xcMp4yaq6kl1JfR6np8MbzRxmGWCRthxnO5W+vHvVefWLf7R5KM20nDEDp/8AWrK8Q3ds9/YjUM/YXjKohYhWmLYw2PbpXow092x40nfVlvWv7Q1GCa0fTvsAmj2NPNcAqFPXAHU+xrVsraDTrOKKBxIFULu4yeOtcrq95Jp2n3djdSGaznic2zyEs0Rx9wnuvoTWpZwtDbwb2dIzEm0Bv9kU58qV+hKvfcdLqMMWnymEPIE6565/wrlr+4gvYCZYUKNjOwYzV7Wra4ttLldG2BjnLHrxXIK0iSCOeSMRyck+ntXBP3tD1sNSaXMibWVcWeyNQFxwQc4HvXJ3cI2oJUAkI4Hauj1m/ijtt4njWJFxgDn8+1eT614nuTfubX/Vp930NVTpSqbHsYWu6GsjYurU7mkIG4mtbRr+PToU37pHHzZAwCe1cho2qT6tqUcF0dsZIyFPWusudOaGTbt+UcAZrSadO0Xud8JQx3vPZG7B4jlmkKsxEZPKgDGPatHQLyO71EqQCinH1/GuS8hRGM8HH41d0ndb4aMnBOee1YNp6mNbAQd/Znot5D9puGRcBGHbgfWtTSbqPSrWXzi8ghQu+xM7QBnk1xtvObmSMqWDA8knPFddbzolhJEQPLdSrc9cjms42Uro8vFUZxiqckJ8OviDaeLmu7a2he3nhy+1zncmcZrrzPJ36DpzXGeB9G0fwzFdppMJje4YNIztuP8Aug9hXTNeqQAOp6CtqtRSd4OyPLVFw0aEuJAflK8dqyrm7I3BkI5wCDkVZlugdwY4Ud8dKxGubiS4DFVEMh+VcdB6n3rl5rnZTo36Glpd07sJMqFBx9a6SK6Zwqrtya5a3GeNoA6jAxVyCaWMDYcgdSTWtOq4aGVegpao6tpCiAsgas+SfdKCF/KoY7wvH8ze1Ph9c8GtqlfmfunLCly7mlHKHIAiOasvGzp8sYB6c1Ws2AcY781pyTKq8V1UWpRbkYTjZ6GcIXyQcD6UkdrJJeJIWbYO2atKwdiMcGr8UaiMbT82OtXRpKWqexE3oVrywguYWSSMMGGDXOWkLW0Kw3UBIDlY2HJx2rpppGhRdxyCcdKp30ZdUaIZ2sDxW1WnfVdCIs5+9+1DPkyqyHA2SDB/+vWZYWLS38yyL5eccN0z7Gul/s+W4mja6YmIHI28c+/rVu7tBtAKhwB9DXN7FtczNFO2iOWl8IWzlmkZmcjgBuBSx+D7IJuBYNjv0Fa80E6wstlcFGJyFlGcVFHqElnGF1HO0nhwDyaycYtlqUkionhiwjH7gypt7h6r2/h7TnvWLSMDnJKYyfxq5qN35kBe3cqG4BU5IrMs9QWJdhtp2fozDHJ/HrS5bSsilJ2u9S/HYafYwuXtvMVTuVnyea43W3kvtREfkIsCYyFUDr0/Tn8a7GG4iuIGWEyGRjgIxAOagXTpbhrrfbiFjgBz1IA64pTV1oyqE1CXNJHJX0lpb2LQLGi/L2GBmvFPEshN48ES7QWOAOmK9d8S6ZcRSzFJxt7huSPcV5i9g9xqZwu8BvmI7msqE0nd9D6nB0XyOcXoO0DSxPb7ScOAPnJ4rqra1CFQmNy45FQW2lvvQIrjkBcdM12llpCW0EbTuGccsqjqOwzWc587djpr1/Y6XumVtT04XGjLdNG39wYGT9cVVtLqSCCNLRHSUnuvr612ejTxTtJaEqEI78HPY1WtdLUapJDjdnLbyM9/50lGyR4rxbbdOpsctewT3EirKrE45G7ili0MvGocZA5Za7e80B4uYxlcDtzUNvbtGxSbByCFJHNZPmu1I6o41KCVI5i4srSC3EYIj4ydrck/Sudmt3XPlMnynPHymtzVYduoRxBsszZ6dB6U28tI4FzMQBn72Ov1q/abI3oRiruT1Zz5vjbwku8quThcgH8K09G8Y3VhKI71VKjoyHJx71j6lZF4lmiYvGDnHp+NYUzOL2NVQMx5BPQfWtoxUkbVKFNxcpanuOkavb3dxFeLcSIpU7ueD6ZHrWR4r1uW7SRBJ5cYPAB+8PX6VwMV21rHgTMg6nFWtPgub4NcLuePOSicsPwp2klZHmRwlKEueT2Oh8OaB/acKOzAsW3FmAOB9K7iG2i0eeC2eYC1mO1QTk7/AP69YXhWOSHT4pIXa3YnDRyLyDXUR2v2kRC8hR3Q5RnHf1FEUo+p52KryqT390n1HSmMaSwxCR05K+tZF55xg+0LPIkzD7kn3QPUH0rsLd5IyqlGLZAPp9azNeskmulhmUiCT7vHAPpXXCnaPMjz51G3ZnnAupo7lzNOr4JAx3Fb2nSw/YC95Moiz8ol7ntj1P0qK58Oqpc5U7SRxwAPWs27t51vMWx2Pb24kim2bmGXw7gdyq4pLVlNpLQ3YbywuGWCQuGTBiWWNlZjnoMjke3pTfFmpzGVV0+GNdjbWVzgnA4I9uayru4ea4JkuvOt2idWUsGEeBlZcjo27AHrmt+TTbZ7S3fUfMWRkU4PYkZIrRO2sepnbXUyLW6l1Kyt96gRbADk85NYXiHT0nvIre3bZxk7Rg4780UVwVO56uGdpWXY4b4kW3kafFHApEasAwzjd7mvLXX58EUUV2YR+4e/hoqUE2WtBdLbWoZWUkA9q91sls7u3EqwgllGMjv60UUYiKm0n2OKX7uo3HQy7jSyzkIVBOSFH/16S1sySFb5c+lFFeZd35T16VWUo3Z0On2QgADHnsBVq7c+TtVsN2oopy0R57fPO8iPS7qVZT58gCjj5Qa6JQwHznI7EUUVEtznrbkF50J7EVBFb/aW3biJEPHPAoooRk9Fc1kiZFBYgsOuO9SIPl460UUGDd9SKOGZ5c7v3a84zitO2YhtvpwfeiimjGo7o0oGxtq9D+9PzE4oorsoK8rM4ZlhotpU59KkjkbzQo7fMfpRRXoRiovQwk7itIrs+4ZHoajMyhcRjIHXtRRWrZmKuQgY4DdfpUU0mcEE80UVFR2iXFK5WkUSIAwqAoUOVIIHZhmiiuGWrNuhzuu2lrezxBGe0lVs7o+h/CknttRa3eFRFJGMYlBww/A0UVk20VHV2ZZ8O2gaYKZA7QvhwVwWPrXSmIjzA78nsB0FFFdMYpXsS9WeaeOzgMqdTxXJ6FpAaT5gCWHJoory5dT6zCNxwuhvCL7JJE/D4/l/jWk6yPnAUL3Xv9QaKKpq2xwOTk1czbhW0+4iuQ7L8wIxyT6V1cM+2W3vu8hG9R6e1FFODsY4v37XOqG25h81OmOh71j3drumbaflYYIoorqxPvRTZ5dGTWxg3+mJFceYQA3b61h62dtsIkx5jN1I7f1ooriS1PZw8m2rmFPbJDEw24Zh8qqeM1gf2a0jumEDH5sCiiri2ketTm9X2Kd3HHsw5OP4scZrU03UYvJCwJIke3HyuRiiit4NjxUVNe8jufDupg6cyRQbmUZRnbjivWbGEvYxeaoV8DIznt0zRRW+GS5rnymM0ehYknEXyKgc46nvUOpZNir7V8xiMelFFela6POe5kCxkkugSw8sjPHc1Wnsku2B2tHcRSHyp42wyHv+B9OlFFcsUV0RP/wj/wBqjUX919piVgwjEKxKzDuwX72KnNtFCoDosw7ByeKKK25E9SeZx2P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several oval eggs and multiple small, brown feces are present in this specimen. A mite is visible in the upper right corner of the image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34294=[""].join("\n");
var outline_f33_31_34294=null;
var title_f33_31_34295="Epidemiology and toxicity of mercury";
var content_f33_31_34295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and toxicity of mercury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Carl-Gustaf Elinder, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34295/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/31/34295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mercury exists in metallic, inorganic and organic forms which are characterized by different toxic properties. Metallic and organic forms, the latter found as methylated mercury in contaminated fish, are toxic to the central nervous system and the fetus whereas inorganic forms of mercury may affect the kidneys. Although mercury is a silvery white liquid, the metal is volatile at room temperature because of its high vapor pressure. Mercury also exists in different oxidation states and can form a number of organomercuric compounds. These physical properties contribute to the considerable toxicity observed with mercury. In order of importance, the principal organ systems affected by mercury poisoning are the central nervous system and the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USES OF MERCURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unique physical properties of mercury have led to its use from prehistoric times to the present day.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colored cave drawings from more than 10,000 years ago have been found to contain the red stone of mercury ore (cinnabar, mercury sulfide, HgS).",
"     </li>",
"     <li>",
"      In the 19th century, epidemics of occupational mercury poisoning resulted from heavy exposure to mercury in the mirror and felt hat industries.",
"     </li>",
"     <li>",
"      Mercury is still used in the manufacture of many technical and medical instruments, including sphygmomanometers, manometers, thermometers, and barometers.",
"     </li>",
"     <li>",
"      Liquid metallic mercury can be used to concentrate gold from crushed ore or sediments. This technique is immediately dangerous to miners; it was commonly performed during the California gold rush and is still used in several countries. It has been estimated, for example, that approximately 500,000 gold miners in Brazil currently use liquid mercury to concentrate gold from sediments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]; this may cause considerable environmental contamination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the Middle Ages, mercury salts were used for the treatment of various diseases such as syphilis. The use of mercury in the treatment of psoriasis and, as a potent diuretic, for congestive heart failure persisted far into the 20th century.",
"     </li>",
"     <li>",
"      Certain mercury compounds still have limited use in human medicine (eg, vaccines, antiseptics, and skin ointments). In addition, human exposure may result from the use of certain types of mercury-containing Chinese traditional medicines and skin lightening creams, or in hair dyes.",
"     </li>",
"     <li>",
"      Amalgam tooth fillings are widely used in dentistry and can be found in hundreds of millions of people around the world. Amalgam or dental silver is composed of a mixture of 50 percent metallic mercury and metal powder (which is usually composed of silver, tin, copper, and zinc in certain proportions).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HUMAN EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are exposed to mercury via many different routes and in different forms. The general population is primarily exposed to the metal from dental amalgam and the diet. As a rule, amalgam fillings are the most important source of inorganic mercury and fish are the most important source of methylated or organic mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Amalgam fillings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The release of mercury from amalgam fillings is proportional to the number of fillings and the total amalgam surface area. It has been difficult to accurately estimate the release from amalgam fillings; however, an expert committee from the World Health Organization believes that the average exposure from dental amalgam is approximately 10",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1\">",
"     1",
"    </a>",
"    ]. Measurements of urinary excretion of mercury have revealed that persons with a habit of tooth grinding release considerably more mercury from their dental fillings than those without this habit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Health studies have focused on identifying the early effects of mercury on the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/2\">",
"     2",
"    </a>",
"    ]. Overall, there is no evidence suggesting a link between exposure to mercury from amalgam fillings and degenerative changes of the nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/9\">",
"     9",
"    </a>",
"    ]. There is also little evidence to support the removal of existing fillings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'General toxicity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Nephrotoxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exposure from diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of mercury is very low in most foodstuffs (below 0.02 mg",
"    <span class=\"nowrap\">",
"     Hg/kg).",
"    </span>",
"    However, certain types of marine fish (such as shark, swordfish, and tuna) and certain fish taken from polluted fresh waters (such as pike, walleye, and bass) may contain high concentrations of mercury. In this setting, mercury is almost completely in the form of methylmercury. It is not uncommon that concentrations of methylmercury in these fish are 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or even higher. Severe epidemics caused by the consumption of fish polluted with mercury have been reported from Minamata in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring of mercury in blood is commonly used to identify and quantify exposure to methylmercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/10\">",
"     10",
"    </a>",
"    ]. Heavy consumers of fish, in particular those who eat mercury-containing species, may have blood mercury levels in excess of 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (normal value less than 5",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"   </p>",
"   <p>",
"    There is also concern that dietary exposure of children and fetuses (via the mother) may result in neuropsychological deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Occupational exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational exposure to inorganic mercury occurs quite commonly in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dentistry",
"     </li>",
"     <li>",
"      Chloralkali industries",
"     </li>",
"     <li>",
"      Thermometer factories",
"     </li>",
"     <li>",
"      Mercury mines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurements of mercury in blood and urine are useful in quantifying the degree of exposure. There is a linear relationship between air and urine concentration of mercury in most situations: the urine concentration (in",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    corresponds to air concentration (in",
"    <span class=\"nowrap\">",
"     mcg/m3)",
"    </span>",
"    multiplied by 1 to 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to mercury has significantly lessened during the last few years because of increased attention to minimizing exposure. In dentistry, for example, ambient mercury concentrations from 1960 to 1970 were frequently around 25",
"    <span class=\"nowrap\">",
"     mcg/m3;",
"    </span>",
"    present values are below 5",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    due to improved ventilation and handling of amalgam.",
"   </p>",
"   <p>",
"    Similarly, mercury miners and chloralkali industrial workers commonly encountered air concentrations of mercury in excess of 100",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    or even higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/12\">",
"     12",
"    </a>",
"    ]. Negative health effects were common at such exposures. The occupational threshold limit value (TLV) has been lowered to 50",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    or less in most countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thimerosal, a mercury-containing preservative used in vaccines, is another potential source of mercury exposure. There have been concerns regarding the potential risk to infants and children from exposure to thimerosal-containing vaccines. This issue is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biochemokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of absorption, route of elimination, and tissue deposition of mercury depends upon the route of exposure and the chemical form of the metal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary absorption of mercury vapor is high [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1\">",
"       1",
"      </a>",
"      ]; however, this form of mercury is only poorly absorbed from the gastrointestinal tract and across the skin. The kidney is the major site of deposition for mercury derived from inhalation exposure of mercury vapor. A significant fraction of the mercury vapor taken into the lung is eliminated via exhalation; most of the absorbed mercury is eliminated in the feces.",
"     </li>",
"     <li>",
"      Gastrointestinal absorption of Hg+1 or Hg+2 is on the order of 15 percent. The kidney is the major site of deposition for mercury derived from inorganic mercury compounds of these valences.",
"     </li>",
"     <li>",
"      Alkyl mercurials such as methylmercury are highly absorbed from the gastrointestinal tract and later de-alkylated. The kidney, hair, and central nervous system are major sites of deposition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENERAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe and sometimes fatal interstitial pneumonitis may result when mercury vapor is inhaled at concentrations in excess of 1000",
"    <span class=\"nowrap\">",
"     mcg/m3.",
"    </span>",
"    Additional symptoms and signs of severe poisoning may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intention tremor",
"     </li>",
"     <li>",
"      Inflammation of the gums with excessive salivation",
"     </li>",
"     <li>",
"      Psychiatric symptoms, such as excitability, insomnia, irritation, and shyness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of signs and symptoms occur after exposure to lower air concentrations of mercury in the range of 100 to 1000",
"    <span class=\"nowrap\">",
"     mcg/m3.",
"    </span>",
"    Typically, the mercury-poisoned patient has a severe intention tremor of the fingers and hands, making handwriting difficult. Mouth symptoms include tender and inflamed gums, excessive salivation, and swollen salivary glands. The third hallmark of mercury poisoning is a change in personality and psychiatric symptoms, including anxiety, erethism, irritability, excitability, fearfulness, shyness, memory loss, depression, fatigue, weakness, and drowsiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1,4,13\">",
"     1,4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occupational health studies have focused on identifying the early effects of mercury on the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/2\">",
"     2",
"    </a>",
"    ]. A dose-response relationship between subjective symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired performance on psychologic tests has been observed in several studies. Increased prevalence of neurotic symptoms may occur due to long-term exposure to mercury vapors at concentrations exceeding 25",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acrodynia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small children who are exposed to high concentrations of mercury vapor may develop acrodynia (pink disease). Acrodynia is a syndrome characterized by a body rash, swelling and irritation of palms and feet followed by skin desquamation, irritability, photophobia, fever, insomnia, and profuse sweating, which may also follow oral exposure to mercury compounds (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acrodynia was common among infants in the United Kingdom and the United States until the late 1940s when it was realized that the condition was primarily caused by exposure to calomel (mercurous chloride) in teething powders and in anthelminthic preparations. Some sort of allergic reaction towards mercury in combination with a highly variable individual susceptibility are considered to be important pathogenetically; affected individuals are almost universally infants and small children, and the syndrome develops only in a small proportion of those who are exposed (less than 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Organic mercury compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organic mercury compounds have given rise to severe epidemics of poisoning in Japan and Iraq [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. As observed with mercury vapor, the central nervous system is affected first, although the symptoms in this setting are slightly different. They include paresthesias (notably around the mouth), malaise, constriction of the visual field, deafness, and ataxia. The fetus is particularly vulnerable and may develop irreversible lesions, even if the pregnant mother shows no signs of toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, children exposed prenatally to relatively low levels of methylmercury (as reflected by maternal hair levels of mercury) perform less well in several cognitive tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organic mercury compounds are defined by their bound hydrocarbon moieties. Among these compounds, dimethylmercury is particularly toxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one case report, for example, the accidental dermal exposure to approximately 1.3 g of dimethylmercury (contained in approximately 0.44 mL) was fatal, despite aggressive direct treatment and general supportive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEPHROTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was recognized as early as 1818 that mercury caused proteinuria in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/18\">",
"     18",
"    </a>",
"    ]. Mercury is now recognized to cause the nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubular injury with tubular dysfunction, with membranous nephropathy being the typical lesion seen with renal biopsy. &nbsp;Proteinuria disappears as exposure to mercury ceases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of mercurial diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/18-23\">",
"     18-23",
"    </a>",
"    ] or other forms of mercury exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/19,24-30\">",
"     19,24-30",
"    </a>",
"    ] may result in the nephrotic syndrome with varying pathologic features. In one report, for example, five cases of nephrosis in infants were reportedly induced by exposure to mercury-containing teething powders or drugs for at least three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/25\">",
"     25",
"    </a>",
"    ]. The cumulative dose of mercury was on the order of several grams. Urinary excretion of mercury was very high in all cases (approximately 1000",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    Four of the infants recovered completely, three of them after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/42/9893?source=see_link\">",
"     dimercaprol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Most cases that were examined pathologically revealed membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/18,19,27\">",
"     18,19,27",
"    </a>",
"    ]. Protein excretion rates as high as 44",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/18\">",
"     18",
"    </a>",
"    ]. Many of these cases in the past were due to the use of injections of organic mercury (chlormerodrin, Mersalyl&reg;) as diuretics in patients with generalized edema. This use has now been supplanted by loop diuretics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    However, mercury exposure may result from certain Chinese traditional medicines and in skin lightening creams or hair dyes, and exposure may be high enough to precipitate renal effects with proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, 11 patients (10 women and 1 man) presenting with proteinuria and normal renal function were described who had mercury exposure from these products for 2 to 60 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/31\">",
"     31",
"    </a>",
"    ]. Urinary mercury concentrations ranged between 12 and &gt;400",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    Three patients had nephrotic syndrome. Light microscopy revealed thickened glomerular basement membrane and mildly proliferative mesangial cells. Acute tubulointerstitial injury occurred in three patients. The immunofluorescence findings showed granular deposits of IgG and C3 along the glomerular capillary wall, mostly accompanied by deposits of C4 and C1q. IgG1 and, to a lesser extent, IgG4 deposits were observed along the glomerular capillary loops. Nine patients reached complete remission after withdrawal of mercury exposure.",
"   </p>",
"   <p>",
"    Renal lesions other than membranous nephropathy may result from mercury exposure. Some cases of Kenyan women who used mercury-containing skin lightening cream, for example, revealed lesions of minimal change disease rather than membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/26\">",
"     26",
"    </a>",
"    ]. Since the urinary excretion of mercury was abnormally high in most of these patients, it was suspected that the mercury-containing cream was involved in the pathogenesis of the nephrotic syndrome. In at least some of these cases, however, the diagnosis of membranous nephropathy may have been missed if only light microscopy had been performed. The diagnosis of membranous nephropathy is confirmed by marked granular staining for IgG on immunofluorescence microscopy and subepithelial immune deposits on electron microscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .) Two cases of nephrotic syndrome from minimal change glomerulonephritis were also reported in Hong Kong after use of a skin lightening cream containing 3 percent mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/32\">",
"     32",
"    </a>",
"    ]. Initially, blood and urine concentrations of mercury were on the order of 30 to 60",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    but decreased to normal levels after cessation of cream use and treatment with D-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The nephrotic syndrome may also occur in association with acrodynia or occupational exposure to mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In two reports, for example, the nephrotic syndrome developed in 2 of 50 workers and 4 of 72 workers exposed to mercury compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. All of these patients completely recovered within a few months after cessation of the exposure. Two cases of membranous nephropathy and nephrotic syndrome were reported from a fluorescent-tube recycling industry in Germany [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/33\">",
"     33",
"    </a>",
"    ]. Heavy occupational exposure to mercury was evident from markedly elevated urinary excretion of mercury (118 and 158 mcg",
"    <span class=\"nowrap\">",
"     Hg/L,",
"    </span>",
"    respectively). Two years after withdrawal from exposure to mercury, urinary excretion of mercury and protein was almost normalized in one patient. The second patient was treated but lost to follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tubular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational exposure to mercury is also associated with subtle abnormalities in tubular function. One study, for example, found a slightly higher prevalence of elevated urinary excretion of albumin, transferrin, retinol binding protein, and the tubular enzyme &szlig;-galactosidase in chloralkali workers with a urinary excretion of mercury exceeding 50",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes presumably reflected tubular injury, leading to the excretion of smaller proteins that are normally filtered and then largely reabsorbed. The tubular lesions are probably dose-related (with large doses [grams] causing acute tubular necrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/1\">",
"     1",
"    </a>",
"    ]. Uptake of mercury by tubular cells may be mediated by organic anion transporter 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15684?source=see_link\">",
"     \"Chapter 3C: Secretory pathways in proximal tubule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of the tubular enzyme N-acetyl-&szlig;-D-glucosaminidase (NAG) appears to be particularly effective in unraveling early evidence of nephrotoxicity from mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]; other early tubular markers have also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/41\">",
"     41",
"    </a>",
"    ]. In a thorough cross-sectional examination of chloralkali workers exposed to mercury at air concentrations of approximately 25",
"    <span class=\"nowrap\">",
"     mcg/m3,",
"    </span>",
"    a significant correlation and dose-response relationship was observed between the urinary excretion of mercury and NAG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/39\">",
"     39",
"    </a>",
"    ] No significant differences were observed between exposed and control patients with respect to other renal parameters, including urinary excretion of albumin, orosomucoid, &szlig;2-microglobulin, or copper, or in the serum creatinine concentration.",
"   </p>",
"   <p>",
"    These more subtle tubular effects from mercury may be reversible. As an example, evidence of nephrotoxicity (or other adverse effects) was not observed after extensive examination among workers previously (average of six years) exposed to relatively low levels of mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no scientifically valid reports of human nephrotoxicity (or other types of adverse health effects, apart from local hypersensitivity in some individuals) caused by the release of mercury from amalgam fillings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/9,43\">",
"     9,43",
"    </a>",
"    ]. In one experimental study, for example, renal function was thoroughly assessed in 10 healthy volunteers shortly before and up to 60 days after removal of an average of 18 tooth surfaces filled with amalgam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/44\">",
"     44",
"    </a>",
"    ]. No evidence of any nephrotoxic effects was observed, despite the possible exposure to significant amounts of mercury. Similar negative results were found in a randomized controlled trial of 534 children aged 6 to 10 years to determine whether mercury released from amalgam fillings caused neuropsychological or renal (glomerular) effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with chelators should be considered in patients with acute symptoms arising from the central nervous system due to confirmed mercury poisoning (eg, via measurement of mercury in blood or urine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinical signs and symptoms from acute poisoning of mercury is unlikely if blood and urine concentrations are below 100",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    but subclinical toxicity may occur below this level.",
"   </p>",
"   <p>",
"    The drugs currently available for mercurial poisoning in humans are thiol-based chelating agents, such as British Anti-Lewisite (BAL),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/13\">",
"     13",
"    </a>",
"    ], and newer drugs, such as unithiol (2,3 dimercaptopropane-1-sulfonate, abbreviated DMPS) and succimer (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12709?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    abbreviated DMSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. One study compared the efficacy of penicillamine with that of DMSA; DMSA increased the excretion of mercury to a greater extent than penicillamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are the standard dose regimens used for mercury chelation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       Penicillamine",
"      </a>",
"      is given with paradoxen at doses of 500 mg PO every six hours for five days.",
"     </li>",
"     <li>",
"      DMPS is administered according to the following regimen: 250 mg IM or IV every four hours on day one, 250 mg IM or IV every six hours on day two, and 250 mg IM or IV every six to eight hours for days three to five. DMPS is not approved for use in the United States.",
"     </li>",
"     <li>",
"      DMSA is given at a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO every eight hours for five days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of chelation therapy should be monitored by repeated clinical assessment and measurement of mercury in blood and urine. Treatment may be required for more than one week in severe cases of mercury poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Renal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment is recommended for renal toxicity from mercury. However, the administration of chelators should be considered if there has been a high degree of exposure. The obvious and most important action is to eliminate, or minimize, exposure to mercury since the nephrotic syndrome due to mercury is usually reversible, although it may take several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34295/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occupational exposure to mercury can be eliminated by the replacement of mercury with less toxic substances of equivalent industrial utility; if this is not feasible, occupational exposure should be kept well below the TLV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mercury exists in metallic, inorganic and organic forms which are characterized by different toxic properties. Metallic and organic forms, the latter found as methylated mercury in contaminated fish, are toxic to the central nervous system and the fetus whereas inorganic forms of mercury may affect the kidneys. Exposure to metallic and inorganic mercury can occur via the inhalation of vapor, oral ingestion or cutaneous absorption from topical preparations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Human exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major source of mercury that causes toxicity to the general public is from ingestion of contaminated fish containing methylated mercury. Although the general public is also exposed to inorganic and metallic mercury from amalgam fillings there are NO data to suggest that this is associated with toxicity. Occupational and accidental exposure to inorganic and metallic forms of mercury may occur in individuals who work in dentistry, chloralkali industries, thermometer factories and mercury mines. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Human exposure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Occupational exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of mercury toxicity depend upon the type and level of exposure. A severe interstitial pneumonitis may result when mercury vapor is inhaled at concentrations in excess of 1000",
"      <span class=\"nowrap\">",
"       mcg/m3.",
"      </span>",
"      Other symptoms and signs of severe poisoning include intention tremor, Inflammation of the gums with excessive salivation and psychiatric symptoms, such as excitability, insomnia, irritation, and shyness. Exposure to lower air concentrations of mercury in the range of 100 to 1000",
"      <span class=\"nowrap\">",
"       mcg/m3",
"      </span>",
"      may cause milder signs and symptoms of toxicity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'General toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small children who are exposed to high concentrations of mercury vapor may develop acrodynia (pink disease). Acrodynia is a syndrome characterized by a body rash, swelling and irritation of palms and feet followed by skin desquamation, irritability, photophobia, fever, insomnia, and profuse sweating. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acrodynia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of toxicity resulting from ingestion of methylated mercury include paresthesias around the mouth, malaise, constriction of the visual field, deafness, and ataxia. The fetus is particularly vulnerable even if the pregnant mother shows no signs of toxicity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Organic mercury compounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nephrotoxicity from inorganic and metallic forms of mercury is manifested by the nephrotic syndrome and signs of tubular dysfunction. Nephrotic syndrome is usually due to membranous nephropathy although minimal change disease has been described. Tubular dysfunction causes elevated urinary excretion of albumin, transferrin, retinol binding protein, and the tubular enzyme &szlig;-galactosidase. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nephrotoxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Tubular dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurements of mercury in blood and urine are useful in quantifying the degree of exposure. Clinically significant poisoning from inorganic mercury is unlikely if blood and urine concentrations are below 100",
"      <span class=\"nowrap\">",
"       mcg/L,",
"      </span>",
"      but subclinical toxicity may occur below this level. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with chelators may be considered in patients with acute symptoms arising from the central nervous system due to confirmed mercury poisoning (eg, via measurement of mercury in air, blood, or urine). The efficacy of chelation therapy should be monitored by repeated clinical assessment and measurement of mercury in blood and urine. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific treatment is recommended for renal toxicity from mercury although the administration of chelators should be considered if there has been a high degree of exposure. Mercury exposure should be eliminated or minimized as much as possible. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Renal toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO. Inorganic mercury. Environmental Health Criteria 118. World Health Organization, Geneva, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/2\">",
"      Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations. N Engl J Med 2003; 349:1731.",
"     </a>",
"    </li>",
"    <li>",
"     Fowler, BA, Whittaker, MH, Elinder, CG. Mercury-induced renal effects. In: Clinical Nephrotoxins. Renal Injury from Drugs and Chemicals, 3rd ed, De Broe, M, Porter, GA (Eds), Springer, New York 2008, p. 811.",
"    </li>",
"    <li>",
"     Schutte, NP, Knight, AL, Jahn, O. Mercury and its compounds. In: Occupational Medicine, 3d ed, Zenz, C, Dickerson, OB, Horovath, EP (Eds), Mosby-Year Book Inc, St. Louis, 1994, p. 549.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/5\">",
"      Byrne, L. Brazil's mercury poisoning disaster. BMJ 1992; 304:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/6\">",
"      Malm O. Gold mining as a source of mercury exposure in the Brazilian Amazon. Environ Res 1998; 77:73.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Methylmercury. Environmental Health Criteria 101. World Health Organization, Geneva 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/8\">",
"      S&auml;llsten G, Barreg&aring;rd L, Osterberg T. [Tooth grinding among wearers of amalgam fillings--a cause of high mercury release?]. Lakartidningen 1991; 88:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/9\">",
"      Bates MN. Mercury amalgam dental fillings: an epidemiologic assessment. Int J Hyg Environ Health 2006; 209:309.",
"     </a>",
"    </li>",
"    <li>",
"     Elinder, CG, Friberg, L, Nordberg, GF, et al. Biological monitoring of metals. Chemical Safety Monographs. International Program on Chemical Safety. WHO/EHG/94.2 1994; 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/11\">",
"      Ronchetti R, Zuurbier M, Jesenak M, et al. Children's health and mercury exposure. Acta Paediatr Suppl 2006; 95:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/12\">",
"      S&auml;llsten G, Barreg&aring;rd L, J&auml;rvholm B. Mercury in the Swedish chloralkali industry--an evaluation of the exposure and preventive measures over 40 years. Ann Occup Hyg 1990; 34:205.",
"     </a>",
"    </li>",
"    <li>",
"     Berlin, M. Mercury. In: Handbook on the toxicology of metals, Vol. II. Friberg, L, Nordberg, GF, Vouk, VB (Eds), Amsterdam: Elsevier 1986. p. 387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/14\">",
"      Clarkson TW. Mercury--an element of mystery. N Engl J Med 1990; 323:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/15\">",
"      Grandjean P, Weihe P, White RF, Debes F. Cognitive performance of children prenatally exposed to \"safe\" levels of methylmercury. Environ Res 1998; 77:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/16\">",
"      Nierenberg DW, Nordgren RE, Chang MB, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 1998; 338:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/17\">",
"      Kulig K. A tragic reminder about organic mercury. N Engl J Med 1998; 338:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/18\">",
"      CAMERON JS, TROUNCE JR. MEMBRANOUS GLOMERULONEPHRITIS AND THE NEPHROTIC SYNDROME APPEARING DURING MERSALYL THERAPY. Guys Hosp Rep 1965; 114:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/19\">",
"      BECKER CG, BECKER EL, MAHER JF, SCHREINER GE. Nephrotic syndrome after contact with mercury. A report of five cases, three after the use of ammoniated mercury ointment. Arch Intern Med 1962; 110:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/20\">",
"      MUNCK O, NISSEN NI. Development of nephrotic syndrome during treatment with mercurial diuretics. Acta Med Scand 1956; 153:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/21\">",
"      BURSTON J, DARMADY EM, STRANACK F. Nephrosis dur to mercurial diuretics. Br Med J 1958; 1:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/22\">",
"      RIDDLE M, GARDNER F, BESWICK I, FILSHIE I. The nephrotic syndrome complicating mercurial diuretic therapy. Br Med J 1958; 1:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/23\">",
"      PREEDY JR, RUSSELL DS. Acute salt depletion associated with the nephrotic syndrome developing during treatment with a mercurial diuretic. Lancet 1953; 265:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/24\">",
"      WILLIAMS NE, BRIDGE HG. Nephrotic syndrome after the application of mercury ointment. Lancet 1958; 2:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/25\">",
"      WILSON VK, THOMSON ML, HOLZEL A. Mercury nephrosis in young children, with special reference to teething powders containing mercury. Br Med J 1952; 1:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/26\">",
"      Barr RD, Rees PH, Cordy PE, et al. Nephrotic syndrome in adult Africans in Nairobi. Br Med J 1972; 2:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/27\">",
"      Oliveira DB, Foster G, Savill J, et al. Membranous nephropathy caused by mercury-containing skin lightening cream. Postgrad Med J 1987; 63:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/28\">",
"      Agner E, Jans H. Mercury poisoning and nephrotic syndrome in two young siblings. Lancet 1978; 2:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/29\">",
"      FRIBERG L, HAMMARSTROM S, NYSTROM A. Kidney injury after exposure to inorganic mercury. AMA Arch Ind Hyg Occup Med 1953; 8:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/30\">",
"      KAZANTZIS G, SCHILLER KF, ASSCHER AW, DREW RG. Albuminuria and the nephrotic syndrome following exposure to mercury and its compounds. Q J Med 1962; 31:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/31\">",
"      Li SJ, Zhang SH, Chen HP, et al. Mercury-induced membranous nephropathy: clinical and pathological features. Clin J Am Soc Nephrol 2010; 5:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/32\">",
"      Tang HL, Chu KH, Mak YF, et al. Minimal change disease following exposure to mercury-containing skin lightening cream. Hong Kong Med J 2006; 12:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/33\">",
"      Aymaz S, Gross O, Krakamp B, et al. Membranous nephropathy from exposure to mercury in the fluorescent-tube-recycling industry. Nephrol Dial Transplant 2001; 16:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/34\">",
"      Roels H, Gennart JP, Lauwerys R, et al. Surveillance of workers exposed to mercury vapour:validation of a previously proposed biological threshold limit value for mercury concentration in urine. Am J Ind Med 1985; 7:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/35\">",
"      Zalups RK, Aslamkhan AG, Ahmad S. Human organic anion transporter 1 mediates cellular uptake of cysteine-S conjugates of inorganic mercury. Kidney Int 2004; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/36\">",
"      Zalups RK, Ahmad S. Homocysteine and the renal epithelial transport and toxicity of inorganic mercury: role of basolateral transporter organic anion transporter 1. J Am Soc Nephrol 2004; 15:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/37\">",
"      Stonard MD, Chater BV, Duffield DP, et al. An evaluation of renal function in workers occupationally exposed to mercury vapour. Int Arch Occup Environ Health 1983; 52:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/38\">",
"      Barreg&aring;rd L, Hultberg B, Sch&uuml;tz A, S&auml;llsten G. Enzymuria in workers exposed to inorganic mercury. Int Arch Occup Environ Health 1988; 61:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/39\">",
"      Langworth S, Elinder CG, Sundquist KG, Vesterberg O. Renal and immunological effects of occupational exposure to inorganic mercury. Br J Ind Med 1992; 49:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/40\">",
"      Van Vleet TR, Schnellmann RG. Toxic nephropathy: environmental chemicals. Semin Nephrol 2003; 23:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/41\">",
"      C&aacute;rdenas A, Roels H, Bernard AM, et al. Markers of early renal changes induced by industrial pollutants. I. Application to workers exposed to mercury vapour. Br J Ind Med 1993; 50:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/42\">",
"      Frumkin H, Letz R, Williams PL, et al. Health effects of long-term mercury exposure among chloralkali plant workers. Am J Ind Med 2001; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/43\">",
"      Brownawell AM, Berent S, Brent RL, et al. The potential adverse health effects of dental amalgam. Toxicol Rev 2005; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/44\">",
"      Sandborgh-Englund G, Nygren AT, Ekstrand J, Elinder CG. No evidence of renal toxicity from amalgam fillings. Am J Physiol 1996; 271:R941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/45\">",
"      Bellinger DC, Trachtenberg F, Barregard L, et al. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. JAMA 2006; 295:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/46\">",
"      Barregard L, Trachtenberg F, McKinlay S. Renal effects of dental amalgam in children: the New England children's amalgam trial. Environ Health Perspect 2008; 116:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/47\">",
"      S&auml;llsten G, Barreg&aring;rd L, Sch&uuml;tz A. Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine. Occup Environ Med 1994; 51:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34295/abstract/48\">",
"      Bluhm RE, Bobbitt RG, Welch LW, et al. Elemental mercury vapour toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part I: History, neuropsychological findings and chelator effects. Hum Exp Toxicol 1992; 11:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7179 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34295=[""].join("\n");
var outline_f33_31_34295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USES OF MERCURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HUMAN EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Amalgam fillings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exposure from diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Occupational exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biochemokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENERAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acrodynia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Organic mercury compounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEPHROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tubular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Renal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15684?source=related_link\">",
"      Chapter 3C: Secretory pathways in proximal tubule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34296="Ankle sprain";
var content_f33_31_34296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ankle sprain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Karen L Maughan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34296/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/31/34296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle injuries are among the most common injuries presenting to primary care offices and emergency departments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with ankle sprains (stretching, partial rupture, or complete rupture of at least one ligament) constitute a large percentage of these injuries.",
"   </p>",
"   <p>",
"    Ankle ligaments provide mechanical stability, proprioceptive information, and directed motion for the joint. Recurrent ankle sprains can lead to functional instability and loss of normal ankle kinematics and proprioception, which can result in recurrent injury, chronic instability, early degenerative bony changes, and chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/2\">",
"     2",
"    </a>",
"    ]. Acute ankle sprains can result in lost days of work and inability to participate in sports.",
"   </p>",
"   <p>",
"    Ankle sprains will be reviewed here. Ankle fractures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36376?source=see_link\">",
"     \"Overview of ankle fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANKLE SPRAINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury generally determines the location of the sprain (",
"    <a class=\"graphic graphic_figure graphicRef86925 \" href=\"mobipreview.htm?15/63/16371\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Lateral ankle sprain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism of ankle injury is inversion of the plantar-flexed foot (",
"    <a class=\"graphic graphic_figure graphicRef60173 \" href=\"mobipreview.htm?0/8/140\">",
"     figure 2",
"    </a>",
"    ), which causes damage to the lateral ligament complex of the ankle. This ligament complex consists of the anterior talofibular ligament, the calcaneofibular ligament, and the posterior talofibular ligament (",
"    <a class=\"graphic graphic_figure graphicRef72462 \" href=\"mobipreview.htm?0/9/159\">",
"     figure 3",
"    </a>",
"    ). The ligaments within this complex are injured in a predictable sequence as forces increase.",
"   </p>",
"   <p>",
"    The anterior talofibular ligament is the first or only ligament to be injured in the majority of ankle sprains. Stronger forces lead to combined ruptures of the anterior talofibular ligament and the calcaneofibular ligament, which can result in significant ankle joint instability. Isolated injury of the calcaneofibular ligament is uncommon. Yet stronger forces result in injury to all three ligaments. Such injuries, while uncommon, are more debilitating and more commonly associated with significant nerve injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Medial ankle sprain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medial deltoid ligament complex (",
"    <a class=\"graphic graphic_figure graphicRef51952 \" href=\"mobipreview.htm?34/57/35728\">",
"     figure 4",
"    </a>",
"    ) is the strongest of the ankle ligaments and is infrequently injured. Forced eversion of the ankle can cause damage to this structure but more commonly results in an avulsion fracture of the medial malleolus because of the strength of the deltoid ligament.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Syndesmotic sprain (high ankle sprain)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsiflexion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eversion of the ankle may cause sprain of the syndesmotic structures, which include the anterior tibiofibular, posterior tibiofibular, and transverse tibiofibular ligaments, and the interosseous membrane (",
"    <a class=\"graphic graphic_figure graphicRef61181 \" href=\"mobipreview.htm?1/55/1904\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/4\">",
"     4",
"    </a>",
"    ]. These structures are critical to ankle stability. Syndesmotic ligament injuries contribute to chronic ankle instability and are more likely to result in recurrent ankle sprain and the formation of heterotopic ossification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/5\">",
"     5",
"    </a>",
"    ]. Syndesmosis sprains range from 1 to 11 percent of all ankle sprains, with a higher rate of injury occurring in contact sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankle sprains have traditionally been classified based upon clinical signs and functional loss from grade I to grade III:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A grade I sprain results from mild stretching of a ligament with microscopic tears. Patients have mild swelling and tenderness. There is no joint instability on examination, and the patient is able to bear weight and ambulate with minimal pain. Due to their benign nature, these injuries are not frequently seen in the office.",
"     </li>",
"     <li>",
"      A grade II sprain is a more severe injury involving an incomplete tear of a ligament. Patients have moderate pain, swelling, tenderness, and ecchymosis. There is mild to moderate joint instability on exam with some restriction of the range of motion and loss of function. Weightbearing and ambulation are painful.",
"     </li>",
"     <li>",
"      A grade III sprain involves a complete tear of a ligament. Patients have severe pain, swelling, tenderness, and ecchymosis. There is significant mechanical instability on exam and significant loss of function and motion. Patients are unable to bear weight or ambulate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although higher grade sprains involve more severe injuries to ligaments, the time for healing is not always proportional to the grade of the sprain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of an injured ankle requires a careful history. It is important to determine:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mechanism of injury in order to direct the rest of the examination (",
"      <a class=\"graphic graphic_figure graphicRef86925 \" href=\"mobipreview.htm?15/63/16371\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Whether or not the patient could walk after the injury in order to help stratify risk of fracture.",
"     </li>",
"     <li>",
"      Whether or not the ankle had been previously injured, as people who sprain ankles are more likely to reinjure the same ankle; a study in basketball players found repeat ankle injuries almost five times as likely as primary injuries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of the ankle includes inspection, palpation, determination of weightbearing ability, and injury-specific physical diagnostic tests.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Look for swelling and ecchymosis.",
"     </li>",
"     <li>",
"      Palpate the entire fibula (a syndesmotic injury may be associated with a fracture of the proximal fibula &mdash; a Maisonneuve fracture), the distal tibia, the foot, and the Achilles tendon. The Thompson test should be performed if any tenderness or a tissue deficit is detected while palpating the Achilles tendon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1030?source=see_link\">",
"       \"Posterior and medial ankle tendinopathies not involving the Achilles tendon\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Check for tenderness in the areas required for the Ottawa ankle rules (posterior edge or tip of the lateral malleolus; posterior edge or tip of the medial malleolus; base of the fifth metatarsal; navicular bone). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ottawa ankle rules'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Tenderness of the distal tibia or fibula may represent fracture associated with inversion or eversion injuries (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Ottawa ankle rules'",
"      </a>",
"      below). Tenderness over the ligamentous structures is a non-specific finding but often indicates injury.",
"      <br/>",
"      <br/>",
"      An eversion or hyperdorsiflexion injury associated with tenderness at the distal tibiofibular joint (",
"      <a class=\"graphic graphic_picture graphicRef66111 \" href=\"mobipreview.htm?1/59/1970\">",
"       picture 1",
"      </a>",
"      ) without significant swelling may suggest a syndesmosis sprain.",
"      <br/>",
"      <br/>",
"      Effusion and pain on palpation of the talocrural joint line (",
"      <a class=\"graphic graphic_picture graphicRef58683 \" href=\"mobipreview.htm?23/26/23969\">",
"       picture 2",
"      </a>",
"      ) may suggest a fracture of the osteochondral talar dome resulting from direct trauma between the talus and the fibula or tibia.",
"     </li>",
"     <li>",
"      Check for pain on gentle passive inversion and eversion of the ankle. In lateral ankle sprains, pain is increased with forced ankle inversion, while the pain of a medial (deltoid) ligament sprain is accentuated by eversion of the ankle.",
"     </li>",
"     <li>",
"      Perform specific examination maneuvers (described below) including the squeeze test, the external rotation stress test, the anterior drawer test, and the talar tilt test.",
"      <br/>",
"      <br/>",
"      If there is no swelling or ecchymosis, physical examination maneuvers do not elicit pain, and the Ottawa ankle criteria for imaging are not met (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Ottawa ankle rules'",
"      </a>",
"      below), there is unlikely to be structural damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8653137\">",
"    <span class=\"h2\">",
"     Special tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Squeeze test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The squeeze test consists of compression of the fibula against the tibia at the mid-calf level. This maneuver elicits pain in the region of the anterior tibiofibular ligament (anterior to the lateral malleolus and proximal to the ankle joint) when a syndesmotic sprain has occurred (",
"    <a class=\"graphic graphic_picture graphicRef55899 \" href=\"mobipreview.htm?23/15/23793\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     External rotation stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external rotation stress test can also help identify a syndesmotic sprain (",
"    <a class=\"graphic graphic_picture graphicRef57674 \" href=\"mobipreview.htm?20/42/21153\">",
"     picture 4",
"    </a>",
"    ). The clinician stabilizes the leg proximal to the ankle joint while grasping the plantar aspect of the foot and rotating the foot externally relative to the tibia. The test is positive if pain is elicited in the region of the anterior tibiofibular ligament (anterior to the lateral malleolus and proximal to the ankle joint).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anterior drawer test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior drawer test detects excessive anterior displacement of the talus on the tibia. If the anterior talofibular lateral ligament is torn by an inversion stress, the talus will sublux anteriorly and laterally out of the mortise. The test is performed with the patient's foot in the neutral position (slightly plantar flexed and inverted). The lower leg is stabilized by the examiner with one hand, and with the opposite hand, the examiner grasps the heel while the patient's foot rests on the anterior aspect of the examiner's arm. An anterior force is gently but steadily applied to the heel while holding the distal anterior leg fixed (",
"    <a class=\"graphic graphic_picture graphicRef58891 \" href=\"mobipreview.htm?22/46/23265\">",
"     picture 5",
"    </a>",
"    ). The amount of movement should be compared with the uninjured side to determine joint laxity. This test has limited usefulness in the acute setting because pain, swelling, and muscle spasm may limit mobility of the joint and interfere with the test's reliability. It is a more helpful test in the evaluation of chronic ankle instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Talar tilt test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The talar tilt test detects excessive ankle inversion. If the ligamentous tear extends posteriorly into the calcaneofibular portion of the lateral ligament, the lateral ankle is unstable and talar tilt occurs. With the ankle in the neutral position, gentle inversion force is applied to the affected ankle, and the degree of inversion is observed and compared with the uninjured side (",
"    <a class=\"graphic graphic_picture graphicRef51938 \" href=\"mobipreview.htm?25/26/26017\">",
"     picture 6",
"    </a>",
"    ). As with the anterior drawer test, this maneuver is of limited usefulness in the acute injury when pain, swelling, and muscle spasm are present, and it may be more important in evaluating chronic ankle instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Deferred examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deferred examination may improve the diagnosis of ligamentous injuries and instability. One study of 160 consecutive patients with inversion injuries found that performing a physical examination five days after the injury improved the accuracy of diagnosing ligament rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/8\">",
"     8",
"    </a>",
"    ]. The positive predictive value for ligament rupture of the triad of pain on palpation of the anterior talofibular ligament, lateral discoloration due to hematoma, and a positive anterior drawer sign was 95 percent.",
"   </p>",
"   <p>",
"    Despite this, most patients with acute ankle injuries can be appropriately managed and triaged without performing a deferred examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RADIOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imaging modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malleolar fractures, distal fibula fractures, talar dome fractures, and syndesmosis separation may be diagnosed with plain x-ray. If indicated, anteroposterior, lateral, and mortise x-rays should be obtained (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86799 \" href=\"mobipreview.htm?20/40/21124\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stress radiography (obtaining plain films while performing a talar tilt or anterior drawer stress maneuver) is sometimes considered; however, it is rarely if ever clinically helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of acute injury, magnetic resonance imaging (MRI) has no advantage over plain x-ray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/10\">",
"     10",
"    </a>",
"    ]. However, MRI should be considered in ankle sprains that are still painful after six to eight weeks of standard therapy. MRI can detect talar dome fractures and may be used to confirm suspected syndesmosis injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Selection of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not well studied in the primary care setting, it is estimated that fracture of the ankle or midfoot occurs in less than 15 percent of patients presenting to an emergency department with an acute ankle sprain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. The Ottawa ankle rules were developed in an effort to reduce the number of unnecessary radiographs in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ottawa ankle rules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ottawa ankle rules were developed, tested, and validated in adult patients presenting to the emergency department with acute ankle injuries. Although their use specifically in the primary care setting has not been assessed, the rules have demonstrated excellent results in both pediatric and adult emergency department patient populations.",
"   </p>",
"   <p>",
"    A systematic review of 27 studies including 15,581 patients found that the Ottawa ankle rules were highly sensitive (96.4 to 99.6 percent) for excluding ankle fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/17\">",
"     17",
"    </a>",
"    ]. Specificity was modest and varied widely (10 to 79 percent), but the rules were purposely calibrated for high sensitivity at the expense of specificity. Less than 2 percent of patients who were negative for fracture according to the rules actually had a fracture. It was estimated that use of these rules in the emergency department for patients presenting with an acute ankle sprain would reduce the number of unnecessary radiographs by 30 to 40 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14711?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation of foot and ankle pain in the young athlete\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should remember that although multiple systematic reviews have found the Ottawa ankle rules to perform extremely well, as with any guidelines there are specific circumstances when clinical judgement should supersede them. As an example, patients with diminished peripheral sensation, such as diabetics, or intoxicated patients may need radiographs regardless of the Ottawa criteria. Missed fractures are a significant cause for litigation in the United States.",
"   </p>",
"   <p>",
"    The rules are as follows (",
"    <a class=\"graphic graphic_figure graphicRef69818 \" href=\"mobipreview.htm?32/53/33618\">",
"     figure 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    An ankle series is only indicated for patients who have pain in the malleolar zone",
"    <strong>",
"     AND",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have bone tenderness at the posterior edge or tip of the lateral or medial malleolus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are unable to bear weight both immediately after the injury and for four steps in the emergency department or doctor's office.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A foot series is only indicated for patients who have pain in the midfoot zone",
"    <strong>",
"     AND",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have bone tenderness at the base of the fifth metatarsal or at the navicular",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are unable to bear weight both immediately after the injury and for four steps in the emergency department or doctor's office.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following apply to the use of the Ottawa ankle rules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient can transfer weight twice to each foot (four steps), he or she is considered able to bear weight even if he or she limps.",
"     </li>",
"     <li>",
"      Palpate the distal 6 cm of the posterior edge of the fibula when assessing for bone tenderness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immediate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All lateral ankle ligament sprains can be treated in a similar fashion. Initial management goals are to limit inflammation and swelling and to maintain range of motion. Early treatment includes RICE (rest, ice, compression, elevation) for the first two to three days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rest is achieved by limiting weightbearing; patients use crutches until they are able to walk with a normal gait.",
"     </li>",
"     <li>",
"      Cryotherapy applied as ice or cold water immersion is recommended for 15 to 20 minutes every two to three hours for the first 48 hours or until swelling is improved, whichever comes first [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compression with an elastic bandage to minimize swelling should be applied early.",
"     </li>",
"     <li>",
"      The injured ankle should be kept elevated above the level of the heart to further alleviate swelling.",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) can be used; no particular NSAID has been shown to be superior. Both oral and topical NSAIDs are more effective than placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. There are no studies comparing topical NSAIDs and oral NSAIDs, nor are there studies comparing NSAIDs with non-NSAID analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ), so it is not clear that an antiinflammatory effect is important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercises including plantar flexion, dorsiflexion, and foot circles (",
"    <a class=\"graphic graphic_figure graphicRef68033 \" href=\"mobipreview.htm?16/36/16974\">",
"     figure 7",
"    </a>",
"    ) should be started early, once acute pain and swelling subside, to maintain range of motion. The intensity of rehabilitation is increased gradually. Ankle splints or braces can limit extremes of joint motion and allow early weightbearing while protecting against reinjury. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rehabilitation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Splints and braces'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of severe (grade III) ankle sprains is controversial. A brief period of immobilization may be helpful in some instances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild (grade 1) ankle sprains do not require immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment with an elastic wrap for a few days following the injury is sufficient. Patients with moderate (grade II) sprains may need sustained support following their injury. The combination of an elastic wrap and an Aircast&trade; or similar splint (",
"    <a class=\"graphic graphic_picture graphicRef57089 \" href=\"mobipreview.htm?23/14/23791\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78043 \" href=\"mobipreview.htm?14/23/14706\">",
"     picture 8",
"    </a>",
"    ) for up to a few weeks is generally sufficient. Ankle support in patients with mild or moderate sprains should not interfere with early rehabilitation. The appropriate type and duration of immobilization in patients with severe ankle sprains remains unclear and is discussed further below.",
"   </p>",
"   <p>",
"    A systematic review of 21 randomized and quasi-randomized trials found that functional rehabilitation was superior to immobilization on seven outcome measures: more patients returned to sport in the long term (RR 1.86, 95% CI 1.22-2.86); the time needed to return to sport was shorter (4.9 days, 95% CI 1.5-8.3); more patients had returned to work at short-term follow-up (RR 5.75, 95% CI 1.01-32.71); the time taken to return to work was shorter (8.2 days, 95% CI 6.3-10.2); fewer patients suffered from persistent swelling at short-term follow-up (RR 1.74, 95% CI 1.17-2.59); fewer patients suffered from objective instability as tested by stress x-ray (2.60, 95% CI 1.24-3.96); and patients treated functionally were more satisfied with their treatment (RR 1.83, 95% CI 1.09-3.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/24\">",
"     24",
"    </a>",
"    ]. Subsequent systematic reviews that did not pool data have reported similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each systematic review noted that many trials are of poor quality and stated that results should be interpreted cautiously. Several studies are hampered by small numbers, incomplete descriptions of interventions, and inconsistent outcome measurements. Furthermore, heterogeneity exists among the functional treatments and immobilization techniques evaluated. In a separate analysis of the higher quality trials, the only significant result was that patients treated with functional rehabilitation returned to work sooner than those treated with immobilization (12.9 days, 95% CI 7.1-18.7).",
"   </p>",
"   <p>",
"    The treatment of severe (grade III) ankle sprains in particular remains controversial. One of the trials included in the systematic review described above assigned 80 patients with grade III lateral ligament ruptures to immobilization in a plaster cast or early mobilization with a stabilizing orthosis. Patients treated with early mobilization resumed work and sports earlier than immobilized patients, and there were no differences in ankle stability or symptoms during activity after one year of follow-up.",
"   </p>",
"   <p>",
"    However, conflicting results were found in a well performed, multicenter, randomized controlled trial of severe ankle sprains performed subsequently to the systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/26\">",
"     26",
"    </a>",
"    ]. In this study, 584 patients with severe ankle sprains were assigned to treatment using a below-knee cast for 10 days, Aircast&trade; brace, Bledsoe&trade; immobilization boot, or tubular compression bandage. Assessment at three months using a validated score for ankle function, found the greatest improvements in the cast group. Few if any patients received functional rehabilitation and the authors note that compliance with treatments other than casting could not be monitored. Follow-up at nine months revealed no significant differences in outcome or complications among the treatment groups. Of note, the most common reason for refusing to participate in the study was an unwillingness to be treated with a cast.",
"   </p>",
"   <p>",
"    Given these results, it is difficult to determine the appropriate role and timing for immobilization and early functional rehabilitation in patients with grade III ankle sprains. It appears reasonable, particularly if mobilization is painful and compliance likely to be difficult, to offer a short period (10 days) of immobilization in a cast for patients with severe ankle sprains. Alternatively, a comparable period of strict nonweightbearing and immobilization using a combination of an Aircast&trade; splint and an elastic wrap may be used. Early functional rehabilitation can be started once immobilization is discontinued. For patients treated without casting, the importance of compliance with the treatment plan (eg, maintaining nonweightbearing status and immobilization for the designated period) should be emphasized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Approach and exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional rehabilitation is of great importance in aiding the return to activity and preventing chronic instability. Early functional rehabilitation includes range of motion exercises (Achilles tendon stretch, foot circles (",
"    <a class=\"graphic graphic_figure graphicRef68033 \" href=\"mobipreview.htm?16/36/16974\">",
"     figure 7",
"    </a>",
"    ), alphabet exercises [have the patient trace letters in the air with his big toe]), muscle strengthening exercises (isometric and isotonic plantar flexion, dorsiflexion, inversion, eversion, toe curls (",
"    <a class=\"graphic graphic_picture graphicRef55497 \" href=\"mobipreview.htm?25/0/25615\">",
"     picture 9",
"    </a>",
"    ) and marble pickups, heel walks and toe walks), and proceeds to proprioceptive training (circular wobble board and walking on different surfaces) and activity-specific training (walk-jog, jog-run) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients with mild or moderate ankle sprains, functional rehabilitation should begin as soon the initial pain and swelling have subsided sufficiently to allow the patient to perform simple exercises. A randomized controlled study of patients with acute grade I and II ankle sprains, showed that patients who started therapeutic exercises within the first week of injury were engaging in weightbearing activities earlier without differences in pain, swelling or rate of reinjury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/31\">",
"     31",
"    </a>",
"    ]. Rehabilitation continues until the patient has returned to pain-free activity.",
"   </p>",
"   <p>",
"    The rehabilitation program should take several weeks in order for the ankle to strengthen and to limit the chance of reinjury. In a study of active-duty marines with grade II ankle sprains, those undergoing a structured rehabilitation program returned to duty up to several months earlier than those without rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patients with severe sprains should have their ankle immobilized for a period of time prior to rehabilitation is controversial (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Immobilization'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Splints and braces",
"    </span>",
"    &nbsp;&mdash;&nbsp;During functional rehabilitation, it may be of benefit to use splints, braces, elastic bandages, or taping to try to reduce instability, protect the ankle from further injury, and to limit swelling. It remains unclear whether taping improves proprioception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of studies looking at the treatment of acute ankle sprains reported the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lace-up ankle supports (",
"      <a class=\"graphic graphic_picture graphicRef87055 \" href=\"mobipreview.htm?10/43/10931\">",
"       picture 10",
"      </a>",
"      ) were superior to semi-rigid ankle supports, elastic bandages, and tape in preventing persistent swelling.",
"     </li>",
"     <li>",
"      Semi-rigid ankle supports (",
"      <a class=\"graphic graphic_picture graphicRef78043 \" href=\"mobipreview.htm?14/23/14706\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71638 \" href=\"mobipreview.htm?8/19/8507\">",
"       table 1",
"      </a>",
"      ) resulted in a quicker return to work and to sports, and less instability at short-term follow-up, than elastic bandages.",
"     </li>",
"     <li>",
"      Tape caused more skin irritation than elastic bandages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of ruptured ankle ligaments is sometimes considered in patients with ankle sprains. A metaanalysis that looked at controlled trials of surgery for acute ruptures of lateral ankle ligaments found that compared with functional treatment, patients treated with surgery were significantly less likely to experience giving-way of the ankle (relative risk 0.23, 95% CI 0.17-0.31) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/34\">",
"     34",
"    </a>",
"    ]. A subsequent systematic review concluded that there were methodologic flaws in all trials making it impossible to determine the relative effectiveness of surgical and conservative treatment for sprains of the lateral ankle ligaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent prospective trial of therapy for lateral ankle ligament rupture allocated 185 patients to surgery and 203 patients to functional treatment based upon the week in which they presented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/36\">",
"     36",
"    </a>",
"    ]. After a median follow-up of eight years, fewer patients treated surgically than with functional treatment reported residual pain (16 versus 25 percent), symptoms of giving-way (20 versus 32 percent), and recurrent sprains (22 versus 34 percent). There was no difference in the percent of patients with worsening radiographic evidence of joint degeneration. At follow-up, patients treated surgically were less likely to have a positive anterior drawer test (30 versus 54 percent); however, this was assessed by clinicians who knew how the patients had been treated. Thus, there were no blinded objective assessments in this trial that demonstrated superiority of surgery.",
"   </p>",
"   <p>",
"    Based on these results, it is unclear whether patients with acute ankle sprains would benefit from surgery. Given costs and operative risks, it is unlikely that most patients with mild or moderate ankle sprains will be treated surgically. It may be reasonable to consider surgery in some patients with severe sprains who are engaged in professional sports or other activities that are likely to impose repeated large stresses on the ankle joint.",
"   </p>",
"   <p>",
"    Although many experts conclude that delayed operative reconstruction of injured ligaments achieves results similar to that with acute repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/34\">",
"     34",
"    </a>",
"    ], we are not aware of any head-to-head trials that examine this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ultrasound and other proposed therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to a systematic review of six trials including 606 patients, ultrasound therapy is",
"    <strong>",
"     not",
"    </strong>",
"    an effective treatment for acute ankle sprain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/37\">",
"     37",
"    </a>",
"    ]. Other therapies that do not appear to be effective include low-level laser [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/38\">",
"     38",
"    </a>",
"    ] and hyperbaric oxygen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for referral to an orthopedic surgeon include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture",
"     </li>",
"     <li>",
"      Dislocation or subluxation",
"     </li>",
"     <li>",
"      Syndesmosis injury",
"     </li>",
"     <li>",
"      Tendon rupture",
"     </li>",
"     <li>",
"      Wound penetrating into the joint",
"     </li>",
"     <li>",
"      Uncertain diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with neurovascular compromise (distal findings of decreased sensation, motion, or circulation) require emergent evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metaanalysis of 31 studies that assessed the outcome of patients with acute ankle sprains noted the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain decreases rapidly during the first two weeks following injury.",
"     </li>",
"     <li>",
"      Approximately 5 to 33 percent of patients report some pain after one year.",
"     </li>",
"     <li>",
"      Healing rates vary widely among studies, with 36 to 85 percent of patients reporting full recovery over the first three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for primary or secondary prevention of ankle injuries include external ankle supports (eg, semi-rigid orthoses (",
"    <a class=\"graphic graphic_table graphicRef71638 \" href=\"mobipreview.htm?8/19/8507\">",
"     table 1",
"    </a>",
"    ), lace up supports, and high-top shoes), taping, stretching, strengthening, and proprioceptive ankle training using a wobble board and other techniques.",
"   </p>",
"   <p>",
"    According to two systematic reviews of trials that assessed the effectiveness of interventions to prevent ankle sprains, commonly used external supports (eg, bracing, taping) all reduce the risk of injury to a comparable degree but only among those patients with a history of ankle sprain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Risk is reduced by approximately 70 percent in this patient group (RR ranged from 0.15 to 0.5 among trials). Ankle supports do not appear to reduce the risk of a fresh ankle sprain among athletes. According to another systematic review of acute ankle sprain management, lace-up braces provide better functional support than elastic bandages and result in less short-term swelling compared with alternatives, and thus they may be useful for prevention as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials have reported that rates of ankle sprain recurrence are significantly reduced by proprioceptive training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/29,30,41,43,44\">",
"     29,30,41,43,44",
"    </a>",
"    ]. In one such trial, the 256 athletes randomly assigned to perform proprioceptive exercises at home sustained 56 recurrent ankle sprains compared to 89 among the 266 athletes assigned to usual care (RR 0.63; 95% CI 0.45 to 0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/43\">",
"     43",
"    </a>",
"    ]. Recurrence among athletes who were fully compliant with the neuromuscular training program was significantly lower than those who were partly or noncompliant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/45\">",
"     45",
"    </a>",
"    ]. Another trial of 80 professional soccer players with a history of inversion ankle sprain reported that only those athletes performing proprioceptive training experienced a significant reduction in recurrence (RR 0.13; 95% CI 0.003-0.93); athletes assigned to strength training alone did not reduce their risk of reinjury. Additional randomized controlled trials conducted with high school and young adult athletes report similar results with proprioceptive balance training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Athletes may have concerns about decreased performance with external ankle supports. A study that looked at running and jumping performance found differing results depending on the specific brace or method (such as taping) used, but in no case did a support decrease performance by more than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34296/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/46/34529?source=see_link\">",
"       \"Patient information: Ankle sprain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of most ankle sprains is an inversion injury to the lateral ligaments of the ankle. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification of ankle sprains'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients presenting with an acute ankle injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a careful history to determine the mechanism of injury (to direct the examination), whether the patient could walk after the injury (important for the Ottawa ankle rules), and whether the ankle had been previously injured (patients with a history of ankle sprains are at increased risk for new sprains). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perform a careful physical examination, with particular attention to the areas covered by the Ottawa ankle rules (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Ottawa ankle rules'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      To rule out an ankle fracture, obtain anteroposterior, lateral, and mortise plain films of the ankle, if indicated by the Ottawa ankle rules (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Ottawa ankle rules'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with a positive squeeze test or positive external rotation stress test may have a syndesmosis injury. Syndesmosis injury can be confirmed with MRI. Patients with a syndesmosis injury should be referred to an orthopedic surgeon. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Squeeze test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthopedic referral is necessary for a fracture, dislocation or subluxation, syndesmosis injury, tendon rupture, wound penetrating into the joint, and an uncertain diagnosis. Patients with neurovascular compromise (distal findings of decreased sensation, motion, or circulation) require emergent evaluation.",
"     </li>",
"     <li>",
"      Initial treatment consists of rest, ice, compression, elevation (RICE), early mobilization, and support orthosis with early weightbearing. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Immediate therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of severe (grade III) sprains is controversial. It is reasonable, particularly if mobilization is painful and compliance likely to be difficult, to initiate treatment with a brief period (10 days) of nonweightbearing and immobilization in a cast or in a combination of a rigid splint and elastic bandage. Early functional rehabilitation can be started once immobilization is discontinued. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a physical therapist for advanced functional rehabilitation can be helpful. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with persistent symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with symptoms that persist for more than six to eight weeks, obtaining an MRI can help to rule out conditions such as talar dome fractures or syndesmosis injury.",
"     </li>",
"     <li>",
"      Referral to an orthopedic surgeon can be useful for patients with chronic ankle instability. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For prevention of ankle injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lace-up supports can help prevent ankle injury during high risk activities among patients with a history of ankle sprain.",
"     </li>",
"     <li>",
"      Proprioception and strength training, possibly under the guidance of a physical therapist, can help reduce the risk of reinjury. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/1\">",
"      Boruta PM, Bishop JO, Braly WG, Tullos HS. Acute lateral ankle ligament injuries: a literature review. Foot Ankle 1990; 11:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/2\">",
"      Anandacoomarasamy A, Barnsley L. Long term outcomes of inversion ankle injuries. Br J Sports Med 2005; 39:e14; discussion e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/3\">",
"      Nitz AJ, Dobner JJ, Kersey D. Nerve injury and grades II and III ankle sprains. Am J Sports Med 1985; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/4\">",
"      Williams GN, Jones MH, Amendola A. Syndesmotic ankle sprains in athletes. Am J Sports Med 2007; 35:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/5\">",
"      Taylor, DC, Englehardt, DL, Bassett, FH III. Syndesmosis sprains of the ankle: The influence of heterotopic ossification. Am J Sports Med 1992; 20:146.",
"     </a>",
"    </li>",
"    <li>",
"     Trojian TH, McKeag DB. Ankle sprains: expedient assessment and management. Physician and Sportsmedicine 1998; 26:10. www.physsportsmed.com/issues/1998/10Oct/mckeag.htm (Accessed on June 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/7\">",
"      McKay GD, Goldie PA, Payne WR, Oakes BW. Ankle injuries in basketball: injury rate and risk factors. Br J Sports Med 2001; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/8\">",
"      van Dijk CN, Lim LS, Bossuyt PM, Marti RK. Physical examination is sufficient for the diagnosis of sprained ankles. J Bone Joint Surg Br 1996; 78:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/9\">",
"      Frost SC, Amendola A. Is stress radiography necessary in the diagnosis of acute or chronic ankle instability? Clin J Sport Med 1999; 9:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/10\">",
"      Nikken JJ, Oei EH, Ginai AZ, et al. Acute ankle trauma: value of a short dedicated extremity MR imaging examination in prediction of need for treatment. Radiology 2005; 234:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/11\">",
"      Brand DA, Frazier WH, Kohlhepp WC, et al. A protocol for selecting patients with injured extremities who need x-rays. N Engl J Med 1982; 306:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/12\">",
"      Brooks SC, Potter BT, Rainey JB. Inversion injuries of the ankle: clinical assessment and radiographic review. Br Med J (Clin Res Ed) 1981; 282:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/13\">",
"      Dunlop MG, Beattie TF, White GK, et al. Guidelines for selective radiological assessment of inversion ankle injuries. Br Med J (Clin Res Ed) 1986; 293:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/14\">",
"      Lloyd S. Selective radiographic assessment of acute ankle injuries in the emergency department: barriers to implementation. CMAJ 1986; 135:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/15\">",
"      Sujitkumar P, Hadfield JM, Yates DW. Sprain or fracture? An analysis of 2000 ankle injuries. Arch Emerg Med 1986; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/16\">",
"      Stiell IG, Greenberg GH, McKnight RD, et al. Decision rules for the use of radiography in acute ankle injuries. Refinement and prospective validation. JAMA 1993; 269:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/17\">",
"      Bachmann LM, Kolb E, Koller MT, et al. Accuracy of Ottawa ankle rules to exclude fractures of the ankle and mid-foot: systematic review. BMJ 2003; 326:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/18\">",
"      Sloan JP, Hain R, Pownall R. Clinical benefits of early cold therapy in accident and emergency following ankle sprain. Arch Emerg Med 1989; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/19\">",
"      Hocutt JE Jr, Jaffe R, Rylander CR, Beebe JK. Cryotherapy in ankle sprains. Am J Sports Med 1982; 10:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/20\">",
"      Mor&aacute;n M. Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res 1991; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/21\">",
"      Slatyer MA, Hensley MJ, Lopert R. A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Am J Sports Med 1997; 25:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/22\">",
"      Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev 2010; :CD007402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/23\">",
"      Seah R, Mani-Babu S. Managing ankle sprains in primary care: what is best practice? A systematic review of the last 10 years of evidence. Br Med Bull 2011; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/24\">",
"      Kerkhoffs GM, Rowe BH, Assendelft WJ, et al. Immobilisation and functional treatment for acute lateral ankle ligament injuries in adults. Cochrane Database Syst Rev 2002; :CD003762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/25\">",
"      Jones MH, Amendola AS. Acute treatment of inversion ankle sprains: immobilization versus functional treatment. Clin Orthop Relat Res 2007; 455:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/26\">",
"      Lamb SE, Marsh JL, Hutton JL, et al. Mechanical supports for acute, severe ankle sprain: a pragmatic, multicentre, randomised controlled trial. Lancet 2009; 373:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/27\">",
"      Wolfe MW, Uhl TL, Mattacola CG, McCluskey LC. Management of ankle sprains. Am Fam Physician 2001; 63:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/28\">",
"      Wester JU, Jespersen SM, Nielsen KD, Neumann L. Wobble board training after partial sprains of the lateral ligaments of the ankle: a prospective randomized study. J Orthop Sports Phys Ther 1996; 23:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/29\">",
"      Verhagen E, van der Beek A, Twisk J, et al. The effect of a proprioceptive balance board training program for the prevention of ankle sprains: a prospective controlled trial. Am J Sports Med 2004; 32:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/30\">",
"      McGuine TA, Keene JS. The effect of a balance training program on the risk of ankle sprains in high school athletes. Am J Sports Med 2006; 34:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/31\">",
"      Bleakley CM, O'Connor SR, Tully MA, et al. Effect of accelerated rehabilitation on function after ankle sprain: randomised controlled trial. BMJ 2010; 340:c1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/32\">",
"      Weinstein ML. An ankle protocol for second-degree ankle sprains. Mil Med 1993; 158:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/33\">",
"      Refshauge KM, Raymond J, Kilbreath SL, et al. The effect of ankle taping on detection of inversion-eversion movements in participants with recurrent ankle sprain. Am J Sports Med 2009; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/34\">",
"      Pijnenburg AC, Van Dijk CN, Bossuyt PM, Marti RK. Treatment of ruptures of the lateral ankle ligaments: a meta-analysis. J Bone Joint Surg Am 2000; 82:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/35\">",
"      Kerkhoffs GM, Handoll HH, de Bie R, et al. Surgical versus conservative treatment for acute injuries of the lateral ligament complex of the ankle in adults. Cochrane Database Syst Rev 2007; :CD000380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/36\">",
"      Pijnenburg AC, Bogaard K, Krips R, et al. Operative and functional treatment of rupture of the lateral ligament of the ankle. A randomised, prospective trial. J Bone Joint Surg Br 2003; 85:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/37\">",
"      van den Bekerom MP, van der Windt DA, Ter Riet G, et al. Therapeutic ultrasound for acute ankle sprains. Cochrane Database Syst Rev 2011; :CD001250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/38\">",
"      de Bie RA, de Vet HC, Lenssen TF, et al. Low-level laser therapy in ankle sprains: a randomized clinical trial. Arch Phys Med Rehabil 1998; 79:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/39\">",
"      Bennett M, Best TM, Babul S, et al. Hyperbaric oxygen therapy for delayed onset muscle soreness and closed soft tissue injury. Cochrane Database Syst Rev 2005; :CD004713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/40\">",
"      van Rijn RM, van Os AG, Bernsen RM, et al. What is the clinical course of acute ankle sprains? A systematic literature review. Am J Med 2008; 121:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/41\">",
"      Verhagen EA, Bay K. Optimising ankle sprain prevention: a critical review and practical appraisal of the literature. Br J Sports Med 2010; 44:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/42\">",
"      Dizon JM, Reyes JJ. A systematic review on the effectiveness of external ankle supports in the prevention of inversion ankle sprains among elite and recreational players. J Sci Med Sport 2010; 13:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/43\">",
"      Hupperets MD, Verhagen EA, van Mechelen W. Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial. BMJ 2009; 339:b2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/44\">",
"      Mohammadi F. Comparison of 3 preventive methods to reduce the recurrence of ankle inversion sprains in male soccer players. Am J Sports Med 2007; 35:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/45\">",
"      Verhagen EA, Hupperets MD, Finch CF, van Mechelen W. The impact of adherence on sports injury prevention effect estimates in randomised controlled trials: looking beyond the CONSORT statement. J Sci Med Sport 2011; 14:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34296/abstract/46\">",
"      Burks RT, Bean BG, Marcus R, Barker HB. Analysis of athletic performance with prophylactic ankle devices. Am J Sports Med 1991; 19:104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 189 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34296=[""].join("\n");
var outline_f33_31_34296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ANKLE SPRAINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Lateral ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Medial ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Syndesmotic sprain (high ankle sprain)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8653137\">",
"      Special tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Squeeze test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - External rotation stress test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Talar tilt test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Deferred examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imaging modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Selection of patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ottawa ankle rules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immediate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Approach and exercises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Splints and braces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ultrasound and other proposed therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/189|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/40/21124\" title=\"diagnostic image 1\">",
"      Plain x-ray normal ankle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/189|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/63/16371\" title=\"figure 1\">",
"      Common mechanisms for ankle sprains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/8/140\" title=\"figure 2\">",
"      Actions of the ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/9/159\" title=\"figure 3\">",
"      Lateral ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/57/35728\" title=\"figure 4\">",
"      Medial ankle ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/55/1904\" title=\"figure 5\">",
"      Syndesmotic sprain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/53/33618\" title=\"figure 6\">",
"      Ottawa ankle rules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/36/16974\" title=\"figure 7\">",
"      Foot ankle circles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/189|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/59/1970\" title=\"picture 1\">",
"      Anterior tibiofibular ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/26/23969\" title=\"picture 2\">",
"      Talocrural joint line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/15/23793\" title=\"picture 3\">",
"      Squeeze test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/42/21153\" title=\"picture 4\">",
"      External rotation ankle stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/46/23265\" title=\"picture 5\">",
"      Ankle anterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/26/26017\" title=\"picture 6\">",
"      Talar tilt test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/14/23791\" title=\"picture 7\">",
"      Air cushioned leg splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/23/14706\" title=\"picture 8\">",
"      Air cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/0/25615\" title=\"picture 9\">",
"      Toe towel curls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/43/10931\" title=\"picture 10\">",
"      Lace up ankle brace",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/19/8507\" title=\"table 1\">",
"      Ankle foot orthosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14711?source=related_link\">",
"      Evaluation of foot and ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36376?source=related_link\">",
"      Overview of ankle fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/46/34529?source=related_link\">",
"      Patient information: Ankle sprain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1030?source=related_link\">",
"      Posterior and medial ankle tendinopathies not involving the Achilles tendon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34297="Indications and contraindications for cardiac transplantation";
var content_f33_31_34297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications and contraindications for cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Donna Mancini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34297/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/31/34297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation is the treatment of choice for many patients with end-stage heart failure (HF) who remain symptomatic despite optimal medical therapy. Risk stratification of patients with end stage heart failure is pivotal for transplant candidate selection. The primary indications for cardiac transplantation along with the specific inclusion and exclusion criteria are discussed here.",
"   </p>",
"   <p>",
"    Prognosis after cardiac transplantation and treatment of refractory HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WAITING LIST AND ALLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Registry of the International Society for Heart and Lung Transplantation (ISHLT) reported 3742 heart transplants worldwide in 2010 (",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries\">",
"     www.ishlt.org/registries",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/1\">",
"     1",
"    </a>",
"    ]. This is probably an underestimate, as reporting to the registry is voluntary outside of the US. In the US, where reporting to the United Network Of Organ Sharing (UNOS) has been mandatory for the past two decades, the number of US heart transplants performed has been stable at approximately 2300 cases annually (",
"    <a class=\"graphic graphic_figure graphicRef83828 \" href=\"mobipreview.htm?16/38/17007\">",
"     figure 1",
"    </a>",
"    ). The majority of centers perform between 10 and 19 heart transplants per year.",
"   </p>",
"   <p>",
"    The number of transplant centers has decreased from 243 in 1996 to 204 in 2007. The ongoing organ donor shortage has been the major limitation to the growth of this therapy. Due to this critical organ shortage, the recipient selection process and donor allocation system have involved both clinical and ethical issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9528521\">",
"    <span class=\"h2\">",
"     Donor allocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to ensure equitable distribution of donor hearts, UNOS (United Network for Organ Sharing, a private organization under contract to the federal government) has created and regularly updates an organ allocation system (Organ Procurement and Transplantation Network,",
"    <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp\">",
"     OPTN",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/2\">",
"     2",
"    </a>",
"    ]. This system delineates prioritization rules that take into account the clinical severity of illness, time accrued on the wait list, blood type compatibility, and geographic distance. With heart procurement, the duration of ischemic time for the donor heart is a limiting factor in organ retrieval, with ischemic times greater than four hours associated with a higher rate of primary graft failure. Accordingly, geographic distance between the donor hospital and the transplant center is measured in 500 nautical mile circular concentric zones. &nbsp;",
"   </p>",
"   <p>",
"    This allocation system is regularly reviewed and revised with input from various sectors, including transplant professionals, organ recipients, and donor families. The current allocation system is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef83792 \" href=\"mobipreview.htm?31/43/32444\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/2\">",
"     2",
"    </a>",
"    ]. The last major change to this allocation system occurred in July 2006 when Status 1A and 1B patients in Zone A (first 500 mile concentric circle) were prioritized over local Status 2 candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite efforts to develop equal sharing of a scarce resource, there continues to be great variability in the median time to transplant that is highly dependent on location, ie, UNOS regions. Median time to heart transplantation in adults in 2009 ranged from 1.1 to 12.4 months depending on the donor service area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9528742\">",
"    <span class=\"h2\">",
"     Waitlist management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though the prevalence of heart failure continues to increase, the number of new patients added to the heart transplant waitlist declined from 3265 patients in 1998 to 2153 in 2005. There has been a subsequent uptrend with 2692 new additions in 2009, but the largest increase in listing has been in the high priority status groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/3\">",
"     3",
"    </a>",
"    ]. A trend toward greater urgency of transplantation over the last 10 years is illustrated by an increase in listed patients who were UNOS 1A from 2.5 percent in 1999 to 5.9 percent in 2009 and an increase in UNOS 1B transplant candidates from 9 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/4\">",
"     4",
"    </a>",
"    ]. According to the",
"    <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/\">",
"     OPTN website",
"    </a>",
"    , as of March 2012, 14 percent of the candidates listed were in Status 1A, and 43 percent in status 1B. Though 36 percent of the heart transplant listed patients were in Status 2, the frequency of transplantation in this group is currently less than 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONSIDERATIONS FOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations relevant to allocation of a heart to a specific patient include the patient&rsquo;s time accrued on the waitlist, geographic distance between the donor center and the transplant center, medical urgency, as well as sensitization, ie, the existence of anti-HLA antibodies in the recipient that would lead to a positive crossmatch with some donors. In the past, the sensitized candidate was typically a multiparous woman or a person with some prior transfusions. However, with the emergence of mechanical assist devices, the incidence of allosensitization has risen due to the multiple transfusions frequently required (at the time of implant or during long-term follow-up) by patients receiving these devices. The need for multi-drug high dose anticoagulation and the development of acquired von Willebrand disease frequently results in blood loss requiring transfusion during the time patients are bridged to transplant with these devices. The percent of sensitized transplant recipients increased from 5.3 percent in 1998 to 10.7 percent in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of technology for detection of specific anti-HLA antibodies (eg, using a Luminex &reg; template) has enabled identification of unacceptable donor antigens for particular candidates. This testing in combination with HLA identification of the donor organ permits the use of long distance &ldquo;virtual cross-matching&rdquo;. This approach enlarges the potential donor pool for sensitized patients in the modern era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, the International Society for Heart and Lung Transplantation (ISHLT) published a consensus statement of listing and management policies for potential cardiac transplantation candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. Non-ischemic cardiomyopathy and coronary artery disease are the disease processes leading to the vast majority of cardiac transplants, though increasing numbers of adults with complex congenital heart disease or requiring re-transplantation are represented (",
"    <a class=\"graphic graphic_figure graphicRef83829 \" href=\"mobipreview.htm?17/49/18207\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/1\">",
"     1",
"    </a>",
"    ]. For additional information see",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Improving survival with medical and device therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival rates in patients with advanced HF have increased as medical therapy has improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. Controlled trials in patients with systolic HF (including those with stable NYHA functional class III to IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    )) have demonstrated mortality benefit from medical management including angiotensin converting enzyme (ACE) inhibitor, beta-blocker, and aldosterone antagonist therapy, and, for African Americans, combination",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"      hydralazine",
"     </a>",
"     /nitrate",
"    </span>",
"    therapy. Randomized trials have also showed improved survival in selected patients with implantable cardioverter-defibrillator (ICD) therapy for primary or secondary prevention of sudden cardiac death and in selected patients with systolic HF with a wide QRS, cardiac resynchronization therapy, often combined with an ICD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis of the US population of heart transplant candidates demonstrated improved survival with medical and device therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/6\">",
"     6",
"    </a>",
"    ]. Survival on the waiting list significantly improved between the era 1990 to 1994 and the era 2000 to 2005 (",
"    <a class=\"graphic graphic_table graphicRef83826 \" href=\"mobipreview.htm?38/29/39389\">",
"     table 3",
"    </a>",
"    ). From 1990 to 1994 and 2000 to 2005, one-year survival for status 1 candidates improved from 49.5 to 69.0 percent and for status 2 candidates it improved from 81.8 to 89.4 percent. Thus, the one-year survival of status 2 candidates approached outcomes with heart transplantation. However, the vast majority of transplant candidates are currently UNOS 1A or 1B. Also, it is important to note that a patient initially registered as a UNOS 2 candidate who deteriorates and is upgraded to another priority status and who subsequently expires is not counted as a Status 2 death. Thus, the reported mortality rate of Status 2 candidates is an underestimate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite advances in treatment, some patients become refractory to medical therapy and require either mechanical or biologic support. Predictors of death shortly after listing include UNOS status 1A, the need for mechanical ventilation, inotropic and intraaortic balloon pump support, pulmonary capillary wedge &gt;20 mmHg, and serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dl,",
"    </span>",
"    failed prior cardiac transplant, valvular cardiomyopathy, age &gt;60 years, Caucasian ethnicity, weight &le;70 kg, as well as lack of ICD on the day of listing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Waiting-list mortality in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 250 to 300 children are added to the waitlist annually. The percentage of listed children who are less than one year of age has increased from 11 percent in 1998 to 22 percent in 2009. Waiting-list mortality in children listed for cardiac transplantation is high and is highest for children below age six years. The vast majority of children who die on the waiting list weigh less than 10 to 15 kg. An analysis of US Scientific Registry of Transplant Recipients data for 3098 children &lt;18 years old listed for cardiac transplantation between 1999 and 2006 found that 17 percent died, 63 percent received transplants, 8 percent recovered, and 12 percent remained listed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/7\">",
"     7",
"    </a>",
"    ]. Although status 1A patients were at higher risk of waiting-list mortality than status 1B or status 2 patients, waiting-list mortality varied by a greater degree within status 1A than between status categories and was best predicted by the level of invasive hemodynamic support (defined as extracorporeal membrane oxygenation versus ventilator versus neither). These findings suggested that the allocation system captured medical urgency poorly and in 2006 the organ allocation criteria were modified to remove geography as a factor for pediatric recipients. Pre-transplant mortality for pediatric patients has declined with the new allocation policy but still remains at an unacceptable level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION OF PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of prognosis in patients with severe HF is the most important component of the selection process. Many univariate predictors of poor prognosis have been identified, including NYHA functional class III or IV, reduced left ventricular ejection fraction (LVEF), and hyponatremia. However, use of an individual factor to identify high risk is frequently problematic, given the complexity of HF and the multiple neurohumoral, hemodynamic, and electrophysiologic factors that may contribute to morbidity and mortality. Peak exercise oxygen consumption is a factor that has been extremely helpful in identifying low risk patients who can continue on medical therapy. Use of multivariable models has significantly improved our ability to identify high risk patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peak VO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the peak VO2 (VO2max) provides an objective assessment of functional capacity in patients with HF and is one of the best predictors of when to list an individual patient for cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/8\">",
"     8",
"    </a>",
"    ]. 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    heart failure guidelines (with 2009 update) include peak VO2 criteria for cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=see_link\">",
"     \"Functional exercise testing: Ventilatory gas analysis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Major society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Beta blocker therapy has improved survival rates in patients with systolic heart failure including patients with very low peak VO2 to as low as 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min. The prognostic power of peak VO2 was initially validated prior to the widespread use of beta blockers, but several studies have demonstrated the continued usefulness of VO2 in the modern drug era with beta blocker use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. With evidence-based HF therapy including beta blockers and devices (ie, implantable cardioverter-defibrillator and cardiac resynchronization therapy), a peak VO2 cut point of &le; 10 to 12",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    appears to be a better threshold than &le;14",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for identification of high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/12\">",
"     12",
"    </a>",
"    ]. In a series of 715 patients with systolic heart failure referred for heart transplantation, one-year event-free survival was 87 percent in patients with VO2 &gt;14",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    77 percent in those with VO2 10.1 to 14",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    and 65 percent in patients with a VO2 &le;10",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Major society guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although peak VO2 has often been the major parameter used to guide the selection of heart transplant candidates, a single variable does not provide an optimal risk profile. As a result, several risk models have been developed that use factors identified in multivariable survival analysis to establish a risk score for prognosis in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis of heart failure\", section on 'Predictive models'",
"    </a>",
"    .) These include the Heart Failure Survival Score (HFSS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/13\">",
"     13",
"    </a>",
"    ] and the Seattle Heart Failure Model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For guiding decisions regarding the listing of patients for cardiac transplantation, these scores are most useful in cases where other predictors are ambiguous (eg, peak VO2 12 to 14",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the prognostic information provided can be considered when making recommendations about transplantation, cardiac transplantation centers do not base determinations on the results of risk models alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Heart Failure Survival Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;One model that has been validated prospectively is the Heart Failure Survival Score (HFSS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/13\">",
"     13",
"    </a>",
"    ]. This score was derived from a multivariable analysis of 268 ambulatory patients referred for consideration of cardiac transplantation from 1986 to 1991 and validated in 199 similar patients from 1993 to 1995. The predictors of survival in the HFSS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence or absence of coronary artery disease",
"     </li>",
"     <li>",
"      Resting heart rate",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction",
"     </li>",
"     <li>",
"      Mean arterial blood pressure",
"     </li>",
"     <li>",
"      Presence or absence of an intraventricular conduction delay on ECG",
"     </li>",
"     <li>",
"      Serum sodium",
"     </li>",
"     <li>",
"      Peak VO2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HFSS stratifies patients into low risk (HFSS &ge;8.10), medium risk (HFSS 7.20-8.09), and high risk (HFSS &le;7.19) categories, based upon a sum of the variables above multiplied by defined coefficients. Among the patients in the validation sample, one-year survival rates without transplant for these three strata were 88, 60, and 35 percent, respectively.",
"   </p>",
"   <p>",
"    Although the prognostic value of the Heart Failure survival score was initially identified prior to widespread use of beta blockers, its prognostic value has been revalidated since then in patients on beta blocker therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. In a series of 715 patients with systolic heart failure referred for heart transplantation, one-year event-free survival was 89 percent in patients with low risk scores, 72 percent in those with VO2 medium risk scores, and 60 percent in patients with high risk scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Seattle Heart Failure Model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the Heart Failure Survival Score, the Seattle Heart Failure Model has incorporated the impact of newer heart failure therapies on survival, including ICDs and CRT. The model was derived in 1125 heart failure patients and prospectively validated in five diverse cohorts including almost 10,000 general outpatients and advanced HF patients who were followed for over 17,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/17\">",
"     17",
"    </a>",
"    ]. The diversity of the patient populations makes the findings more generalizable to clinical practice.",
"   </p>",
"   <p>",
"    The model provides an accurate estimate of one-, two-, and three-year survival (r values ranging from 0.97 to 0.99) with the use of easily obtained clinical, pharmacologic, device, and laboratory characteristics. It also allows the operator to add in the estimated effect of interventions on an individual patient's prognosis.",
"   </p>",
"   <p>",
"    The Seattle Heart Failure Model is available online at",
"    <a class=\"external\" href=\"file://www.seattleheartfailuremodel.org/\">",
"     www.SeattleHeartFailureModel.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18660611\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18660619\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend heart transplantation for adults with one or more of the following indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic shock requiring either continuous intravenous inotropic support or circulatory support with an intraaortic balloon pump counterpulsation device or mechanical circulatory support",
"     </li>",
"     <li>",
"      Persistent New York Heart Association functional class IV HF symptoms refractory to maximal medical therapy (left ventricular ejection fraction &lt;20 percent; peak VO2 &lt;12",
"      <span class=\"nowrap\">",
"       mL/kg/min)",
"      </span>",
"     </li>",
"     <li>",
"      Intractable or severe anginal symptoms in patients with coronary artery disease not amenable to percutaneous or surgical revascularization or severe transplant coronary artery disease.",
"     </li>",
"     <li>",
"      Intractable life-threatening arrhythmias unresponsive to medical therapy, catheter ablation, surgery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      implantable cardioverter-defibrillator.",
"     </li>",
"     <li>",
"      Congenital heart disease with New York Heart Association functional class III-IV HF not amenable to palliative or corrective surgery. Patients with complex intracardiac abnormalities and significant pulmonary vascular obstructive disease may require",
"      <span class=\"nowrap\">",
"       heart/lung",
"      </span>",
"      transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    heart failure guidelines (unchanged by the 2009 focused update) and the 2012 European Society of Cardiology recommend referral for cardiac transplantation in potentially eligible patients with refractory end-stage HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. The 2006 Canadian Cardiovascular Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/21\">",
"     21",
"    </a>",
"    ] and the 2010 Heart Failure Society of America (HFSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/22\">",
"     22",
"    </a>",
"    ] guidelines recommend cardiac transplantation evaluation for selected patients with severe HF, debilitating refractory angina, or ventricular arrhythmia that cannot be controlled despite drug, device, or alternative surgical therapy.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines include the following indications for cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Absolute indications in appropriate patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For hemodynamic compromise due to HF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Refractory cardiogenic shock",
"     </li>",
"     <li>",
"      Documented dependence on intravenous inotropic support to maintain adequate organ perfusion",
"     </li>",
"     <li>",
"      Peak VO2 less than 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min with achievement of anaerobic metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe symptoms of ischemia that consistently limit routine activity and are not amenable to coronary artery bypass surgery or percutaneous coronary intervention.",
"     </li>",
"     <li>",
"      Recurrent symptomatic ventricular arrhythmias refractory to all therapeutic modalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peak V02 of 11 to 14",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute (or 55 percent predicted) and major limitation of the patient's daily activities",
"     </li>",
"     <li>",
"      Recurrent unstable ischemia not amenable to other intervention",
"     </li>",
"     <li>",
"      Recurrent instability of fluid",
"      <span class=\"nowrap\">",
"       balance/renal",
"      </span>",
"      function not due to patient noncompliance with medical regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insufficient indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low left ventricular ejection fraction",
"     </li>",
"     <li>",
"      History of functional class II or IV symptoms of HF",
"     </li>",
"     <li>",
"      Peak VO2 greater than 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute (or greater than 55 percent predicted) without other indications",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Combined organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multi-organ transplants have been increasing. Patients with end-stage heart disease who also have renal failure can be considered for dual organ transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2009, 3 percent of patients received combined heart-kidney transplants.",
"     </li>",
"     <li>",
"      Patients with end-stage lung disease who also have severe left ventricular dysfunction or other cardiac diseases that would preclude a successful outcome with lung transplantation alone may be candidates for combined heart-lung transplantation. The demand for heart-lung transplantation has been declining with only 61 patients listed nationwide for heart-lung transplant as of March 2, 2012.",
"     </li>",
"     <li>",
"      Combined heart and liver transplantation can be used in select candidates and was reported in 0.6 percent of cardiac transplants in 2009. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22775?source=see_link&amp;anchor=H12#H12\">",
"       \"Prognosis after cardiac transplantation\", section on 'Heart-kidney transplantation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/99?source=see_link\">",
"       \"Heart-lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is kidney transplantation in patients who develop renal failure after heart transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34250?source=see_link&amp;anchor=H10#H10\">",
"     \"Renal function and nonrenal solid organ transplantation\", section on 'Cardiac transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CRITERIA FOR PATIENT EXCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who meet the above requirements are excluded from transplantation when one or more absolute contraindications are demonstrated by standard evaluation procedures (",
"    <a class=\"graphic graphic_table graphicRef83788 \" href=\"mobipreview.htm?7/27/7613\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, relative contraindications must be taken into account in judging whether a patient is likely to benefit from heart transplantation. These contraindications impact the short- and long-term survival of the grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Increased pulmonary vascular resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major hemodynamic factor excluding cardiac transplantation is a non-reversible pulmonary vascular resistance (PVR) greater than 6 Wood units (320 to 480",
"    <span class=\"nowrap\">",
"     dynes-sec/cm",
"     <sup>",
"      5",
"     </sup>",
"     )",
"    </span>",
"    (normal is &le;1.5 Wood units [120",
"    <span class=\"nowrap\">",
"     dynes-sec/cm5]).",
"    </span>",
"    Patients with an elevated PVR or a transpulmonary gradient (mean pulmonary artery pressure minus mean pulmonary capillary wedge pressure) above 15 mmHg have an increased risk of right ventricular failure in the immediate postoperative period, a time at which the normal donor right ventricle is acutely subjected to a marked increase in workload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, pulmonary hypertension in most patients with HF is due to neuro-humoral vasoconstriction, not structural changes in the pulmonary vasculature, such as calcification or intimal or medial hyperplasia. Accordingly, an elevated PVR can be often reduced acutely or chronically by using agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , prostaglandin E1, prostacyclin, phosphodiesterase type 3 inhibitors, and inhaled nitric oxide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. A continuous infusion of milrinone, dobutamine, or prostaglandin E1 for several weeks has been used in some patients as a bridge to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A study of 68 patients found that prostaglandin E1 was more effective than prostacyclin or dobutamine for preventing a worsening of HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with persistent pulmonary hypertension may be treated with the addition of oral PDE 3 inhibitors or implantation of a left ventricular assist device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients whose PVR can be acutely reduced (usually in the cardiac catheterization lab or at the bedside with pulmonary artery catheter monitoring) pharmacologically to below 4 Wood units (320",
"    <span class=\"nowrap\">",
"     dynes-sec/cm",
"     <sup>",
"      5",
"     </sup>",
"     )",
"    </span>",
"    are usually considered acceptable candidates for transplantation. In one report, the three-month mortality rate was higher in patients whose PVR was above 2.5 Wood units compared to those with lower values (17.9 versus 6.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in patients with initially high PVR that was reduced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , the three-month mortality was only 3.8 percent compared to 41 and 28 percent, respectively, in those who were resistant to nitroprusside or who only responded at a dose that caused systemic hypotension. None of the patients with reversible pulmonary hypertension developed right ventricular failure after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An absolute contraindication to transplantation includes active malignancy of any kind, which can be worsened by the immunosuppressive therapy given to prevent transplant rejection. Even without pre-existing disease, the incidence of malignancy (eg, skin cancers, lymphoproliferative disorders, and some solid tumors such as thyroid or cervical cancers) is increased following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with a remote history of cured malignancy, many of whom develop their cardiomyopathy as a consequence of chemotherapy given for the malignancy, are considered reasonable candidates for transplantation. However, these patients do have an increased risk of developing a second malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9529895\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another absolute contraindication to transplantation is active infection, which can become fulminant in the setting of immunosuppressive therapy. However, with the increasing use of mechanical device support as a bridge to transplant, transplantation is considered the treatment for ongoing controlled device infections. Whether the survival of infected device patients is comparable to standard recipients is actively being investigated.",
"   </p>",
"   <p>",
"    Similarly, heart transplantation in patients with clinically important chronic viral infection remains a subject of active debate. Individuals with chronic hepatitis B or hepatitis C infections who undergo heart transplantation have an increased frequency of liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, it has been difficult to show that survival after heart transplantation is reduced in the presence of positive hepatitis B or C serology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ]. As a result, practices of individual centers differ. Since the frequency of progressive liver disease appears to be more common with hepatitis B than with hepatitis C, many transplant programs will accept candidates who are anti-HCV antibody positive, but not those who are HBsAg positive. Evaluation of such patients usually includes assessment for the level of active viremia and often includes liver biopsy to assess for the presence of cirrhosis.",
"   </p>",
"   <p>",
"    HIV infection has been considered to be an absolute contraindication to heart transplantation, primarily because of concerns about the increased frequency of infectious and malignant complications and the previously poor survival of such patients. However, the advent of highly active antiretroviral therapy (HAART) has changed the prognosis of HIV. As a result, HIV infection may not be sufficient reason to refuse transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/39\">",
"     39",
"    </a>",
"    ]. As an example, a case series of seven HIV positive cardiac transplant recipients with low or undetectable viral loads without recent significant infections at the time of transplant reported 100 percent survival over a five-year period without AIDS related infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/40\">",
"     40",
"    </a>",
"    ]. Immunosuppressive drugs were well tolerated and HIV remained quiescent in these carefully screened patients. These observations require confirmation by other cardiac transplant centers. Given the use of concomitant antiretroviral therapy, the dosing of calcineurin inhibition must be reduced and carefully monitored. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15321?source=see_link&amp;anchor=H7#H7\">",
"     \"Solid organ transplantation in HIV-infected individuals\", section on 'Heart transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the relative contraindications to cardiac transplantation, age has historically been a major factor (",
"    <a class=\"graphic graphic_table graphicRef83788 \" href=\"mobipreview.htm?7/27/7613\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. Many programs have routinely excluded patients over the age of 60 to 65, but most feel that physiologic age is more important than chronologic age. Some centers will perform transplants up to age 72 years with the older patients having to meet additional selection criteria such as less than two prior open heart procedures, preserved renal function, no prior cerebrovascular events, and preserved hepatic function.",
"   </p>",
"   <p>",
"    A report based on UNOS data for 14,401 first-time transplant recipients between 1999 and 2006 demonstrated that patients &ge;60 years of age more frequently had comorbidities than younger patients and that their overall survival post-transplant was lower than in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/41\">",
"     41",
"    </a>",
"    ]. However, cumulative five-year survival for patients &ge;60 years of age was only slightly lower than that for younger patients (69 versus 75 percent). Multivariate analysis revealed recipient age &ge;60 years, donor age, ischemic time, creatinine, HTN, and DM to be independent predictors of mortality.",
"   </p>",
"   <p>",
"    Carefully selected patients over 60 years of age have a survival rate comparable to that in younger patients. This was illustrated in a report that compared 63 patients transplanted at 65 years of age or older (mean age 67) to 63 matched younger patients (mean age 48) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/42\">",
"     42",
"    </a>",
"    ]. Survival was comparable for both groups at 1, 3, 5, and 10 years; there was also no significant difference in the incidence of rejection or infection. As a result of such findings, most centers now focus on the patient's \"physiologic\" age, with emphasis on the functional integrity of major organ systems and the absence of exclusionary comorbid diseases. The 2006 ISHLT update on the listing criteria and management of cardiac transplantation candidates suggested that most patients 70 years of age or younger and carefully selected patients over age 70 can be considered for cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes mellitus, particularly with evidence of significant end-organ damage (eg, neuropathy or nephropathy, but not retinopathy), is a relative contraindication to heart transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. However, single center studies have reported that carefully selected diabetic patients on insulin or drug therapy can undergo successful cardiac transplantation with similar morbidity and mortality as non-diabetic subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/43\">",
"     43",
"    </a>",
"    ]. Analysis of the United Network of Organ Sharing database confirmed comparable survival in patients with uncomplicated diabetes but not in those diabetics with significant renal insufficiency (creatinine &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    morbid obesity, peripheral vascular disease, or past history of stroke) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/44\">",
"     44",
"    </a>",
"    ]. In diabetics without significant renal dysfunction, the effect of calcineurin inhibitor on renal function was comparable to non-diabetics over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/45\">",
"     45",
"    </a>",
"    ]. In diabetics with renal dysfunction, combined heart renal transplant can be considered as the reported outcomes of combined heart-kidney transplant are comparable to heart alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advanced obstructive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restrictive lung disease is associated with a higher incidence of postoperative lung complications, including infection associated with immunosuppressive therapy. Objective exclusion criteria include a forced one-second expiratory volume (FEV1) of less than 1.0 liter, a forced vital capacity of less than 50 percent of predicted, or a forced expiratory volume-to-vital capacity ratio of less than 1.0.",
"   </p>",
"   <p>",
"    In addition, recent pulmonary embolism with or without infarction should delay transplantation, because secondary infection in the affected lobe may occur postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/47\">",
"     47",
"    </a>",
"    ]. Before putting the patient on the transplant list, most centers treat this disorder with systemic anticoagulants for six to eight weeks or until radiographic evidence of resolution is seen.",
"   </p>",
"   <p>",
"    Other relative exclusion criteria for cardiac transplantation include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced hepatic disease. Cirrhosis, for example, can limit survival and increase perioperative morbidity, particularly if a coagulopathy is present.",
"     </li>",
"     <li>",
"      Impaired renal function as manifested by a stable plasma creatinine concentration above 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      or a creatinine clearance below 40",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      The concern in this setting is the superimposed nephrotoxicity of long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Combined kidney-heart transplantation may be offered to those who require transplantation of both organs with expected outcomes that may be similar to those receiving a heart transplant alone. Among such patients, it is essential that reversible impairment of either organ be excluded. These issues are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22775?source=see_link&amp;anchor=H12#H12\">",
"       \"Prognosis after cardiac transplantation\", section on 'Heart-kidney transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of other conditions increase the rate of perioperative complications or interact poorly with immunosuppressive agents. Included in this group are advanced peripheral vascular disease, morbid obesity (BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      active peptic ulcer disease, cholelithiasis, and diverticulosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All cardiac transplant candidates should undergo a complete psychosocial evaluation during the initial screening process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. This may identify social and behavioral factors that cause difficulty during the waiting period, convalescence, and long-term postoperative management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The patient must understand that full cooperation and compliance are critical to the safe and effective use of immunosuppressive agents.",
"   </p>",
"   <p>",
"    Finally, patients must be screened for the use and abuse of alcohol and other recreational drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"     5",
"    </a>",
"    ]. Active drug or alcohol abuse should be considered an absolute contraindication for transplantation. Although post-transplant recidivism is a frequent occurrence in patients in \"recovery,\" survival may not be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BRIDGING THE PATIENT TO TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular assist devices (VADs) can provide mechanical support to \"bridge\" selected patients to transplantation who are extremely ill and have a high expected mortality while waiting for an appropriate donor heart. Alternatively, VADs may be used as \"destination\" therapy (permanent or lifetime circulatory support) for patients deemed not to be transplant candidates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=see_link&amp;anchor=H22787795#H22787795\">",
"     \"Intermediate- and long-term mechanical cardiac support\", section on 'Categories of use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of a left ventricular assist device (LVAD) as a mechanical bridge to heart transplantation has grown substantially since its inception in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/3\">",
"     3",
"    </a>",
"    ]. LVAD support is offered to transplant candidates who are rapidly deteriorating despite maximal medical therapy, or are developing end-organ damage despite maximal medical therapy or are inotrope dependent with an anticipated long waitlist time, ie, large size blood type O recipients. These categories correspond to the Interagency Registry for Mechanically Assisted Circulatory Support Levels 1 to 3 (",
"    <a class=\"graphic graphic_table graphicRef83827 \" href=\"mobipreview.htm?22/23/22907\">",
"     table 5",
"    </a>",
"    ). Use of the LVAD as a bridge to transplantation requires that LVAD recipients be accepted for cardiac transplantation and thus meet the same inclusion criteria previously detailed. (See",
"    <a class=\"local\" href=\"#H18660611\">",
"     'Indications for transplantation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Criteria for patient exclusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The number of our patients requiring a mechanical support continues to increase (",
"    <a class=\"graphic graphic_figure graphicRef83830 \" href=\"mobipreview.htm?8/5/8286\">",
"     figure 3",
"    </a>",
"    ). Increased device use has salvaged many transplant candidates but concerns have been raised by reports of decreased post-transplant survival in device-supported patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/51\">",
"     51",
"    </a>",
"    ]. Multivariate analysis by the International Society for Heart Transplantation Registry has shown mechanical support to be associated with increased mortality post-transplant but this analysis includes biventricular support, short-term support, and left ventricular support with long-term devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/1\">",
"     1",
"    </a>",
"    ]. Some single-center studies have actually shown improved survival with device support following transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34297/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/5/92?source=see_link\">",
"       \"Patient information: Heart transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whenever possible, patients with refractory heart failure should be referred to a program specialized in management of refractory HF. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"       \"Management of refractory heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since the major indication for cardiac transplantation is to improve survival, the ability to estimate prognosis in patients with severe HF is the most important component of the selection process. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation of prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For appropriate patients with advanced HF and major limitation of daily activities despite optimization of medical therapy and a peak VO2 after cardiac rehabilitation of &le;10 to 12",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute that is consistent on repeated measurements, we recommend referral for cardiac transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A peak VO2 threshold &le;10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute may be the preferred threshold for cardiac transplantation given the impact of current medical and device therapies. (See",
"      <a class=\"local\" href=\"#H18660611\">",
"       'Indications for transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absolute contraindications to cardiac transplantation include fixed pulmonary hypertension, systemic illness that would limit survival despite heart transplantation, current malignancy, and any systemic process with a high probability of recurring in the transplanted heart. Relative contraindications include advanced age, peripheral vascular disease not amenable to revascularization, diabetes mellitus with end organ damage, severe lung disease, active systemic infection, and psychosocial impairment that would jeopardize post-transplant survival (",
"      <a class=\"graphic graphic_table graphicRef83788 \" href=\"mobipreview.htm?7/27/7613\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Criteria for patient exclusion'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The ultimate decision to place a patient on the heart transplant waiting list is made by clinicians at the transplanting center based upon a combination of test data and clinical judgment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3336996\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Drs. Wilson S. Colucci and Ileana L. Pi&ntilde;a for their contributions as authors to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/1\">",
"      Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant 2011; 30:1078.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on June 28, 2012).",
"    </li>",
"    <li>",
"     Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Sy, Rockville, 2011.",
"    </li>",
"    <li>",
"     The 2009 Annual Report of the OPTN and SRTR: Transplant Data 1999-2008; Chapter VI: Heart Transplantation in the US 1999-2008. file://optn.transplant.hrsa.gov/ar2009/ (Accessed on June 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/5\">",
"      Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006; 25:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/6\">",
"      Lietz K, Miller LW. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005. J Am Coll Cardiol 2007; 50:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/7\">",
"      Almond CS, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation 2009; 119:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/8\">",
"      Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/9\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/10\">",
"      O'Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005; 111:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/11\">",
"      Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 2004; 43:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/12\">",
"      Goda A, Lund LH, Mancini D. The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. J Heart Lung Transplant 2011; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/13\">",
"      Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/14\">",
"      Alla F, Brian&ccedil;on S, Juilli&egrave;re Y, et al. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J 2000; 139:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/15\">",
"      Hansen A, Haass M, Zugck C, et al. Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure. J Am Coll Cardiol 2001; 37:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/16\">",
"      Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/17\">",
"      Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/18\">",
"      Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004; 23:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/19\">",
"      Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010; 122:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/20\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/21\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/22\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/23\">",
"      Kirklin JK, Naftel DC, Kirklin JW, et al. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/24\">",
"      Costard-J&auml;ckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/25\">",
"      Murali S, Uretsky BF, Armitage JM, et al. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 1992; 11:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/26\">",
"      Givertz MM, Hare JM, Loh E, et al. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996; 28:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/27\">",
"      Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/28\">",
"      Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004; 109:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/29\">",
"      Pacher R, Stanek B, H&uuml;lsmann M, et al. Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results. Eur Heart J 1997; 18:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/30\">",
"      Canver CC, Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg 2000; 69:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/31\">",
"      Stanek B, Sturm B, Frey B, et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/32\">",
"      Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007; 31:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/33\">",
"      Etz CD, Welp HA, Tjan TD, et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 2007; 83:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/34\">",
"      Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol 2009; 103:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/35\">",
"      Hosenpud JD, Pamidi SR, Fiol BS, et al. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 2000; 19:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/36\">",
"      Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/37\">",
"      Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/38\">",
"      Castella M, Tenderich G, Koerner MM, et al. Outcome of heart transplantation in patients previously infected with hepatitis C virus. J Heart Lung Transplant 2001; 20:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/39\">",
"      Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/40\">",
"      Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/41\">",
"      Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. J Heart Lung Transplant 2008; 27:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/42\">",
"      Morgan JA, John R, Weinberg AD, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg 2003; 76:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/43\">",
"      Lang CC, Beniaminovitz A, Edwards N, Mancini DM. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003; 22:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/44\">",
"      Russo MJ, Chen JM, Hong KN, et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation 2006; 114:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/45\">",
"      Almuti K, Haythe J, Tsao L, et al. Does renal function deteriorate more rapidly in diabetic cardiac transplant recipients? Transplantation 2007; 83:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/46\">",
"      Russo MJ, Rana A, Chen JM, et al. Pretransplantation patient characteristics and survival following combined heart and kidney transplantation: an analysis of the United Network for Organ Sharing Database. Arch Surg 2009; 144:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/47\">",
"      Young JN, Yazbeck J, Esposito G, et al. The influence of acute preoperative pulmonary infarction on the results of heart transplantation. J Heart Transplant 1986; 5:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/48\">",
"      Mai FM, McKenzie FN, Kostuk WJ. Psychiatric aspects of heart transplantation: preoperative evaluation and postoperative sequelae. Br Med J (Clin Res Ed) 1986; 292:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/49\">",
"      Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/50\">",
"      Hanrahan JS, Eberly C, Mohanty PK. Substance abuse in heart transplant recipients: a 10-year follow-up study. Prog Transplant 2001; 11:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/51\">",
"      Patlolla V, Patten RD, Denofrio D, et al. The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. J Am Coll Cardiol 2009; 53:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34297/abstract/52\">",
"      Russo MJ, Hong KN, Davies RR, et al. Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 138:1425.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3528 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-46D95CF9A3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34297=[""].join("\n");
var outline_f33_31_34297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WAITING LIST AND ALLOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9528521\">",
"      Donor allocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9528742\">",
"      Waitlist management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONSIDERATIONS FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Improving survival with medical and device therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Waiting-list mortality in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION OF PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peak VO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis scores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Heart Failure Survival Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Seattle Heart Failure Model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18660611\">",
"      INDICATIONS FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18660619\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Combined organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CRITERIA FOR PATIENT EXCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Increased pulmonary vascular resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9529895\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BRIDGING THE PATIENT TO TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3336996\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3528|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/38/17007\" title=\"figure 1\">",
"      Number of heart transplants reported by year",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/49/18207\" title=\"figure 2\">",
"      Diagnosis in adult heart transplants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/5/8286\" title=\"figure 3\">",
"      Patients bridged with mechanical circulatory support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/43/32444\" title=\"table 1\">",
"      UNOS priority status for HT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/29/39389\" title=\"table 3\">",
"      Pre-transplant mortality among adults wait-listed for HT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/27/7613\" title=\"table 4\">",
"      Contraindications to cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/23/22907\" title=\"table 5\">",
"      INTERMACS levels of limitation at the time of implant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33398?source=related_link\">",
"      Functional exercise testing: Ventilatory gas analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34250?source=related_link\">",
"      Renal function and nonrenal solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34298="Chronic kidney disease and coronary heart disease";
var content_f33_31_34298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic kidney disease and coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Mark Sarnak, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/31/34298/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/31/34298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) is an independent risk factor for the development of coronary artery disease, and for more severe coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. CKD is also associated with adverse outcomes in those with existing cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. This includes increased mortality after an acute coronary syndrome, after percutaneous coronary intervention (PCI) with or without stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/9-16\">",
"     9-16",
"    </a>",
"    ], and after coronary artery bypass. In addition, patients with CKD are more likely to present with atypical symptoms, which may delay diagnosis and adversely affect outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of chronic kidney disease and coronary heart disease is presented in this topic review. Issues related to coronary heart disease in patients with end-stage renal disease and general discussions of risk factors for cardiovascular disease and interventions for secondary prevention are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE AS AN INDEPENDENT RISK FACTOR FOR CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both decreased GFR and increased proteinuria increase the risk of cardiovascular disease. These associations have been shown in both community-based populations (ie, cohorts that were not selected specifically to enroll individuals with CKD or cardiovascular disease), and in populations of patients at high cardiovascular risk (ie, cohorts in which patients with preexisting cardiovascular disease or cardiovascular disease risk factors were specifically recruited).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Association between CKD and CHD in community-based populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous observational studies have shown that a reduced glomerular filtration rate (GFR) and proteinuria are both independently associated with an increased risk of cardiovascular events in community-based populations of patients who were not selected based upon the presence of known kidney or cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/1,6,18-51\">",
"     1,6,18-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data come from a meta-analysis of general population cohorts that included 105,872 participants with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants with urine protein dipstick measurements; all had documented baseline estimated GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/20\">",
"     20",
"    </a>",
"    ]. Compared with participants whose estimated GFR was 95",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    , hazard ratios (HR) for all-cause mortality during 7.9 years of follow-up were 1.18 (95% CI 1.05-1.32), 1.57 (95% CI 1.39-1.78), and 3.14 (95% CI 2.39-4.13) for estimated GFRs of 60, 45, and 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , respectively. Similar outcomes were observed for cardiovascular mortality, and similar results were obtained in older and younger individuals (age greater than 65 years versus 65 years or less). A higher risk for all-cause mortality was observed at estimated GFRs greater than 105",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ; however, this association may reflect either reduced muscle mass from ill health leading to a lower creatinine value, or a high prevalence of individuals with diabetes or obesity causing hyperfiltration and a low creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteinuria was independently associated with increased all-cause and cardiovascular mortality in this study. Compared to an albumin-to-creatinine ratio (ACR) of 0.6",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/g),",
"    </span>",
"    the adjusted hazard ratio for all-cause mortality was 1.20 (95% CI 1.15-1.26); 1.63 (95% CI 1.50-1.77); and 2.20 (95% CI 1.97-2.51) for ACRs of 1.1 (10",
"    <span class=\"nowrap\">",
"     mg/g);",
"    </span>",
"    3.4 (30",
"    <span class=\"nowrap\">",
"     mg/g);",
"    </span>",
"    and 33.9",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    (300",
"    <span class=\"nowrap\">",
"     mg/g),",
"    </span>",
"    respectively. Similar findings were observed for cardiovascular mortality. An ACR greater than 3.4",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/g)",
"    </span>",
"    was associated with a greater than twofold mortality risk for all levels of estimated GFR except the lowest (&lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ). Among participants with dipstick determination of proteinuria, a trace urine positive dipstick was also associated with increased all-cause and cardiovascular mortality for all levels of kidney function, although large heterogeneity was present between studies that provided only dipstick measurement of protein.",
"   </p>",
"   <p>",
"    Given that CKD alone appears to increase the risk of CHD in the general population, it is not surprising that the Framingham risk score, the traditional method to analyze future cardiovascular risk among individuals without CKD, provides poor overall accuracy in predicting cardiovascular events in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/53\">",
"     53",
"    </a>",
"    ]. This may be partly due to the markedly increased cardiac event rate and overall death rate among such patients. Although altering the Framingham risk equations may increase their predictive accuracy, new prediction equations must be developed to help predict future events among patients with CKD.",
"   </p>",
"   <p>",
"    Despite the preponderance of evidence in favor of an increase in risk with CKD alone, a few studies have found that less severe renal disease is not an independent risk factor for adverse cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Association between CKD and CHD among those at high cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous secondary analyses of studies that enrolled patients with known risk factors for cardiovascular disease (such as hypertension and diabetes), or preexisting cardiovascular disease, have shown that the presence or development of various degrees of renal dysfunction is independently associated with cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/18,50,51,56-66\">",
"     18,50,51,56-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this association was illustrated in a collaborative meta-analysis of 10 cohorts with 266,975 patients who had hypertension, diabetes, cardiovascular disease, or a combination of these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/56\">",
"     56",
"    </a>",
"    ]. Compared with a reference estimated GFR of 95",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , the hazard ratios for cardiovascular mortality were 1.11 for an estimated GFR of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , 1.73 for an estimated GFR of 45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , and 3.08 for an estimated GFR of 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . Similar findings were noted for all-cause mortality, and the associations were similar in younger and older patients. A monotonic association between higher ACR and risk of both cardiovascular and all-cause mortality was also noted.",
"   </p>",
"   <p>",
"    Even if CKD is an independent risk factor for cardiovascular disease among patients already at high cardiovascular risk, it may not substantially improve the ability to risk-stratify patients beyond traditional risk factors. This was shown in a pooled analysis of 27,620 patients in two randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/67\">",
"     67",
"    </a>",
"    ]. Lower GFRs and higher urinary albumin excretions were each independent risk factors for cardiovascular events and death, although their addition to a model with traditional cardiovascular risk factors did not significantly enhance the model's ability to predict events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CKD as a CHD risk equivalent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above evidence that mild to moderate CKD is associated with an adverse cardiovascular prognosis led both the National Kidney Foundation and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association to recommend that CKD be considered a CHD risk equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/1,68-71\">",
"     1,68-71",
"    </a>",
"    ]. Consistent with this, the number of cardiovascular events attributable to CKD in the Alberta Kidney Disease Network and Atherosclerosis Risk In Communities (ARIC) studies were comparable to the number of events attributable to diabetes, another factor considered to be a CHD risk equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/35,72\">",
"     35,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the nine-year rates of cardiovascular death among 1899 individuals in the Cardiovascular Health Study (CHS) were as follows (CKD was defined as an eGFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of myocardial infarction, but no diabetes or CKD: 15.7 percent",
"     </li>",
"     <li>",
"      History of diabetes, but no myocardial infarction or CKD: 15.8 percent",
"     </li>",
"     <li>",
"      History of CKD, but no myocardial infarction or diabetes: 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although CKD was a powerful risk factor for cardiovascular disease in these and other studies, the generalization that CKD is a CHD risk equivalent for all persons with CKD may not be warranted for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies contradict the concept that CKD is a CHD risk equivalent. In the Alberta Kidney Disease Network cohort, for example, the four-year incidence of myocardial infarction was nearly threefold higher among those who had a prior history of myocardial infarction (7.7 percent) compared with those without a prior history of myocardial infarction but who had CKD (2.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/72\">",
"       72",
"      </a>",
"      ]. The incidence of myocardial infarction among those who had a prior history of myocardial infarction but no diabetes and no CKD was more than twice the incidence among those with CKD but not prior myocardial infarction. Similarly, a secondary analysis from the ARIC study suggested that the risk associated with CKD was not comparable to the risk associated with a prior myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of heart disease in those with CKD appears to vary based upon absolute level of renal function and degree of proteinuria, as well as the rate at which these factors change. The simultaneous presence of both decreased renal function and increased proteinuria further enhance the risk for cardiovascular disease compared with the risk associated with either problem alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/19-21,56,72\">",
"       19-21,56,72",
"      </a>",
"      ]. In addition, the rate of decline of kidney function and the rate of increase of proteinuria also correlate with varying risks of adverse cardiovascular events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/75-77\">",
"       75-77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Even patients with the same degree of renal dysfunction may",
"      <strong>",
"       not",
"      </strong>",
"      have the same risk of cardiovascular disease, since the risk of cardiovascular disease in a patient with CKD is in part related to the presence and extent of significant comorbidities. As an example, the overall risk for a 25-year-old nonsmoking man with moderate CKD due to IgA nephropathy is not the same as that of a 65-year-old man with a similar degree of CKD but with a long history of smoking, hypertension, and elevated serum cholesterol levels. Thus, the proper assessment of overall cardiovascular risk in patients with CKD requires an adequate assessment for the presence and severity of the other major risk factors for cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The concept of CHD risk equivalency was developed by expert panels as a means to help clinicians make decisions about how aggressively to treat their patients to prevent CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/78\">",
"     78",
"    </a>",
"    ]. As an example, while it is fairly simple to identify a patient who has diabetes or CKD, and thus institute aggressive therapy for secondary prevention of CHD, it is more cumbersome to calculate every patient's 10-year cardiovascular risk. About half of adults in the United States with CKD have another CHD risk equivalent, specifically a prior history of myocardial infarction or stroke, diabetes, angina, or a calculated Framingham 10-year CHD risk greater than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, the question of whether CKD is a CHD risk equivalent is germane to whether millions of additional patients with CKD should receive aggressive therapy to lower their LDL cholesterol and blood pressure, and whether they should receive antiplatelet therapy. These issues are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Reduction of CHD risk in patients with CKD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations of the data",
"    </span>",
"    &nbsp;&mdash;&nbsp;One possible limitation in nearly all of the above reports is that kidney function was indirectly estimated. Since the various estimates provide results that may differ from each other, the association between kidney function and cardiovascular risk is affected by the method selected to estimate kidney function. The association may be further compromised because some of the formulas utilized are based directly upon variables linked with cardiovascular risk, such as age, weight, and body mass index.",
"   </p>",
"   <p>",
"    This difficulty was shown using data from 8592 participants in the PREVEND study, in which the association between various cardiovascular risk factors and kidney function was examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Kidney function was estimated using creatinine clearance (based upon two 24-hour urine collections), and the Cockcroft-Gault and Modification of Diet in Renal Disease (MDRD) formulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/80\">",
"     80",
"    </a>",
"    ]; the various cardiovascular risk factors examined included blood pressure, serum cholesterol and glucose levels, age, sex, weight, waist-to-hip ratio, and body mass index. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Markedly different relationships emerged when each method for estimating kidney function was plotted against each cardiovascular risk factor. These varied relationships were most pronounced for age, weight, and body mass index, and less pronounced (but still statistically significant) for blood pressure, and serum cholesterol and glucose levels. As a result, caution must be exercised when studying the relationships among cardiovascular risk factors, indirect estimates of kidney function, and cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786389950\">",
"    <span class=\"h3\">",
"     Cystatin C and other markers of kidney function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential limitation of kidney function estimates in the vast majority of studies mentioned above is that level of glomerular filtration rate (GFR) may not be accurately assessed using creatinine-based questions, particular in those with estimated GFR values greater than 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    . In these individuals, cystatin C and other markers of kidney function (such as beta-trace protein and beta-2-microglobulin) may be a more sensitive measures of decreased GFR, and also more strongly associated with fatal and nonfatal cardiovascular events than creatinine and creatinine-based estimated of GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/41-48,82\">",
"     41-48,82",
"    </a>",
"    ]. As an example, the risk of death relative to the cystatin C concentration increased in a dose-response fashion in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/41\">",
"     41",
"    </a>",
"    ]. Relative to the first quintile, the adjusted hazard ratio of cardiovascular death for the third, fourth and fifth quintiles (the fifth quintile further subdivided into thirds) of cystatin C levels were 1.93, 1.99, and 2.48 to 2.83, respectively. By comparison, a significant association with adverse outcomes was only observed among those in the lowest quintile of GFR estimated from the plasma creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H23#H23\">",
"     \"Assessment of kidney function\", section on 'Serum cystatin C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These results suggest that elevated plasma cystatin C concentration may be a more accurate measure of cardiovascular risk than elevated plasma creatinine concentration. However, some have postulated that non-renal determinants of cystatin C levels, such as increased inflammation and other cardiovascular factors, may underlie this association. In addition, cystatin C is not routinely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599735133\">",
"    <span class=\"h1\">",
"     PRESENCE OF TRADITIONAL AND NONTRADITIONAL CARDIOVASCULAR RISK FACTORS IN CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CKD often have numerous traditional and nontraditional risk factors for the development of cardiovascular disease. Traditional risk factors appear to be associated with much larger absolute increases in risk in the earlier stages of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599735140\">",
"    <span class=\"h2\">",
"     Traditional risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional cardiovascular risk factors, such as hypertension (which may be accompanied by left ventricular hypertrophy), smoking, diabetes, dyslipidemia and older age, are highly prevalent in CKD populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/1,84,85\">",
"     1,84,85",
"    </a>",
"    ]. The number of cardiovascular risk factors appears to correlate with the severity of kidney dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/85\">",
"     85",
"    </a>",
"    ]. These are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CKD are also more likely to have the metabolic syndrome, which could contribute to the increase in cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/3,86\">",
"     3,86",
"    </a>",
"    ]. This syndrome is defined as some combination of insulin resistance, dyslipidemia, elevated serum glucose, abdominal obesity, and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599735147\">",
"    <span class=\"h2\">",
"     Nontraditional risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible risk factors that are relatively unique to patients with moderate to severe CKD include retention of uremic toxins, anemia, elevated levels of certain cytokines, increased calcium intake, abnormalities in bone mineral metabolism,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an \"increased inflammatory-poor nutrition\" state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/4,87\">",
"     4,87",
"    </a>",
"    ]. How these risk factors may lead to cardiovascular disease is unclear. As an example, disorders of bone mineral metabolism in patients with CKD have often been linked to coronary artery calcification. However, while there is a consistent association between CKD and a higher burden of coronary artery calcification, the associations among phosphorus, calcium, and parathyroid hormone with coronary artery calcification in these patients is inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated levels of C-reactive protein (CRP) and asymmetric dimethylarginine, both of which are typically found in patients with CKD, were both independently associated with an increased risk of all cause and cardiovascular mortality in the Modification of Diet in Renal Disease study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/91,92\">",
"     91,92",
"    </a>",
"    ], although a similar relation between CRP and cardiovascular disease was not observed in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    for Diabetic Nephropathy trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/93\">",
"     93",
"    </a>",
"    ]. Hyperhomocysteinemia has also been inconsistently associated with increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a relationship between cardiovascular disease and microalbuminuria among nondiabetic patients with normal estimated glomerular filtration rate. However, some disagree with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO working groups that isolated microalbuminuria (ie, without a reduction in glomerular filtration rate or some other renal abnormality) necessarily reflects kidney disease among nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/68\">",
"     68",
"    </a>",
"    ]. It correlates best with generalized endothelial dysfunction and is associated with an increase in cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Definition and classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599734827\">",
"    <span class=\"h1\">",
"     COMPETING RISKS OF CARDIOVASCULAR AND END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality from cardiovascular disease among those with CKD is high. The risk of death, particularly due to cardiovascular disease, is typically higher than the risk of eventually requiring renal replacement therapy. However, this risk varies with age and other factors. In many studies, older patients with less severe CKD and lower levels of proteinuria are more likely to die (usually due to cardiovascular disease) before needing renal replacement therapy, while younger patients with proteinuria and diseases localized to the kidney are more likely to ultimately need renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/18,63,97-101\">",
"     18,63,97-101",
"    </a>",
"    ]. This is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following three studies largely include older patients identified through Medicare participation or through the Veteran's Affairs Network:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of over 1,000,000 individuals enrolled in the Medicare program in the United States, outcomes were reported for several groups, including those with CKD but no diabetes (2.2 percent) and both CKD and diabetes (1.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/18\">",
"       18",
"      </a>",
"      ]. After two years of follow-up, the rates for requiring renal replacement therapy were 1.6 and 3.4 per 100 patient-years for patients with CKD alone and those with both disorders, respectively; by comparison, the death rates were 17.7 and 19.9 per 100 patient-years. In addition, rates for atherosclerotic vascular disease for these two groups were 35.7 and 49.1, while heart failure rates were 30.7 and 52.3, respectively.",
"     </li>",
"     <li>",
"      A longitudinal follow-up of nearly 30,000 older patients with estimated glomerular filtration rates (GFRs) of less than 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      reported the rate of renal replacement and death at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/97\">",
"       97",
"      </a>",
"      ]. The rate of renal replacement therapy in those with stage 2, 3, or 4 disease was 1.1, 1.3, and 19.9 percent, respectively; by comparison, the mortality rate was 19.5, 24.3, and 45.7 percent. A higher incidence of coronary artery disease, heart failure, diabetes mellitus, and anemia was noted in those who died.",
"     </li>",
"     <li>",
"      In a report of over 12,000 older patients with diabetes, 48 percent had CKD defined as GFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , or proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/98\">",
"       98",
"      </a>",
"      ]. After three years of follow-up, mortality rates were 6, 10, 20 and 30 percent for patients with CKD stages 2, 3, 4 and 5, respectively, compared to 5 percent for those with preserved kidney function at baseline. Rates of progression to end-stage renal disease (ESRD) were much lower, less than 1 percent for stages 2 and 3, and 14 percent for stage 4.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nondiabetic patients enrolled in the MDRD study included a broad range of ages, causes of kidney disease, baseline GFR, and baseline protein excretion. After nearly 12 years of follow-up, 936 patients (56 percent) developed ESRD, and 369 (22 percent) died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/102\">",
"       102",
"      </a>",
"      ]. Death prior to ESRD was more likely to occur in older as compared with younger individuals. In those patients older than 65 years, for example, 42 percent developed ESRD and 22 percent died before developing ESRD. However, in those 45 years or younger, 65 percent developed ESRD and less than 1 percent died before developing ESRD.",
"     </li>",
"     <li>",
"      The following are two studies with long-term observations from two cohorts of younger individuals with type 1 diabetes and nephropathy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rate of ESRD incidence was substantially greater than the mortality rate (35.5 versus 9.5 percent) in a cohort of 592 young (median age 42 years) patients with type 1 diabetes followed for 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/99\">",
"       99",
"      </a>",
"      ]. All patients in this study had at least 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of proteinuria, and 60 percent of patients had an estimated GFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      Similar results were observed in cohort of 423 young (median age 39 years) patients with type 1 diabetes, at least 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of proteinuria, and a median baseline estimated GFR of 66",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/100\">",
"       100",
"      </a>",
"      ]. During 15 years of follow-up, 41 percent of patients developed ESRD, while 7 percent died without developing ESRD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these data suggest that age differences determine whether or not patients with CKD will develop ESRD before dying, this observation may be biased by study design. Patients enrolled into studies of cardiovascular disease tend to be older and have less severe kidney disease than patients enrolled into studies of kidney disease. In addition, older patients with severe renal dysfunction are more likely to develop ESRD before dying, as was observed in 3228 older individuals with type 2 diabetes and nephropathy (mean age 59 years, estimated GFR 44",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , and mean urine albumin-to-creatinine ratio 1.37",
"    <span class=\"nowrap\">",
"     g/g)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/103\">",
"     103",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REDUCTION OF CHD RISK IN PATIENTS WITH CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without CKD, risk factor modification and beneficial lifestyle changes can substantially decrease morbidity and mortality in those with coronary, cerebrovascular, or peripheral artery disease. These modalities include therapy with statins, control of hypertension, cessation of smoking, maintaining ideal body weight and an active lifestyle, glycemic control in diabetes, and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . A review of the data supporting these interventions is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, patients with CKD were largely excluded from clinical trials of patients with coronary artery disease. A 2006 survey of the published literature noted that 75 percent of coronary artery disease trials excluded patients with CKD and only 7 percent reported baseline renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/104\">",
"     104",
"    </a>",
"    ]. Similar observations were reported in a contemporaneous survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/105\">",
"     105",
"    </a>",
"    ]. However, randomized trials have subsequently been performed specifically in patients with CKD, particularly regarding statin therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'CKD as a CHD risk equivalent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As noted above, we do",
"    <strong>",
"     not",
"    </strong>",
"    agree with the generalization that CKD is a CHD risk equivalent for all persons with CKD. Our approach is instead based upon the available data and an assessment of future cardiovascular risk. This evidence, which is presented below, supports the following approach to reduce the risk of atherosclerotic cardiovascular disease in most patients with CKD not requiring dialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statin therapy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Statin therapy'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In patients with proteinuric CKD (defined as proteinuria greater than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      we recommend angiotensin blockade as part of the antihypertensive regimen and a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. In patients with non-proteinuric CKD, we recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Blood pressure control'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Antiplatelet therapy'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      In all patients, smoking cessation, maintenance of an ideal body weight, an active lifestyle, and, in patients with diabetes, glycemic control. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other issues'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KDIGO guidelines also consider persistent proteinuria, including microalbuminuria, to be part of CKD and therefore associated with increased CHD risk even if estimated GFR is normal. We do not agree with applying this paradigm to all patients. As an example, it is unknown whether a 25-year-old nonsmoker with IgA nephropathy, normal serum creatinine concentration, and normal blood pressure is at increased cardiovascular risk in the absence of progressive disease. Such patients should clearly be followed carefully and patient values should be taken into account when considered how aggressively one would modify coronary risk factors. Issues related to microalbuminuria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary prevention of cardiovascular disease and management of coronary artery disease in patients with end-stage renal disease on maintenance dialysis or those with a kidney transplant are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26984?source=see_link\">",
"     \"Treatment of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most evidence for the use of statins in patients with mild to moderate CKD comes from post-hoc sub-group analyses of randomized trials that were not intended to include patients with decreased kidney function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H6#H6\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Cholesterol lowering with a statin'",
"    </a>",
"    .) One randomized trial, the Study of Heart and Renal Protection (SHARP) trial, specifically evaluated cholesterol lowering with a statin to prevent major vascular events in patients with CKD.",
"   </p>",
"   <p>",
"    The findings from the SHARP trial echoed the observations made in CKD subgroups from other randomized trials: treatment of patients with CKD not requiring dialysis with a statin leads to a significant reduction in cardiovascular events. Patients who received statin therapy in SHARP also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    , although it is not clear if ezetimibe contributed to the clinical benefit. A detailed discussion of these findings and recommendations regarding statin use in CKD are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H6#H6\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Cholesterol lowering with a statin'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    However, these trials mainly enrolled older patients with various comorbid conditions such as smoking, diabetes, and hypertension. Whether statin therapy would be beneficial in younger patients who have CKD due to primary kidney disease (such as IgA nephropathy or autosomal dominant polycystic kidney disease) rather than a systemic disease (such as diabetes) is unclear. We would initiate statin therapy in patients who have an estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    if they are older than 40 years of age, since such patients are similar to those enrolled in the SHARP trial. In addition, we suggest initiating statin therapy in patients with CKD who have additional cardiovascular risk factors such as smoking, diabetes, hypertension, and proteinuria. &nbsp;",
"   </p>",
"   <p>",
"    A related issue is whether statins provide cardiovascular protection due in part to their pleiotropic effects that are independent of lipid-lowering in patients with and without CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are as yet no trials that have compared cardiovascular outcomes among patients with dyslipidemia who were randomly assigned to specific target lipid levels rather than specific statin doses. When the results of multiple trials are considered, each using a fixed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    dose, the rate of major cardiovascular events falls linearly with the reduction in LDL cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/106\">",
"     106",
"    </a>",
"    ]. However, there is as yet no good evidence that titrating statin therapy to achieve specific target LDL levels in patients at increased cardiovascular risk is associated with improved cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H7#H7\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Statin dose versus goal LDL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence is weak, there are also data suggesting that lipid-lowering with statins may be associated with a slower rate of loss of glomerular filtration rate in patients with mild to moderate CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link&amp;anchor=H7#H7\">",
"     \"Statins and chronic kidney disease\", section on 'Statins and kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous trials of patients with essential hypertension have shown that blood pressure control improves cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-hoc analyses of CKD subgroups from cardiovascular trials suggests that antihypertensive therapy (typically with ACE inhibitors) reduces the risk of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/57,64,107\">",
"     57,64,107",
"    </a>",
"    ]. The PROGRESS trial of 6105 patients with a prior stroke or transient ischemic attack, for example, compared the effect of perindopril-based antihypertensive therapy with placebo; only one-half of patients were hypertensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/64\">",
"     64",
"    </a>",
"    ]. A post hoc analysis evaluated the 29 percent of patients with a creatinine clearance less than 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Antihypertensive therapy reduced the risk of risk of all major cardiovascular events by 35 percent in the patients with CKD, preventing one event among every 11 patients treated for five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=see_link&amp;anchor=H4#H4\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\", section on 'PROGRESS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal blood pressure is similar for patients with diabetic and non-diabetic CKD, differing primarily based upon the presence or absence of proteinuria. The evidence for a lower blood pressure goal is stronger in patients with proteinuric CKD. These issues are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Goal blood pressure in non-proteinuric CKD is a separate issue. There are no reliable data demonstrating that targeting blood pressure to below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg reduces the risk of progressive kidney failure or cardiovascular disease. As a result, we recommend that a blood pressure of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg be achieved in patients with non-proteinuric CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The desired degree of blood pressure control can usually be safely achieved with combined therapy. In proteinuric patients, the regimen should include an ACE inhibitor or angiotensin II receptor blocker. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Choice of antihypertensive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy reduces the risk of subsequent myocardial infarction (MI), stroke, and vascular death among patients",
"    <strong>",
"     without",
"    </strong>",
"    CKD, but with a wide range of prior manifestations of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are fewer data related to the effectiveness and safety of antiplatelet therapy in patients",
"    <strong>",
"     with",
"    </strong>",
"    CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. The best data come from a meta-analysis of 27,139 patients with CKD who participated in 50 randomized trials that tested the efficacy of antiplatelet agents (mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) for prevention of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/108\">",
"     108",
"    </a>",
"    ]. Antiplatelet therapy significantly reduced the incidence of fatal or nonfatal myocardial infarction as compared with either placebo or no therapy (6.7 versus 7.0 percent, or 3 myocardial infarctions prevented for every 1000 patients treated). However, antiplatelet therapy also significantly increased the rate of major bleeding (4.4 versus 2.9 percent, or 15 additional major bleeding events for every 1000 patients treated). Antiplatelets had no effect on stroke or mortality. The results were similar in patients of all CKD stages.",
"   </p>",
"   <p>",
"    Based upon these data, we suggest that decisions about antiplatelet therapy to prevent cardiovascular disease in patients with CKD be individualized depending upon the patient's overall risk for CHD (for example, a prior history of myocardial infarction) and for bleeding, and also upon their preferences. This suggestion is broadly consistent with guidelines made by the Kidney Disease Improving Global Outcomes (KDIGO) report on the management of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to cardiovascular disease,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy may reduce the risk of cancer incidence. This should also be considered in the decision about whether or not to use aspirin in patients with CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prescription of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is probably safe in most patients with CKD. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for controlling the epidemic of CV disease in CRD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, similar considerations apply to patients with and without renal dysfunction concerning interventions for cessation of smoking, maintaining ideal body weight and an active lifestyle, and glycemic control in diabetes. Recommendations concerning these issues are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures aimed at correcting other nontraditional cardiovascular risk factors in those with CKD, such as anemia, calcium-phosphate disorders, systemic inflammation and increased oxidative stress, may also improve cardiovascular outcomes. This is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CKD require drug dose adjustments and have a higher risk of drug-related adverse effects. Despite the increased risk of adverse effects, the treatments used for established coronary heart disease and acute coronary syndrome that are used in patients with normal kidney function (eg, revascularization) may have similar benefits in patients with CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=see_link\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=see_link\">",
"     \"Coronary artery bypass graft surgery after acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have reported that medical therapy commonly used in patients without CKD is employed significantly less frequently in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/13,14,111-116\">",
"     13,14,111-116",
"    </a>",
"    ]. As an example, a study of 889 patients with an acute coronary syndrome (ACS) evaluated the association between renal dysfunction, defined as an estimated GFR below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , and in-hospital management and outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/14\">",
"     14",
"    </a>",
"    ]. Renal dysfunction was associated with a lower likelihood of receiving percutaneous coronary intervention, and a reduction in the use of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, although the frequency of coronary artery bypass grafting was similar in those with and without renal dysfunction. Less frequent utilization of angiography, revascularization, and standard medical therapy (eg, angiotensin converting enzyme inhibitors, beta blockers) in CKD patients after ACS has also been observed in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is not clear that the usual treatments used in patients with normal renal function should be universally applied in patients with CKD. As an example, a meta-analysis of 9969 CKD patients who were having an ACS or percutaneous coronary intervention found that the use of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    increased major bleeding episodes without preventing cardiovascular events or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS OF CORONARY HEART DISEASE IN PATIENTS WITH CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pervasive finding among patients who suffer coronary events or who have coronary interventions is that those with impaired kidney function have a worse prognosis. The mechanisms which underlie the poor prognosis in patients with CKD are not entirely clear.",
"   </p>",
"   <p>",
"    One possibility is that patients who have a coronary event and abnormal kidney function are more likely to have other predictors of adverse outcomes such as older age, hypotension, and lower body weight; these factors may confound the associations observed in the various studies despite statistical adjustment. A second potential explanation is that the adverse outcome (eg, death, recurrent vascular event) ascribed to worse kidney function may instead reflect a more severe acute coronary syndrome (ACS). Because only baseline creatinine values (at the time of presentation with an ACS) were used in most studies to define the presence of CKD, patients with hemodynamic compromise would have been more likely to be defined as having CKD. The formulas used to estimate GFR based upon serum creatinine are predicated on there being a",
"    <strong>",
"     stable",
"    </strong>",
"    creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348910377\">",
"    <span class=\"h2\">",
"     Prognosis after acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adverse association between mild to moderate renal dysfunction and cardiovascular prognosis in patients with ACS has been reported, both in patients with ST elevation myocardial infarction and non-ST elevation ACS. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prognosis after CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are some reports of equivalent outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/117\">",
"     117",
"    </a>",
"    ], most studies demonstrate that decreased kidney function at the time of coronary artery bypass grafting (CABG) is associated with higher risk of adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/111,118\">",
"     111,118",
"    </a>",
"    ]. As a consequence, renal function is included in a commonly used risk prediction algorithm for cardiac surgical mortality (",
"    <a class=\"graphic graphic_table graphicRef82521 \" href=\"mobipreview.htm?18/8/18573\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=see_link&amp;anchor=H10#H10\">",
"     \"Operative mortality after coronary artery bypass graft surgery\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In-hospital complication rates and in-hospital as well as long-term mortality are highest among patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26984?source=see_link\">",
"     \"Treatment of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CKD who develop acute kidney injury after CABG may require temporary or permanent dialysis. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H22#H22\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prognosis after PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of even mild CKD appears to predict an adverse prognosis after percutaneous coronary intervention (PCI) with or without stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/15,16,123-126\">",
"     15,16,123-126",
"    </a>",
"    ], and renal function is incorporated into a commonly used risk score that predicts one-year mortality following PCI in patients with acute myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef70537 \" href=\"mobipreview.htm?2/61/3036\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H443272420#H443272420\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Other risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=see_link&amp;anchor=H16#H16\">",
"     \"Intracoronary stent restenosis\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The observation that revascularization for restenosis is required less frequently when stents are deployed has been made in patients with CKD as it has in patients with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/127\">",
"     127",
"    </a>",
"    ]. In addition, CKD does not appear to mitigate the angiographic benefits observed with drug-eluting stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether the presence of CKD is associated with higher rates of restenosis. While some studies have found an increased risk of restenosis in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/126,130\">",
"     126,130",
"    </a>",
"    ], other studies have reported that CKD is not associated with increased restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/123,128\">",
"     123,128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H786391182\">",
"    <span class=\"h2\">",
"     PCI versus CABG in patients with CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have compared outcomes with PCI versus CABG specifically in patients with moderate to severe CKD. The relative efficacies of PCI with stenting and CABG in patients with mild CKD was addressed in a subgroup analysis from the ARTS trial, which compared multivessel PCI with bare metal stenting to CABG in patients with stable angina. Among the 1205 patients, 290 had CKD as defined by an estimated creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (mean 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/124\">",
"     124",
"    </a>",
"    ]. A more complete description of this study is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H13#H13\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'ARTS I trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After three years of follow-up, the rate of the primary composite end point of death, myocardial infarction, or stroke was similar with PCI and CABG (adjusted hazard ratio 0.93) but, as in the patients without CKD, CABG was associated with a much lower risk of subsequent revascularization (RR 0.28, 95% CI 0.14-0.54) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/124\">",
"     124",
"    </a>",
"    ]. This difference persisted at five years, as the rate of a second revascularization procedure remained higher with PCI than CABG (19 versus 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/31/34298/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the applicability of the findings in ARTS to current practice is uncertain given the widespread use of drug-eluting stents. Uncontrolled observations from ARTS II suggested that outcomes with drug-eluting stents approached those with CABG but data in patients with CKD are not available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link&amp;anchor=H13#H13\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'ARTS I trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INCREASED SERUM CARDIAC ENZYMES AND ACUTE CORONARY EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponins are the preferred marker for the diagnosis of myocardial injury among patients with",
"    <strong>",
"     normal",
"    </strong>",
"    renal function because of their increased specificity compared with CK-MB and other markers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac troponins are also used in the diagnosis of myocardial infarction in patients with CKD and a suspected acute coronary syndrome, although minor chronic elevations in serum troponins are commonly observed in patients with CKD who do not have clinical evidence of a myocardial infarction. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1172085258\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both decreased glomerular filtration rate (GFR) and increased proteinuria increase the risk of cardiovascular disease. These associations have been shown in both community-based populations (ie, cohorts that were not selected specifically to enroll individuals with chronic kidney disease [CKD] or cardiovascular disease) and in populations of patients at high cardiovascular risk (ie, cohorts in which patients with preexisting cardiovascular disease or cardiovascular disease risk factors were specifically recruited). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chronic kidney disease as an independent risk factor for CHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CKD often have numerous traditional and nontraditional risk factors for the development of cardiovascular disease. Traditional risk factors (hypertension, smoking, diabetes, dyslipidemia, and older age) appear to be more important risk factors during the earlier stages of CKD. Nontraditional risk factors include uremic toxins, anemia, elevated levels of certain cytokines, an increased calcium load, abnormalities in bone mineral metabolism,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an increased inflammatory-poor nutrition state. (See",
"      <a class=\"local\" href=\"#H599735133\">",
"       'Presence of traditional and nontraditional cardiovascular risk factors in CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those with CKD, the risk of death, particularly due to cardiovascular disease, is typically higher than the risk of eventually requiring renal replacement therapy. However, this risk varies with age and other factors. In many studies, older patients with less severe CKD and lower levels of proteinuria are more likely to die (usually due to cardiovascular disease) before needing renal replacement therapy, while younger patients with proteinuria and diseases localized to the kidney are more likely to ultimately need renal replacement therapy. (See",
"      <a class=\"local\" href=\"#H599734827\">",
"       'Competing risks of cardiovascular and end-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our general approach to reduce the risk of atherosclerotic cardiovascular disease in most patients with CKD not requiring dialysis includes the following (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Reduction of CHD risk in patients with CKD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Statin therapy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Statin therapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In patients with proteinuric CKD (defined as proteinuria greater than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      we recommend angiotensin blockade as part of the antihypertensive regimen and a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. In patients with non-proteinuric CKD, we recommend a goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individualized decisions about antiplatelet therapy (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Antiplatelet therapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In all patients, smoking cessation, maintenance of an ideal body weight, an active lifestyle, and, in patients with diabetes, glycemic control. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CKD require drug dose adjustments and have a higher risk of drug-related adverse effects. Despite the increased risk of adverse effects, the treatments used for established coronary heart disease (CHD) and acute coronary syndrome that are used in patients with normal kidney function (eg, revascularization) may have similar benefits in patients with CKD. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CKD who suffer an acute coronary syndrome or who have coronary interventions (ie, coronary artery bypass grafting, percutaneous coronary intervention [PCI]) have a worse prognosis than patients with normal kidney function who have similar events or procedures (",
"      <a class=\"graphic graphic_table graphicRef82521 \" href=\"mobipreview.htm?18/8/18573\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70537 \" href=\"mobipreview.htm?2/61/3036\">",
"       table 2",
"      </a>",
"      ). The mechanisms which underlie the poor prognosis in patients with CKD are not entirely clear. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis of coronary heart disease in patients with CKD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/1\">",
"      Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/2\">",
"      US Renal Data System. USRDS 2009 Annual Data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/3\">",
"      Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/4\">",
"      Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/5\">",
"      Ix JH, Shlipak MG, Liu HH, et al. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003; 14:3233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/6\">",
"      Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/7\">",
"      Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/8\">",
"      Shlipak MG, Stehman-Breen C, Vittinghoff E, et al. Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 2004; 43:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/9\">",
"      Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/10\">",
"      Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/11\">",
"      Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/12\">",
"      Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/13\">",
"      McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002; 162:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/14\">",
"      Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/15\">",
"      Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/16\">",
"      Reinecke H, Trey T, Matzkies F, et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 2003; 63:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/17\">",
"      Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006; 47:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/18\">",
"      Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/19\">",
"      Hallan S, Astor B, Romundstad S, et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med 2007; 167:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/20\">",
"      Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/21\">",
"      Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011; 154:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/22\">",
"      Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004; 15:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/23\">",
"      Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/24\">",
"      Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/25\">",
"      Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/26\">",
"      Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 2004; 15:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/27\">",
"      Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/28\">",
"      Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/29\">",
"      Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/30\">",
"      Fox CS, Larson MG, Keyes MJ, et al. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: the Framingham Heart Study. Kidney Int 2004; 66:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/31\">",
"      Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/32\">",
"      Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/33\">",
"      Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006; 333:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/34\">",
"      Van Biesen W, De Bacquer D, Verbeke F, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/35\">",
"      Weiner DE, Tighiouart H, Griffith JL, et al. Kidney disease, Framingham risk scores, and cardiac and mortality outcomes. Am J Med 2007; 120:552.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/36\">",
"      McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/37\">",
"      van Domburg RT, Hoeks SE, Welten GM, et al. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 2008; 19:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/38\">",
"      Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/39\">",
"      Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/40\">",
"      Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/41\">",
"      Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/42\">",
"      Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/43\">",
"      Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16:3728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/44\">",
"      Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16:3721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/45\">",
"      Bibbins-Domingo K, Chertow GM, Fried LF, et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/46\">",
"      Menon V, Shlipak MG, Wang X, et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/47\">",
"      Astor BC, Levey AS, Stevens LA, et al. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol 2009; 20:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/48\">",
"      Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/49\">",
"      Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/50\">",
"      Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/51\">",
"      Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/52\">",
"      Leoncini G, Viazzi F, Pontremoli R. Overall health assessment: a renal perspective. Lancet 2010; 375:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/53\">",
"      Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/54\">",
"      Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/55\">",
"      Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/56\">",
"      van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/57\">",
"      Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/58\">",
"      Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/59\">",
"      Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/60\">",
"      Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int 2002; 62:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/61\">",
"      Knobler H, Zornitzki T, Vered S, et al. Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol 2004; 44:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/62\">",
"      Kong AP, So WY, Szeto CC, et al. Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney Int 2006; 69:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/63\">",
"      Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/64\">",
"      Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/65\">",
"      Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/66\">",
"      Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/67\">",
"      Clase CM, Gao P, Tobe SW, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011; 154:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/68\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/69\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/70\">",
"      Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/71\">",
"      Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/72\">",
"      Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/73\">",
"      Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 2008; 102:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/74\">",
"      Wattanakit K, Coresh J, Muntner P, et al. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 2006; 48:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/75\">",
"      Matsushita K, Selvin E, Bash LD, et al. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 2009; 20:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/76\">",
"      Shlipak MG, Katz R, Kestenbaum B, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009; 20:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/77\">",
"      Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/78\">",
"      Tonelli M. Should CKD be a coronary heart disease risk equivalent? Am J Kidney Dis 2007; 49:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/79\">",
"      Hyre AD, Fox CS, Astor BC, et al. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/80\">",
"      Verhave JC, Gansevoort RT, Hillege HL, et al. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 2004; 15:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/81\">",
"      Verhave JC, Hillege HL, Burgerhof JG, et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/82\">",
"      Astor BC, Shafi T, Hoogeveen RC, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 2012; 59:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/83\">",
"      Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/84\">",
"      Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/85\">",
"      Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/86\">",
"      Kobayashi S, Maesato K, Moriya H, et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/87\">",
"      Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/88\">",
"      Russo D, Palmiero G, De Blasio AP, et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/89\">",
"      Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/90\">",
"      Dellegrottaglie S, Saran R, Gillespie B, et al. Prevalence and predictors of cardiovascular calcium in chronic kidney disease (from the Prospective Longitudinal RRI-CKD Study). Am J Cardiol 2006; 98:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/91\">",
"      Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/92\">",
"      Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/93\">",
"      Friedman AN, Hunsicker LG, Selhub J, et al. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005; 68:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/94\">",
"      Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/95\">",
"      Menon V, Sarnak MJ, Greene T, et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006; 113:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/96\">",
"      Shishehbor MH, Oliveira LP, Lauer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/97\">",
"      Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/98\">",
"      Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005; 46:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/99\">",
"      Forsblom C, Harjutsalo V, Thorn LM, et al. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011; 22:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/100\">",
"      Rosolowsky ET, Skupien J, Smiles AM, et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011; 22:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/101\">",
"      Nicola LD, Minutolo R, Chiodini P, et al. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney Int 2012; 82:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/102\">",
"      Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int 2008; 73:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/103\">",
"      Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/104\">",
"      Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 2006; 70:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/105\">",
"      Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/106\">",
"      LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/107\">",
"      Solomon SD, Rice MM, A Jablonski K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/108\">",
"      Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2:CD008834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/109\">",
"      Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 156:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/110\">",
"      KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. file://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/111\">",
"      Gibney EM, Casebeer AW, Schooley LM, et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int 2005; 68:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/112\">",
"      Newsome BB, Warnock DG, Kiefe CI, et al. Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease. Am J Kidney Dis 2005; 46:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/113\">",
"      Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 2006; 119:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/114\">",
"      Patel UD, Ou FS, Ohman EM, et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am J Kidney Dis 2009; 53:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/115\">",
"      Charytan D, Mauri L, Agarwal A, et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006; 152:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/116\">",
"      Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/117\">",
"      Tabata M, Takanashi S, Fukui T, et al. Off-pump coronary artery bypass grafting in patients with renal dysfunction. Ann Thorac Surg 2004; 78:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/118\">",
"      Zakeri R, Freemantle N, Barnett V, et al. Relation between mild renal dysfunction and outcomes after coronary artery bypass grafting. Circulation 2005; 112:I270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/119\">",
"      Anderson RJ, O'brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/120\">",
"      Dacey LJ, Liu JY, Braxton JH, et al. Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg 2002; 74:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/121\">",
"      Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000; 102:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/122\">",
"      Massad MG, Kpodonu J, Lee J, et al. Outcome of coronary artery bypass operations in patients with renal insufficiency with and without renal transplantation. Chest 2005; 128:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/123\">",
"      Pinkau T, Mann JF, Ndrepepa G, et al. Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. Am J Kidney Dis 2004; 44:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/124\">",
"      Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J 2005; 149:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/125\">",
"      Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005; 95:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/126\">",
"      Attallah N, Yassine L, Fisher K, Yee J. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol 2005; 64:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/127\">",
"      Stigant C, Izadnegahdar M, Levin A, et al. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis 2005; 45:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/128\">",
"      Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. Am Heart J 2005; 150:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/129\">",
"      Charytan DM, Varma MR, Silbaugh TS, et al. Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. Am J Kidney Dis 2011; 57:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/130\">",
"      Charytan D, Forman JP, Cutlip DE. Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant 2007; 22:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/31/34298/abstract/131\">",
"      Aoki J, Ong AT, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J 2005; 26:1488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7190 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34298=[""].join("\n");
var outline_f33_31_34298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1172085258\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHRONIC KIDNEY DISEASE AS AN INDEPENDENT RISK FACTOR FOR CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Association between CKD and CHD in community-based populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Association between CKD and CHD among those at high cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CKD as a CHD risk equivalent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations of the data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H786389950\">",
"      - Cystatin C and other markers of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599735133\">",
"      PRESENCE OF TRADITIONAL AND NONTRADITIONAL CARDIOVASCULAR RISK FACTORS IN CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599735140\">",
"      Traditional risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599735147\">",
"      Nontraditional risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H599734827\">",
"      COMPETING RISKS OF CARDIOVASCULAR AND END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REDUCTION OF CHD RISK IN PATIENTS WITH CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS OF CORONARY HEART DISEASE IN PATIENTS WITH CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348910377\">",
"      Prognosis after acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prognosis after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prognosis after PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H786391182\">",
"      PCI versus CABG in patients with CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INCREASED SERUM CARDIAC ENZYMES AND ACUTE CORONARY EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1172085258\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7190|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/8/18573\" title=\"table 1\">",
"      EuroSCORE risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/61/3036\" title=\"table 2\">",
"      CADILLAC risk score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/22/6505?source=related_link\">",
"      Coronary artery bypass graft surgery after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/38/22120?source=related_link\">",
"      Operative mortality after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26984?source=related_link\">",
"      Treatment of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_31_34299="Anticoagulant herbs PI";
var content_f33_31_34299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticoagulant herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anticoagulants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alfalfa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Angelica",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aniseed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arnica",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asafoetida",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chamomile, German",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chamomile, Roman",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clove",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fenugreek",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Feverfew",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fucus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Garlic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ginger",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ginkgo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ginseng, Panax",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Horse-chestnut",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Horseradish",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Liquorice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meadowsweet",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Poplar",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prickly ash, northern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prickly ash, southern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quassia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Red clover",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Willow",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Newall, CA, Anderson, LA, Phillipson, JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34299=[""].join("\n");
var outline_f33_31_34299=null;
var title_f33_31_34300="Phys class causes dys";
var content_f33_31_34300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic classification of causes of dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Increased ventilatory demand",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Increased physiologic dead space",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Pulmonary embolism",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Extrinsic compression of pulmonary artery",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Emphysema",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Metabolic",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Exercise",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Altered pCO",
"           <sub>",
"            2",
"           </sub>",
"           set point",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Early metabolic acidosis due to deconditioning",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Neurohumeral",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Pain",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Anxiety",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Depression",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Impaired Mechanical Response",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Airway Obstruction",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Chronic bronchitis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Tumor",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Decreased Chest Wall Compliance",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Post-thoracotomy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Obesity",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Decreased parenchymal elasticity",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Pulmonary fibrosis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Pulmonary vessel congestion secondary to left heart failure",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2_single\">",
"           Inspiratory muscle weakness",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Neuromuscular disease",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Cachexia due to cancer",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Steroid myopathy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"indent1\">",
"           Electrolyte imbalance",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34300=[""].join("\n");
var outline_f33_31_34300=null;
var title_f33_31_34301="Ig class switching";
var content_f33_31_34301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Ig class switching",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Before class-switching. A rearranged VDJH gene is at the left, the first five CH genes are shown (and the&nbsp;&epsilon; pseudogene). All CH genes, except C&delta;, have a 5' associated sequence called the switch (S) region, or switch sequence. These are the sites where DNA is cut during the switching process. (B) The class-switching intermediate. Two switch sequences are juxtaposed, in this case S&micro; and S&gamma;1. The intervening DNA is excised in a fashion similar to V gene recombination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bona, C, Bonilla, FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright &copy; 1996 Overseas Publishers Association, N.V. Permission granted by Gordon and Breach Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34301=[""].join("\n");
var outline_f33_31_34301=null;
var title_f33_31_34302="Intimate partner violence screening algorithm";
var content_f33_31_34302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Intimate partner violence screening algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IPV: intimate partner violence.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Futures Without Violence. Available at:",
"        <a href=\"file://www.futureswithoutviolence.org\">",
"         www.futureswithoutviolence.org",
"        </a>",
"        (Accessed on September 19, 2012).",
"       </li>",
"       <li>",
"        Massachusetts Medical Society. Use your \"RADAR\" to recognize and treat intimate partner violence. Available at:",
"        <a href=\"file://www.massmed.org/AM/Template.cfm?Section=Home6&amp;TEMPLATE=/CM/ContentDisplay.cfm&amp;CONTENTID=7357\">",
"         www.massmed.org/AM/Template.cfm?Section=Home6&amp;TEMPLATE=/CM/ContentDisplay.cfm&amp;CONTENTID=7357",
"        </a>",
"        (Accessed on February 08, 2012).",
"       </li>",
"      </ol>",
"      Courtesy of Kathleen M Franchek-Roa, MD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34302=[""].join("\n");
var outline_f33_31_34302=null;
var title_f33_31_34303="Vocal cord edema Endosc";
var content_f33_31_34303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Vocal cord edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopic views of normal (left) and edematous (right) vocal cords following extubation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_31_34303=[""].join("\n");
var outline_f33_31_34303=null;
